A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell With Marrow Transplantation From Human Leukocyte Antigen (HLA) Compatible Unrelated Donors (BMT CTN #0201)
Phase: PHASE3
Conditions: Leukemia, Myeloproliferative Disorders, Myelodysplastic-Myeloproliferative Diseases
Sponsor: Medical College of Wisconsin

BMT CTN 0201 
A Phase III Randomized, Multicenter Trial 
Comparing G-CSF Mobilized Peripheral Blood Stem 
Cell with Marrow Transplantation from HLA 
Compatible Unrelated Donors 
NCT00075816 

 
 
A Phase III Randomized, Multicenter Trial Comparing  
G-CSF Mobilized Peripheral Blood Stem Cell with Marrow 
Transplantation from HLA Compatible Unrelated Donors 
 
 
BMT CTN PROTOCOL 0201 
Version 9.0 
 
Study Chairperson 
Claudio Anasetti, M.D. 1 
 
Protocol Team 
Paolo Anderlini, M.D. 2 
William Bensinger, M.D. 1 
Shelly Carter, Sc.D. 3 
Dennis L. Confer, M.D. 4 
Cathy Gurgol, M.S.3 
Mary Horowitz, M.D., M.S. 5 
Chatchada Karanes, M.D. 6 
Roberta J. King, M.P.H. 4 
Stephanie J. Lee, M.D. 7 
Susan Leitman, M.D. 8 
Brent Logan, Ph.D. 5 
Scott D. Rowley, M.D. 9 
Edmund K. Waller, M.D., Ph.D. 10 
Daniel Weisdorf, M.D. 11 
John R. Wingard, M.D. 12 
 
 
Sponsored by the National Institutes of Health 
National Heart, Lung, and Blood Institute 
National Cancer Institute 
and the National Marrow Donor Program 
 
 
 
1 Fred Hutchinson Cancer Research Center 
2 M.D. Anderson Cancer Center 
3 The EMMES Corporation 
4 National Marrow Donor Program 
5 Center for International Blood and Marrow 
Transplant Research, Medical College of 
Wisconsin 
6City of Hope  
7 Dana Farber Cancer Institute  
8 NIH Department of Transfusion Medicine 
9 Hackensack University Medical Center 
10 Emory University Hospital 
11 University of Minnesota 
12 University of Florida, Shands Hospital  

BMT CLINICAL TRIALS NETWORK 
 
Core Study Participants: 
 Non-Core Study Participants: 
City of Hope National Medical Center 
City of Hope Samaritan 
Dana Farber/Partners Cancer Center 
Duke University Medical Center 
Fred Hutchinson Cancer Research Center 
Hackensack University Medical Center (PBMTC) 
Karmanos Cancer Institute (PBMTC) 
Oregon Health Sciences University (CWRU/PBMTC) 
Schneider Children's Hospital (PBMTC) 
St. Louis Children’s Hospital (PBMTC) 
Stanford Hospital and Clinics 
UCSD Medical Center 
University Hospitals of Cleveland (CWRU) 
University of Florida School of Medicine, Shands Hospital 
University of Michigan Medical Center 
University of Minnesota 
University of Nebraska Medical Center 
University of Pennsylvania Cancer Center 
University of Texas, MD Anderson Cancer Research Center 
Utah BMT/Primary Children's Medical Center (PBMTC) 
Vanderbilt University (PBMTC) 
Washington University of St. Louis (CWRU) 
 Baylor College of Medicine 
Baylor University Medical Center 
CancerCare Manitoba 
Centre Hospitalier L’hotel Dieu de Quebec 
CHA Hôpital L’Enfant – Jésus 
Emory University Hospital 
Hackensack Univ Medical Center (Adults) 
Hamilton Health Sciences 
Hôpital Maisonneuve – Rosemont 
Indiana BMT at Beech Grove 
Kansas City Cancer Centers 
Karmanos Cancer Institute (Adults) 
Loyola University Medical Center 
Mayo Clinic 
McGill University 
Ottawa General Hospital 
Queen Elizabeth II Health Sciences Centre 
Roswell Park Cancer Institute 
Saskatoon Cancer Centre 
Texas Transplant Institute 
Tom Baker Cancer Centre 
University of Alabama at Birmingham 
University of Iowa Hospitals 
University of Maryland 
University of Oklahoma Health Sciences Center 
University of Pittsburgh 
University of Toronto/Princess Margaret Hospital 
Utah BMT/Univ of Utah Medical School (Adults) 
Virginia Commonwealth University 
Wake Forest University 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
i 
PROTOCOL SYNOPSIS – BMT CTN PROTOCOL 0201 
 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood 
Stem Cell with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
 
Principal Investigator: 
Claudio Anasetti, M.D. 
 
Study Design: 
The study is designed as a Phase III, randomized, open label, 
multicenter, prospective, comparative trial of granulocyte colony 
stimulating factor (G-CSF)-mobilized peripheral blood stem cells 
(PBSC) versus marrow from unrelated donors for transplantation in 
patients with hematologic malignancies.  Recipients will be stratified 
by transplant center and disease risk and will be randomized to either 
the PBSC or marrow arm in a 1:1 ratio. 
 
Primary Objective: 
The primary objective is to compare two-year survival probabilities 
between patients in the two study arms using an intent-to-treat 
analysis. 
 
Secondary Objectives: 
Patients randomized to the two study arms and actually transplanted 
will be compared for the following endpoints (patients who do not 
receive a transplant will be excluded from the following analyses): 
survival, incidences of neutrophil and platelet engraftment, graft 
failure, acute graft-versus-host disease (GVHD), chronic GVHD, 
time off all immunosuppressive therapy, relapse, infections, adverse 
events, immune reconstitution, and quality of life.  Donors in each 
arm of the study will be compared for time to return to baseline 
toxicity score, CBC and WBC differential values after donation and 
quality of life. 
 
Eligibility Criteria: 
Eligible patients are up to 66.00 years of age, have acute leukemia, 
myelodysplasia, 
chronic 
myeloid 
leukemia, 
or 
other 
myeloproliferative disorders, adequate organ function, a 6/6 or 5/6 
HLA-A, B and DRB1 matched unrelated donor, and are able to give 
signed informed consent prior to enrollment.  Donors must be 18 
years of age, meet National Marrow Donor Program (NMDP) 
criteria for donor eligibility and give informed consent prior to 
enrollment. 
 
Treatment Description: 
Patients will receive one of four conditioning regimens as described 
in the protocol, at the discretion of the transplant physician.  The 
GVHD prophylaxis regimen will be per institutional standard, but 
may not contain Phase I agents.  The transplant physician must 
declare the conditioning and GVHD prophylaxis regimens prior to 
randomization to the PBSC versus marrow arm.  Marrow cells will 
be collected from the donors using standard procedures.  PBSC 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
ii 
donors will receive G-CSF ~10mcg/kg/d x 5 days and cells will be 
collected by a single large volume apheresis on Day 5, or two 
smaller volume apheresis procedures on Days 5 and 6. Marrow or 
blood cells will not be T-depleted or frozen prior to transplantation.  
 
Accrual Objective: 
Patients who are candidates for transplantation of G-CSF–mobilized 
PBSC or marrow from HLA-compatible unrelated donors will be 
targeted for accrual.  Approximately 275 patients will be accrued per 
study arm (total of 550 patients). 
 
Accrual Period: 
The estimated accrual period is three years. 
 
Study Duration: 
Patients and donors will be followed for two years for evaluation of 
the primary endpoint, with additional follow-up to three years after 
transplantation or donation for evaluation of certain secondary 
endpoints. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
iii 
TABLE OF CONTENTS 
 
 
1. 
BACKGROUND AND RATIONALE .............................................................................. 1-1 
1.1. 
Rationale ........................................................................................................................... 1-1 
1.2. 
Marrow Cell Dose Effect .................................................................................................. 1-1 
1.3. 
PBSC Characteristics........................................................................................................ 1-2 
1.4. 
Safety of G-CSF in Normal Donors .................................................................................. 1-2 
1.5. 
Results of Randomized Trials of PBSC versus Marrow from HLA-Identical Siblings .. 1-3 
1.5.1. 
Engraftment ........................................................................................................................ 1-3 
1.5.2. 
Acute GVHD ...................................................................................................................... 1-3 
1.5.3. 
Chronic GVHD ................................................................................................................... 1-3 
1.5.4. 
Survival and Relapse........................................................................................................... 1-4 
1.6. 
Results of Phase II Studies of PBSC from Unrelated Donors .......................................... 1-4 
1.6.1. 
European Studies ................................................................................................................ 1-4 
1.6.2. 
Preliminary NMDP Phase II Data in Unrelated Donor PBSC Transplants ............................ 1-4 
2. 
STUDY DESIGN ............................................................................................................... 2-1 
2.1. 
Study Overview ................................................................................................................. 2-1 
2.2. 
Hypothesis and Specific Objectives .................................................................................. 2-1 
2.2.1. 
Primary Hypothesis............................................................................................................. 2-1 
2.2.2. 
Secondary Hypotheses ........................................................................................................ 2-1 
2.2.3. 
Study Objectives ................................................................................................................. 2-2 
2.3. 
Patient Eligibility for Randomization .............................................................................. 2-2 
2.3.1. 
Patient Inclusion Criteria ..................................................................................................... 2-2 
2.3.2. 
Patient Exclusion Criteria.................................................................................................... 2-4 
2.4. 
Additional Patient Exclusion Criteria for Transplant Conditioning ............................... 2-4 
2.5. 
Donor Selection Criteria ................................................................................................... 2-5 
2.5.1. 
Donor Inclusion .................................................................................................................. 2-5 
2.5.2. 
Donor Exclusion ................................................................................................................. 2-5 
2.6. 
Treatment Plan ................................................................................................................. 2-6 
2.6.1. 
Conditioning Regimens ....................................................................................................... 2-6 
2.6.2. 
GVHD Prophylaxis Regimen .............................................................................................. 2-8 
2.6.3. 
Cyclosporine or Tacrolimus Treatment Regimen ................................................................. 2-9 
2.6.4. 
Methotrexate Treatment Regimen ..................................................................................... 2-11 
2.6.5. 
PBSC Mobilization and Collection .................................................................................... 2-11 
2.6.6. 
Marrow Collection ............................................................................................................ 2-13 
2.6.7. 
PBSC or Marrow Infusion ................................................................................................. 2-14 
2.6.8. 
No Blinding of Marrow and PBSC Infusions ..................................................................... 2-15 
2.6.9. 
PBSC Collection or Marrow Harvesting for Additional Stem Cell Products....................... 2-15 
2.6.10. 
Supportive Care ................................................................................................................ 2-15 
2.6.11. 
Growth Factors ................................................................................................................. 2-15 
2.6.12. 
Blood Products ................................................................................................................. 2-16 
2.6.13. 
Prophylaxis against Infections ........................................................................................... 2-16 
2.6.14. 
Intravenous Immune Globulin (IVIG) ............................................................................... 2-16 
2.6.15. 
Failure to Engraft .............................................................................................................. 2-16 
2.6.16. 
Post-transplant Donor Leukocyte Infusions (DLI) ............................................................. 2-16 
2.6.17. 
Risks and Toxicities .......................................................................................................... 2-17 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
iv 
3. 
STUDY ENDPOINTS ....................................................................................................... 3-1 
3.1. 
Primary Endpoint ............................................................................................................. 3-1 
3.2. 
Secondary Endpoints ........................................................................................................ 3-1 
3.2.1. 
Two-Year Post-transplant Survival...................................................................................... 3-1 
3.2.2. 
Neutrophil Engraftment > 500/mcL ..................................................................................... 3-1 
3.2.3. 
Primary Graft Failure .......................................................................................................... 3-1 
3.2.4. 
Secondary Graft Failure ...................................................................................................... 3-1 
3.2.5. 
Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent ............................ 3-1 
3.2.6. 
Acute GVHD of Grades II-IV and III-IV ............................................................................. 3-2 
3.2.7. 
Chronic GVHD ................................................................................................................... 3-2 
3.2.8. 
Current Immunosuppressive (IS) Free Survival ................................................................... 3-2 
3.2.9. 
Relapse of the Original Malignancy .................................................................................... 3-2 
3.2.10. 
Donor Lymphocyte Infusion (DLI)...................................................................................... 3-4 
3.2.11. 
Infections ............................................................................................................................ 3-4 
3.2.12. 
Immune Reconstitution ....................................................................................................... 3-4 
3.2.13. 
Patient and Donor Quality of Life ....................................................................................... 3-4 
3.2.14. 
Three-year Survival ............................................................................................................ 3-4 
3.2.15. 
Donor Recovery to Baseline Toxicity Scores ....................................................................... 3-4 
3.2.16. 
Donor Recovery to Baseline CBC and WBC Differential Values ......................................... 3-4 
4. 
PATIENT AND DONOR REGISTRATION, ENROLLMENT AND EVALUATION .. 4-1 
4.1. 
Donor Search Initiation .................................................................................................... 4-1 
4.2. 
Approaching Patients About the Study ............................................................................ 4-2 
4.3. 
Screening for Patient Eligibility ....................................................................................... 4-2 
4.4. 
Patient Consent to Randomization ................................................................................... 4-2 
4.5. 
Patient Refusal .................................................................................................................. 4-2 
4.6. 
Donor Selection and Work-Up ......................................................................................... 4-2 
4.7. 
Donor Deferral .................................................................................................................. 4-3 
4.8. 
Donor Consent .................................................................................................................. 4-3 
4.9. 
Donor Refusal ................................................................................................................... 4-3 
4.10. 
Transplant Protocol Registration ..................................................................................... 4-3 
4.11. 
Randomization .................................................................................................................. 4-3 
4.12. 
Treatment Scheduling ....................................................................................................... 4-3 
4.13. 
Patient Evaluation............................................................................................................. 4-4 
4.14. 
Patient Deferral ................................................................................................................. 4-4 
4.15. 
Study Monitoring .............................................................................................................. 4-5 
4.15.1. 
Case Report Forms.............................................................................................................. 4-5 
4.15.2. 
Reporting Patient Deaths ..................................................................................................... 4-6 
4.15.3. 
Reporting Serious Adverse Events ...................................................................................... 4-6 
4.15.4. 
Patient Assessments ............................................................................................................ 4-6 
4.15.5. 
Required Observations for Donor ...................................................................................... 4-10 
5. 
STATISTICAL CONSIDERATIONS .............................................................................. 5-1 
5.1. 
Study Design...................................................................................................................... 5-1 
5.1.1. 
Accrual ............................................................................................................................... 5-1 
5.1.2. 
Randomization .................................................................................................................... 5-1 
5.1.3. 
Primary Endpoint ................................................................................................................ 5-1 
5.1.4. 
Primary Hypothesis............................................................................................................. 5-1 
5.2. 
Analysis of the Primary Hypothesis ................................................................................. 5-2 
5.2.1. 
Comparison of Two-year Survival....................................................................................... 5-2 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
v 
5.2.2. 
Comparison and Interim Monitoring of Six-month Mortality ............................................... 5-2 
5.3. 
Sample Size and Power Considerations ........................................................................... 5-3 
5.4. 
Accrual .............................................................................................................................. 5-4 
5.5. 
Interim Analyses ............................................................................................................... 5-7 
5.6. 
Demographic and Baseline Characteristics...................................................................... 5-7 
5.7. 
Analysis of Secondary Endpoints ..................................................................................... 5-7 
5.7.1. 
Two-year Survival among Transplanted Patients ................................................................. 5-8 
5.7.2. 
Neutrophil Engraftment > 500/mcL ..................................................................................... 5-8 
5.7.3. 
Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent ............................ 5-8 
5.7.4. 
Acute GVHD of Grades II-IV and III-IV ............................................................................. 5-8 
5.7.5. 
Chronic GVHD ................................................................................................................... 5-8 
5.7.6. 
Current Immunosuppressive (IS) Free Survival ................................................................... 5-8 
5.7.7. 
Relapse of the Original Malignancy .................................................................................... 5-9 
5.7.8. 
Donor Lymphocyte Infusion ............................................................................................... 5-9 
5.7.9. 
Bacterial, Viral and Invasive Fungal Infection ..................................................................... 5-9 
5.7.10. 
Patient and Donor Quality of Life ....................................................................................... 5-9 
5.7.11. 
Three-Year Survival............................................................................................................ 5-9 
5.8. 
Safety Analysis .................................................................................................................. 5-9 
5.8.1. 
Adverse Events ................................................................................................................. 5-10 
5.9. 
Laboratory Tests ............................................................................................................. 5-10 
5.10. 
Donor Recovery .............................................................................................................. 5-10 
5.11. 
Subgroup Analyses.......................................................................................................... 5-11 
6. 
INFECTIOUS COMPLICATIONS OF TRANSPLANTATION .................................... 6-1 
6.1. 
Required Data Elements for Collection ............................................................................ 6-1 
6.1.1. 
Pre-transplant Infections that may have an Impact on the Transplant by Recurrence ............ 6-1 
6.1.2. 
Infectious Disease Prophylaxis ............................................................................................ 6-1 
6.1.3. 
Specific Reporting of Individual Infections ......................................................................... 6-2 
7. 
PATIENT QUALITY OF LIFE ....................................................................................... 7-1 
7.1. 
Background and Significance ........................................................................................... 7-1 
7.2. 
Overview and Rationale.................................................................................................... 7-1 
7.3. 
Preliminary Work ............................................................................................................. 7-2 
7.4. 
Specific Aims ..................................................................................................................... 7-2 
7.5. 
Hypotheses ........................................................................................................................ 7-2 
7.6. 
Eligibility and Exclusion Criteria ..................................................................................... 7-3 
7.6.1. 
Inclusion Criteria ................................................................................................................ 7-3 
7.6.2. 
Exclusion Criteria ............................................................................................................... 7-3 
7.7. 
Study Procedures .............................................................................................................. 7-3 
7.7.1. 
Study Design ...................................................................................................................... 7-3 
7.7.2. 
Study Endpoints .................................................................................................................. 7-4 
7.7.3. 
Instruments ......................................................................................................................... 7-4 
7.7.4. 
Required Data ..................................................................................................................... 7-6 
7.8. 
Description of Study Process ............................................................................................ 7-6 
7.8.1. 
Identification of Eligible Patients ........................................................................................ 7-6 
7.8.2. 
Informed Consent ............................................................................................................... 7-7 
7.8.3. 
Collection of QOL Data ...................................................................................................... 7-7 
7.8.4. 
Location of Missing Patients ............................................................................................... 7-7 
7.8.5. 
Withdrawal of Consent for QOL Data Collection ................................................................ 7-7 
7.8.6. 
Fifth Year Contact .............................................................................................................. 7-7 
7.8.7. 
Letter of Appreciation and Communication of Findings ...................................................... 7-8 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
vi 
7.8.8. 
Management of Adverse Reactions ..................................................................................... 7-8 
7.9. 
Statistical Considerations ................................................................................................. 7-8 
7.9.1. 
Sample Size ........................................................................................................................ 7-8 
7.9.2. 
Missing Data....................................................................................................................... 7-9 
7.9.3. 
Modified Intent-to-Treat ..................................................................................................... 7-9 
7.10. 
Risks and Discomforts .................................................................................................... 7-10 
7.10.1. 
Potential Risks to Research Subjects ................................................................................. 7-10 
7.10.2. 
Adequacy of Protection Against Risks............................................................................... 7-10 
7.10.3. 
Sources of Research Materials........................................................................................... 7-10 
7.10.4. 
Potential Benefits .............................................................................................................. 7-10 
7.10.5. 
Potential Benefits of the Proposed Research to the Subjects and Others ............................. 7-10 
7.11. 
Monitoring and Quality Assurance ................................................................................ 7-11 
7.11.1. 
Patient Tracking ................................................................................................................ 7-11 
7.11.2. 
Oversight of Project Staff .................................................................................................. 7-11 
8. 
DONOR QUALITY OF LIFE .......................................................................................... 8-1 
8.1. 
Background and Significance ........................................................................................... 8-1 
8.2. 
Specific Aims and Hypotheses .......................................................................................... 8-2 
8.2.1. 
Hypotheses ......................................................................................................................... 8-2 
8.3. 
Eligibility and Exclusionary Criteria ............................................................................... 8-2 
8.3.1. 
Inclusion criteria ................................................................................................................. 8-2 
8.3.2. 
Exclusion Criteria ............................................................................................................... 8-3 
8.4. 
Study Procedures .............................................................................................................. 8-3 
8.4.1. 
Study Design ...................................................................................................................... 8-3 
8.4.2. 
Study Endpoints .................................................................................................................. 8-3 
8.4.3. 
Measures ............................................................................................................................ 8-3 
8.5. 
Description of Study Process ............................................................................................ 8-5 
8.5.1. 
Contact Information ............................................................................................................ 8-5 
8.5.2. 
Informed Consent ............................................................................................................... 8-5 
8.5.3. 
Collection of QOL Data ...................................................................................................... 8-5 
8.5.4. 
Withdrawal of Consent for QOL Data Collection ................................................................ 8-6 
8.5.5. 
Letter of Appreciation and Summary of Results .................................................................. 8-6 
8.6. 
Statistical Considerations ................................................................................................. 8-6 
8.6.1. 
Sample Size ........................................................................................................................ 8-6 
8.6.2. 
Group Comparisons ............................................................................................................ 8-6 
8.6.3. 
Missing Data....................................................................................................................... 8-6 
8.7. 
Risks and Discomforts ...................................................................................................... 8-7 
8.8. 
Potential Benefits .............................................................................................................. 8-7 
8.9. 
Monitoring and Quality Assurance .................................................................................. 8-7 
LIST OF APPENDICES 
APPENDIX A 
RATIONALE FOR THE STUDY DESIGN 
APPENDIX B-1 
RECIPIENT CONSENT FORM 
APPENDIX B-2 
DONOR CONSENT FORM 
APPENDIX B-3 
ASSENT TO PARTICIPATE FORMS 
APPENDIX C 
LABORATORY PROCEDURES 
APPENDIX D 
HUMAN SUBJECTS 
APPENDIX E 
DONOR MANAGEMENT 
APPENDIX F 
REFERENCES 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
1-1 
CHAPTER 1 
 
 
1. BACKGROUND AND RATIONALE 
 
1.1. 
Rationale 
 
Many studies of allogeneic marrow transplantation have shown that a higher dose of marrow 
cells correlates with more robust hematopoietic engraftment and lower mortality from infectious 
complications.  Peripheral blood stem cells (PBSC) collected after mobilization with granulocyte 
colony stimulating factor (G-CSF) contain a larger number of CD34-positive (CD34) progenitors 
and total cells than bone marrow.  These observations led to the hypothesis that transplantation 
of PBSC would lead to lower mortality compared to transplantation of marrow.  In addition, 
PBSC grafts have a higher T cell content, predicting a possibly more powerful anti-leukemia 
effect.  However, the higher T cell content of PBSC may also lead to increased incidence and 
severity of acute and chronic graft-versus-host disease (GVHD).  This concern is especially 
serious when the donor is unrelated to the recipient.  This prospective, randomized, multicenter 
clinical trial of unrelated donor transplantation will test the hypothesis that transplantation of 
PBSC leads to similar patient survival compared to transplantation of marrow. 
 
1.2. 
Marrow Cell Dose Effect 
 
Early in the history of hematopoietic stem cell transplantation, marrow cell dose was recognized 
as a limiting factor for engraftment and patient survival.  In patients with aplastic anemia 
conditioned with cyclophosphamide and transplanted with marrow from HLA-identical siblings, 
infusion of fewer than 3 x 108 cells per kilogram (kg) was associated with increased risks of graft 
failure and death (1).  The authors of that report suggested: “The greatest possible amount of 
donor marrow, perhaps supplemented by stem cells derived from the peripheral blood, should be 
obtained.”  Subsequent studies have supported this concept. Improved survival was associated 
with transplantation of higher marrow cell doses in patients with acute myeloid leukemia (AML) 
in first remission (2).  The number of hematopoietic precursor cells in T-replete marrow grafts 
was associated with better survival after transplantation from HLA-identical siblings (3).  A 
higher number of CD34 cells, a population that includes hematopoietic progenitors, was 
associated with improved survival after T cell depleted (4), or T-replete marrow grafts from 
HLA-identical siblings (5). 
 
Cell dose is limiting with transplantation of HLA incompatible unrelated cord blood (6, 7), and 
with transplantation of HLA incompatible related donor marrow (8).  However engraftment 
across the HLA barrier was achieved with the use of T-depleted PBSC containing a large dose of 
CD34 cells (9). 
 
Studies of unrelated donor transplants have shown similar results.  In patients with acute 
leukemia receiving T-replete marrow from unrelated donors, transplantation of a marrow 
nucleated cell dose above 3.65 x 108/kg was associated with faster neutrophil and platelet 
engraftment, decreased incidence of severe GVHD, less non-leukemic deaths and better 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
1-2 
leukemia-free survival (10, 11).  Similar findings were reported in children receiving unrelated 
donor transplants for chronic myeloid leukemia (CML) (12) or Hurler’s syndrome (13).  Thus, 
there is abundant evidence that marrow is a limiting source of hematopoietic progenitors for 
human transplantation.  This supports the hypothesis that cell doses higher than the average 
marrow harvest might improve transplant outcome. 
 
1.3. 
PBSC Characteristics 
 
Hematopoietic precursors circulate in the peripheral blood at a low steady state concentration.  
However, administration of a recombinant growth factor, such as G-CSF, causes a rapid increase 
in hematopoietic progenitors in the circulation.  Transplantation of G-CSF-mobilized PBSC can 
produce durable hematopoietic reconstitution when infused after myeloablative conditioning into 
autologous, syngeneic or allogeneic transplant recipients, and engraftment is more rapid with 
PBSC compared to marrow transplantation (14, 15, 16).  After transplantation, PBSC can 
differentiate into mature hepatocytes and epithelial cells in the skin and gastrointestinal tract, 
indicating that they contain true stem cells (17).  PBSC components collected after G-CSF 
administration contain two to five-fold greater numbers of CD34 cells compared to marrow, 10-
fold greater numbers of T cells (18), 24-fold greater numbers of monocytes, 13-fold greater 
numbers of natural killer (NK) cells (19), and 5-fold greater number of plasmacytoid dendritic 
cells (20).  Therefore, more rapid engraftment of PBSC compared to marrow grafts may not be 
entirely due to increased numbers of CD34 cells, but may result from altered properties of CD34 
cells, or from the infusion of more cells belonging to other lineages.  Clinical studies indicate 
that the risk of acute GVHD is perhaps increased after PBSC transplantation, but is definitely not 
as high as one would expect with the infusion of 1–2 logs more T cells as compared to marrow 
transplantation.  Possible explanations are that T cells are functionally altered in G-CSF-
mobilized PBSC or that infused accessory cells regulate T cell function (21, 22, 23).  Thus, there 
are multiple quantitative and qualitative differences between PBSC and marrow transplants. 
 
1.4. 
Safety of G-CSF in Normal Donors 
 
The advantages for the donor of PBSC apheresis over marrow harvesting include the avoidance 
of general anesthesia and surgical complications.  A randomized study of sibling transplantation 
demonstrated similar levels of physical discomfort for marrow and PBSC donors, but quicker 
resolution of symptoms for PBSC donors (24).  The administration of G-CSF in doses up to  
16 mcg/kg/day in normal donors has been associated with bone pain, malaise, myalgias, 
headache, leukocytosis and mild thrombocytopenia as common side effects (25).  These are 
usually reversed within two days of discontinuing the drug.  Self-limited laboratory 
abnormalities include elevated alkaline-phosphatase, lactate dehydrogenase, uric acid, alanine 
aminotransferase, -glutamyl transpeptidase, and decreased potassium and magnesium. G-CSF 
also causes transient hemostatic changes, including increases in prothrombin fragment, 
thrombin–antithrombin complex and D-dimer (26).  Case reports have described rare events, 
such as myocardial infarction (27), or stroke (28), in association with G-CSF administration.  
These thrombotic complications have occurred in donors with a history of peripheral vascular 
disease or myocardial infarction and are unlikely to occur in healthy donors.  Spontaneous spleen 
rupture constitutes an unusual and rare adverse event following G-CSF administration for PBSC 
collection from normal donors (29, 30).  Preliminary National Marrow Donor Program (NMDP) 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
1-3 
experience with PBSC collection from unrelated donors indicates a favorable short-term safety 
profile (31).  The existence of late side effects from G-CSF will not be known until many donors 
are evaluated for a long period of time. 
 
1.5. 
Results of Randomized Trials of PBSC versus Marrow from HLA-Identical Siblings 
 
1.5.1. Engraftment 
 
Eight randomized trials compared transplantation of mobilized PBSC and marrow from HLA-
identical sibling donors (32, 33, 34, 35, 36, 37, 38, 39).  Each of these trials enrolled 30 to 350 
patients.  Neutrophil engraftment occurred significantly earlier with PBSC in seven trials, and 
platelet engraftment occurred significantly earlier with PBSC in all trials. 
 
1.5.2. Acute GVHD 
 
The risks of acute grades II–IV GVHD were similar in seven trials, while the European Blood 
and Marrow Transplant (EBMT) study (40) noted a 13% greater incidence of grade II–IV GVHD 
and a 12% greater incidence of grade III–IV GVHD with PBSC.  The following are differences 
among the trials that might explain the reason for discrepant results: 
 
1. All trials utilized the combination of cyclosporine and methotrexate for GVHD 
prevention.  However, the EBMT study omitted the Day 11 methotrexate from the 
regimen while the next two largest trials in the U.S. (41) and Canada (42) included the 
Day 11 methotrexate.  In prior studies of marrow transplantation, the omission of Day 11 
methotrexate increased the risks of GVHD (43). 
 
2. The EBMT trial employed G-CSF post-transplant while the U.S. and the Canadian trials 
did not employ G-CSF.  There is no obvious relationship between post-transplant G-CSF 
and GVHD. 
 
3. The EBMT trial was the largest and therefore had the most statistical power to detect a 
difference. 
 
1.5.3. Chronic GVHD 
 
All trials suggested that PBSC transplantation was associated with more chronic GVHD, and 
three trials found a statistically significant increase of chronic GVHD with PBSC.  The Day 11 
dose of methotrexate was omitted in the three trials where PBSC led to a statistically significant 
increase in incidence of chronic GVHD.  While this observation does not directly explain a 
higher incidence of chronic GVHD, patients who have acute GVHD are more likely to develop 
chronic GVHD and patients who do not receive the Day 11 dose of methotrexate are more likely 
to develop acute GVHD. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
1-4 
1.5.4. Survival and Relapse 
 
The second and third largest trials, involving 228 and 172 patients in Canada and the United 
States (U.S.), respectively, showed statistically better survival or disease-free survival with 
PBSC.  In the U.S. study, the survival difference of 13% at 2 years was greatest among patients 
with advanced hematologic malignancies.  Both reduced transplant-related mortality and relapse 
contributed to the improved survival.  In comparison to the other trials, the U.S. study enrolled a 
larger number of patients with advanced hematologic malignancies, where it found a benefit for 
PBSC.  The U.S. trial failed to detect improved survival with PBSC in patients with early stage 
disease, perhaps because of the relatively small sample size or perhaps because both transplant-
related mortality and relapse are lower in this group regardless of graft source.  The Canadian 
trial enrolled patients with early leukemia, and found a significant survival advantage with PBSC 
of 10% at 2 years, primarily due to reduced non-relapse mortality.  The EBMT trial enrolled 
almost exclusively patients with early leukemia, but showed no differences in disease-free 
survival or overall survival.  Differences between the EBMT and the Canadian trials were 
discussed above.  One interpretation of the results of these randomized trials is that the 
administration of post-grafting methotrexate using the full dose and schedule may be critical to 
prevent acute and chronic GVHD after PBSC transplantation and to realize the potential for 
PBSC to improve patient survival by 10–13% at 2 years (44). 
 
1.6. 
Results of Phase II Studies of PBSC from Unrelated Donors 
 
1.6.1. European Studies 
 
Initial reports demonstrated the feasibility and potential safety of G-CSF-mobilized PBSC 
transplants from unrelated donors (45, 46, 47, 48).  In matched-cohort studies by Ringden (49) 
and Remberger (50), PBSC achieved faster neutrophil and platelet engraftment compared to 
marrow transplantation, but there was no difference in acute GVHD, relapse, treatment-related 
mortality, or survival.  Elmaagacli and colleagues (51) proposed that for patients with CML in 
chronic phase, PBSC transplants are associated with decreased relapse and improved survival 
when compared with bone marrow from HLA-compatible unrelated donors. 
 
1.6.2. Preliminary NMDP Phase II Data in Unrelated Donor PBSC Transplants 
 
A prospective study was conducted by the NMDP to test the feasibility of harvesting PBSC from 
volunteer donors and the safety of transplanting those PBSC to patients with hematological 
disorders.  Donors were treated daily with G-CSF 10 mcg/kg and PBSC were harvested on Days 
5 and 6.  Cells collected on Day 5 were stored at 2-8oC. The two-day collection was transported 
at 2-8oC and infused fresh into the recipient.  An interim analysis evaluated results of 222 
transplants facilitated by 55 apheresis centers and 57 transplant centers over the first year of 
study.  PBSC were obtained in a one-day (n=47) or two-day (n=175) collection.  The median 
blood volume processed was 12 liters per day, and 24 liters per total collection.  Transplant 
regimens varied according to institutional protocols.  The incidence of engraftment was 96%, 
acute GVHD grades II-IV 47%, acute GVHD grades III-IV 33%, extensive chronic GVHD 36%, 
mortality from causes other than relapse 18% at 100 days and 41% at one year, relapse 26%, 
survival 35% and disease-free survival 32% at one year.  Outcomes of PBSC and marrow 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
1-5 
transplants conducted at the same institutions over the same period were compared.  Multivariate 
analyses were used to adjust for differences in patient age, gender, cytomegalovirus serology, 
performance status, diagnosis and stage, interval from diagnosis to transplant, donor age, HLA 
matching, transplant center, year of transplant, conditioning and immunosuppressive regimen.  
PBSC were associated with faster neutrophil and platelet engraftment, similar risk of GVHD 
grades II-IV, increased GVHD grades III-IV, and similar rates of relapse, survival and disease-
free survival (Table 1.6.2). 
 
 
Table 1.6.2: Multivariate Analyses of Unrelated Donor Transplant Outcomes Assessing 
the Risks Associated with PBSC Compared to Bone Marrow 
 
 
Odds Ratio 
95% Confidence Interval 
p value 
Neutrophil engraftment on Day 21 
4.6 
2.5-8.5 
< 0.0001 
Platelet engraftment on Day 21 
5.2 
3.1-8.8 
< 0.0001 
 
 
Relative Risk 
95% Confidence Interval 
p value 
Acute GVHD grades II-IV 
1.3 
0.9-1.7 
0.12 
Acute GVHD grades III-IV  
1.7 
1.2-2.5 
0.004 
Chronic extensive GVHD 
1.3 
0.8-1.9 
0.26 
 
 
 
 
Relapse 
1.0 
0.7-1.4 
0.85 
Disease-free survival  
0.9 
0.7-1.1 
0.28 
 
Overall death 
0.8 
0.6-1.0 
0.10 
Death first 100 days 
0.6 
0.4-0.8 
0.003 
Death beyond 100 days 
1.2 
0.8-1.7 
0.39 
 
 
Models were controlled for transplant center and year, recipient age, gender, diagnosis, Karnofsky 
score and CMV, donor age, HLA matching, conditioning and immunosuppressive regimens. 
 
Since the survival model did not meet criteria for hazard proportionality over time, two separate 
models tested the association between PBSC and survival.  Within the initial 100 days after 
transplantation, PBSC was associated with a lower hazard of death (RR 0.6, 95% C.I. 0.4-0.8, 
p=0.003), while after the 100 days there was no association (RR 1.2, 95% C.I. 0.8-1.7, p=0.39).  
When reduced-intensity transplants, defined by the use of whole body irradiation at a dose below 
800 cGy, or the use of mycophenolate mofetil were excluded from the analysis, the proportional 
hazards assumption was no longer violated and PBSC was associated with a small and not 
statistically significant survival advantage at 100 days (RR=0.7, p=0.10) and similar overall 
survival (RR=0.95, p=0.73).  A multivariable analysis restricted to PBSC recipients evaluated a 
potential association of CD34 cell dose with outcome.  The analysis found that the highest 
quintile of CD34 cell doses (i.e. > 107 per kg) was associated with an increased risk of chronic 
GVHD but had no association with survival.  The lowest dose of CD34 cells (i.e. < 4 x 106 per 
kg) was not associated with worse outcome. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
1-6 
We conclude that harvest and transplantation of PBSC from volunteer donors are feasible and, 
within the constraints of this initial study, appear at least as safe and effective as marrow grafts. 
Since this study was not randomized and the groups of patients who received PBSC and marrow 
differed for many variables, we cannot conclude with certainty that PBSC is better, worse, or the 
same as marrow.  Although the benefits and risks of PBSC transplants from unrelated donors are 
not proven, the utilization of unrelated donor PBSC in the U.S. is increasing: from 223 in the 
year 2000, to 372 in the year 2001, to 523 in the year 2002.  The continued rise in utilization of 
PBSC, in the absence of definitive data demonstrating any long-term advantages over marrow 
and concern about possible increased risks of chronic GVHD, supports the rationale for the 
timely conduct of a prospective randomized trial of PBSC versus marrow in unrelated donor 
transplantation. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-1 
CHAPTER 2 
 
 
2. STUDY DESIGN 
 
2.1. 
Study Overview 
 
This is a Phase III randomized, open label, multicenter clinical trial sponsored by the NMDP and 
the National Institutes of Health (NIH).  The objective of the trial is to test the null hypothesis 
that there is no difference in overall survival after PBSC versus marrow transplants from HLA 
compatible unrelated donors.  The study will compare G-CSF-mobilized PBSC transplantation 
with bone marrow transplantation from HLA-compatible unrelated donors for patients with 
leukemia, myelodysplastic or myeloproliferative syndromes.  Conditioning and GVHD 
prophylaxis regimens will vary by center and within centers, however, the center must declare 
before randomization what regimens will be used for each patient.  The primary endpoint of this 
trial is two-year survival following randomization.  Secondary analyses will consider neutrophil 
and platelet recovery, acute and chronic GVHD, time off all immunosuppressive therapy, 
relapse, infections, adverse events and immune reconstitution.  The trial will include evaluation 
of patient and donor quality of life, composition of the graft, and immune reconstitution.  
Accrual is anticipated for three years with a follow-up period of three years. 
 
2.2. 
Hypothesis and Specific Objectives 
 
2.2.1. Primary Hypothesis 
 
The null hypothesis of this randomized clinical trial is that there is no difference in the two-year 
survival between PBSC and marrow transplantation.  The alternative statistical hypothesis is that 
survival after PBSC transplantation differs from survival after marrow transplantation; no 
assumption is made about the direction of the difference. 
 
2.2.2. Secondary Hypotheses 
 
PBSC recipients will have faster hematopoietic recovery, improved immune reconstitution, 
lower risks of infection and relapse, higher risks of grades III-IV acute GVHD and chronic 
GVHD, and longer requirement for immune suppressive medications than marrow recipients.  
There will be no detectable difference in the physical, functional, psycho-emotional quality of 
life and the rate of return to work between PBSC and marrow recipients.  There will be 
differences in the pattern of donor quality of life over time from donation between the groups, 
but no detectable differences in overall scores.  PBSC donors will experience more rapid 
recovery from the donation with fewer prolonged painful or disabling complications than 
marrow donors.  There will be no long-term impact on post-donation blood counts in either the 
PBSC or marrow group. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-2 
2.2.3. Study Objectives 
 
The primary objective of the trial is to compare two-year survival rates of the two groups of 
patients starting from the time of randomization to the PBSC or marrow arm.  Secondary 
objectives include comparisons of survival rates after transplantation and incidences of 
neutrophil and platelet recovery, acute GVHD, chronic GVHD, time off all immunosuppressive 
therapy, relapse, infections, adverse events, immune reconstitution and quality of life.  
Additional secondary objectives are to compare donor donation experiences and recovery and 
donor quality of life.  In addition, the study will analyze variables affecting the composition of 
the graft, and assess the relationships between cell subsets in marrow or PBSC grafts and 
transplant outcomes. 
 
2.3. 
Patient Eligibility for Randomization 
 
2.3.1. Patient Inclusion Criteria 
 
Diagnoses to be included: 
1. Acute Myelogenous Leukemia at the following stages: 
 First Remission 
 Second Remission 
 Third or Subsequent Remission 
 Not in Remission 
Complete remission will be defined as all of the following according to the revised 
recommendations of the international working group:52 
 
A bone marrow aspirate containing spicules with < 5% blasts with a count of at 
least 200 nucleated cells and no Auer rods seen.  If spicules are absent in the 
aspirate, a bone marrow biopsy should confirm that < 5% blasts are present. 
 
No evidence of a persistently abnormal leukemic population by flow cytometry. 
 
ANC > 1,000 μL and platelet count > 100,000 μL. 
 
No extramedullary leukemia. 
 
No blasts in peripheral blood. 
2. Acute Lymphoblastic Leukemia at the following stages: 
 First Remission 
 Second Remission 
 Third or Subsequent Remission 
 Not in Remission 
Complete remission will be defined as all of the following according to the revised 
recommendations of the international working group:52 
 
A bone marrow aspirate containing spicules with < 5% blasts with a count of at 
least 200 nucleated cells and no Auer rods seen.  If spicules are absent in the 
aspirate, a bone marrow biopsy should confirm that < 5% blasts are present. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-3 
 
No evidence of a persistently abnormal leukemic population by flow cytometry. 
 
ANC > 1,000 μL and platelet count > 100,000 μL. 
 
No extramedullary leukemia. 
 
No blasts in peripheral blood. 
3. Chronic Myelogenous Leukemia at the following stages: 
 Chronic Phase: 
o Stable, not hematologic remission: blasts present in marrow and/or PB, but 
disease does not qualify as accelerated or blast phase 
o Hematological remission: no blast cells or precursor cells in the blood or marrow 
o Partial cytogenetic remission: Ph+ metaphases >0% but < 35% 
o Complete cytogenetic remission: absence of Ph+ metaphases 
 Accelerated Phase - any one of the following symptoms: 
o WBC difficult to control (> 50 x 109/L despite therapy) 
o Rapid doubling of WBC (< 5 days) 
o ≥ 10% blasts in blood or marrow 
o ≥ 20% blasts and/or promyelocytes in blood or marrow 
o ≥ 20% basophils and/or eosinophils in blood 
o Anemia or thrombocytopenia unresponsive to standard treatment 
o Persistent thrombocytosis (> 1000 x 109/L) 
o Cytogenetic abnormalities in addition to Ph+ 
o Increasing splenomegaly 
o Marrow fibrosis 
 Blast Phase: 
o More than 30% blasts and/or promyelocytes in blood or bone marrow 
o More than 20% blasts 
4. Myelodysplastic syndromes at the following stages: 
 
Refractory anemia 
 
Refractory anemia with ringed sideroblasts 
 
Refractory cytopenia with multilineage dysplasia 
 
Refractory cytopenia with multilineage dysplasia and ringed sideroblasts 
 
Refractory anemia with excess blasts-1 (5-10% blasts) 
 
Refractory anemia with excess blasts-2 (10-20% blasts) 
 
Myelodysplastic syndrome, unclassified 
 
MDS associated with isolated del (5q) 
5. Myeloproliferative diseases: 
 Chronic Myelomonocytic Leukemia 
 Agnogenic Myeloid Metaplasia with Myelofibrosis (Idiopathic Myelofibrosis) 
 Juvenile Myelomonocytic Leukemia 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-4 
6. Patients with therapy-related AML or MDS whose prior malignancy has been in 
remission for at least 12 months.  If the remission is less than 12 months, Medical 
Monitor or Protocol Chair approval is required. 
7. Signed informed consent 
8. Age range: 0.00-66.00 years 
9. Transplant Center location in the United States (U.S.) or Canada 
 
2.3.2. Patient Exclusion Criteria 
 
1. Patients with prior allogeneic or autologous transplants using any hematopoietic stem cell 
source will be excluded from this trial.  Patients with secondary malignancies who have 
had a prior autologous transplant will be eligible.  The prior autologous transplant must 
have been performed for the primary malignancy (such as lymphoma) and must have 
occurred 12 or more months prior to enrollment. 
2. Diseases to be excluded are: lymphoma (11% of 2001 NMDP transplants), other 
malignant disorders (6%), and non-malignant disorders (9%).  The diseases are excluded 
because they are rarely transplanted or are most often transplanted using reduced 
intensity regimens. 
 
2.4. 
Additional Patient Exclusion Criteria for Transplant Conditioning 
 
1. HIV infection 
2. Pregnancy (positive serum β-HCG) or breastfeeding  
3. Creatinine or bilirubin or ALT or AST greater than two times the upper limit of normal 
for the laboratory, whatever the etiology of the abnormal test except for isolated 
hyperbilirubinemia attributed to Gilbert’s Syndrome 
4. Pulmonary disease with FVC, FEV1 or DLCO parameters < 45% predicted (corrected for 
hemoglobin) or O2 saturation < 92% of room air 
5. Cardiac insufficiency or coronary artery disease requiring treatment 
6. Active infection requiring systemic antibiotic therapy with antibacterial, antifungal or 
antiviral agents 
7. Concomitant enrollment on Phase I study 
8. Patients with prior malignancies except resected basal cell carcinoma or treated 
carcinoma in-situ.  Cancer treated with curative intent < 5 years previously will not be 
allowed unless approved by the Medical Monitor or Protocol Chair.  Cancer treated with 
curative intent > 5 years previously will be allowed.  This criteria does not apply to 
patients with therapy-related AML or MDS as this is discussed above in Section 2.3.1, 
item 8. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-5 
2.5. 
Donor Selection Criteria 
 
The evaluation of donors shall be in accordance with existing NMDP Standards Policies and 
Procedures.  All donors shall meet the health criteria for both marrow and PBSC donation. 
 
2.5.1. Donor Inclusion 
 
1. Matched for HLA-A, B and DRB1 antigens 
 One antigen mismatch at HLA-A, B or DRB1 is acceptable with or without mismatch 
at HLA-C 
 Typing is by DNA techniques: intermediate resolution for A, B and C, and high 
resolution for DRB1.  HLA-C typing is mandatory but will not count in the match. 
2. Signed informed consent.  Donor must consent to both bone marrow harvest and G-CSF 
administration with apheresis.  Donor must provide written informed consent to 
randomization for either marrow or PBSC collection. 
3. Donor must have adequate peripheral venous access for leukapheresis or must agree to 
placement of a central catheter. 
4. Donor center affiliation with NMDP. 
5. Donor must be 18 years of age or older. 
6. General donor inclusion criteria specified in the Donor Companion Manual. 
 
2.5.2. Donor Exclusion 
 
1. Females who are pregnant (positive serum β-HCG) or uninterruptible breastfeeding 
2. Known allergy to G-CSF or to E. Coli-derived recombinant protein products 
3. History of autoimmune disorders 
4. History of deep vein thrombosis or venous thromboembolism 
5. History of iritis or episcleritis 
6. History of serious adverse reaction to anesthesia 
7. Thrombocytopenia (platelets < 150,000 per mcL) at baseline evaluation 
8. Current treatment with lithium 
9. Presence of sickle hemoglobin as demonstrated by appropriate testing such as 
hemoglobin electrophoresis 
10. Donors receiving experimental therapy or investigational agents 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-6 
2.6. 
Treatment Plan 
 
2.6.1. Conditioning Regimens 
 
Four broad groups of conditioning regimens will be included in the protocol: 
1. Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at 
least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI. 
2. Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg 
busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a 
targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL 
at steady state and at least 120 mg/kg cyclophosphamide. 
3. Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of 
least 120 mg per m2 and a melphalan dose of at least 140 mg per m2. 
4. Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a 
fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 
busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG.  
Institutional standards should be followed for targeting plasma levels. 
 
2.6.1.1. 
Additional drugs 
 
Additional drugs including anti-T cell antibodies may be added at the transplant center’s 
discretion with the exception of Alemtuzumab (Campath-1H) because of the impaired immune 
reconstitution and increased mortality observed with Alemtuzumab in combination with post-
grafting cyclosporine and methotrexate that will be employed in this study (53). 
 
2.6.1.2. 
Choice of conditioning regimen 
 
Transplant centers may use different regimens for patients with different diseases as required by 
institutional protocol.  However, the transplant center must declare before randomization what 
conditioning regimen and GVHD prophylaxis regimens will be used for each patient.  The 
specified regimens will be used for the patient whether randomized to receive PBSC or marrow, 
unless there is approval from the Protocol Chair to alter the regimen. 
 
2.6.1.3. 
Order of administration of cyclophosphamide and TBI 
 
The order of administration of cyclophosphamide and TBI is at the discretion of the transplant 
center.  Within each institution, all patients should receive the cyclophosphamide and TBI in the 
same order.  If cyclophosphamide is given last, there should be at least a one-day rest period 
before the marrow or PBSC infusion. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-7 
2.6.1.4. 
TBI administration 
 
Fractionated TBI will be administered according to the schedules utilized by the participating 
clinical centers.  Radiation sources, dose rates, details of lung shielding, and sites receiving boost 
radiation will also be defined by the institution.  TBI may be delivered from either linear 
accelerator or Cobalt sources.  Lung shielding is preferred but not required during TBI.  For 
institutions using lung shielding, an electron boost to the chest wall should be used, if necessary, 
to achieve a rib dose within the desired therapeutic range. 
 
2.6.1.5. 
Cyclophosphamide administration 
 
Cyclophosphamide will be administered intravenously.  Mesna is allowed, but not required. 
 
2.6.1.6. 
Cyclophosphamide and busulfan dose adjustments 
 
Cyclophosphamide and busulfan dose adjustments for ideal body weight are recommended, but 
not required. 
 
Ideal Body Weight Formulas: 
 
Patients Over 18 Years 
Males IBW = 50 kg + 2.3 kg/inch over 5 feet 
Females IBW = 45.5 kg + 2.3 kg/inch over 5 feet 
 
Patients 1 to 18 Years of Age 
 
Less than 60 inches 
IBW = (ht2 x 1.65)/1000 where ht = cm, IBW = kg 
 
More than 60 inches 
Males IBW = 39.0 + [2.27 x (ht - 60)] where ht = inches, IBW = kg 
Females IBW = 42.2 + [2.27 x (ht - 60)] where ht = inches, IBW = kg 
 
2.6.1.7. 
Busulfan 
 
Busulfan may be administered either orally or intravenously.  Busulfan dose may be adjusted 
based on drug clearance estimated before or after starting the conditioning regimen. 
 
2.6.1.8. 
Fludarabine 
 
Fludarabine will be administered intravenously at the minimum total dose of 120 mg per m2, 
divided into three or more doses administered once daily.  Fludarabine is not recommended for 
patients with severe renal impairment, i.e., a creatinine clearance (CrCl) less than  
30 milliliters/minute/1.73 square meter (mL/min/1.73 m2).  For patients with moderate renal 
impairment (CrCl of 30 to 70 mL/min/1.73 m2), the fludarabine dose should be reduced by 20% 
to 50% (54).  Fludarabine administration should be dosed based on the patient’s actual body 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-8 
weight.  It is recommended, though not required, that for patients weighing more than 100% of 
their IBW, fludarabine be dosed based on the adjusted ideal body weight (AIBW). 
 
 
Ideal Body Weight Formulas: 
 
See Section 2.6.1.6 
 
 
Adjusted Ideal Body Weight Formula: 
 
AIBW = IBW + [(0.25) x (ABW - IBW)] 
 
2.6.1.9. 
Melphalan 
 
Melphalan will be administered intravenously at the minimum dose of 140 mg per m2. 
 
2.6.1.10. ATG 
 
ATG will be administered at a dose of at least 40 mg/kg equine or 4 mg/kg rabbit.  The Physician 
Desk Reference’s manufacturer’s guidelines should be followed for administration of ATG. 
 
2.6.1.11. Allopurinol 
 
Allopurinol is recommended for patients with high tumor bulk.  A common regimen employs 
allopurinol at the daily dose of 300 mg, beginning at least six hours before the start of 
conditioning and until the day before marrow or PBSC infusion. 
 
2.6.1.12. Intravenous hydration 
 
Intravenous hydration is recommended to prevent tumor lysis syndrome in patients with bulky 
tumor and to prevent hemorrhagic cystitis in patients treated with cyclophosphamide.  Hydration 
should begin at least 12 hours prior to the first dose of chemotherapy and continue for 24 hours 
following the last dose. 
 
2.6.1.13. Testicular irradiation 
 
Testicular irradiation with 400 cGy may be given to male patients with ALL or other acute 
leukemia according to local institutional practice. 
 
2.6.1.14. Central Nervous System prophylaxis 
 
Central Nervous System (CNS) prophylaxis will be given according to institutional practice. 
 
2.6.2. GVHD Prophylaxis Regimen 
 
The choice of GVHD prophylaxis regimen is by institutional preference.  Any regimen or 
protocol may be used, with the exception that Phase I GVHD prophylaxis protocols are not 
allowed.  The regimen and dosing employed must not be dependent on graft source assignment, 
i.e., marrow or PBSC. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-9 
 
The two most commonly used GVHD prophylaxis regimens following unrelated donor 
transplantation are: 
1. Cyclosporine/methotrexate 
2. Tacrolimus/methotrexate 
 
The recommended doses and schedule of administration of cyclosporine, tacrolimus and 
methotrexate are as detailed in Sections 2.6.3 and 2.6.4.  This information is provided only as a 
guideline. 
 
Alternative or additional agents/dosing may be used per institutional preference.  However, the 
use of Phase I agents is prohibited.  
 
The transplant center will declare before randomization what GVHD prophylaxis regimen will 
be used for that particular patient.  The declared regimen must be used whether the patient is 
randomized to receive PBSC or marrow.  There is no requirement for the institution to use the 
same regimen for each subsequent patient enrolled. 
 
2.6.3. Cyclosporine or Tacrolimus Treatment Regimen 
 
Either cyclosporine or tacrolimus is administered beginning at least one day before 
transplantation for a minimum of six months.  The initial dose should be based on the ideal body 
weight of the recipient.  Subsequent doses are based on blood levels (see below).  
Determinations of blood levels should be performed at least once weekly for the initial three 
months.  Dose reductions should be made if toxicity is present or whole blood levels are above 
the recommended range, in the absence of toxicity.  Dose reductions for high levels without 
toxicity should be conservative, e.g. 25%, to avoid inadequate immunosuppression.   
 
If there is nausea and vomiting, the drug should be given intravenously.  Patients with severe 
intolerance of cyclosporine may be placed on tacrolimus and vice versa. 
 
2.6.3.1. 
Taper 
 
Fifty or more days after transplantation, in the absence of GVHD, the dose is slowly tapered over 
a minimum of 20 weeks and discontinued. 
 
2.6.3.2. 
Cyclosporine 
 
The cyclosporine regimen for GVHD prophylaxis will initially employ an intravenous total daily 
dose of 3 mg/kg/day.  Subsequent cyclosporine doses are adjusted to target whole blood levels 
between 150 and 450 nano (n)g/mL. 
 
Oral formulations of cyclosporine have variable bioavailability (intestinal absorption), and 
Neoral appears to have a higher and more predictable bioavailability than other formulations.  
When a patient is switched from intravenous cyclosporine to Neoral (preferred) or other oral 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-10 
formulation, the dose is increased by 2.5-3 fold to adjust for the lower bioavailability of Neoral 
compared to intravenous cyclosporine. 
 
Drugs that may affect cyclosporine levels: 
1. Caspofungin, phenobarbital, phenytoin, rifampin, carbamazepine, rifabutin, St. John’s 
Wort (lowers levels) 
2. Glucocorticoids, fluconazole, voriconazole, ketoconazole, itraconazole, grapefruit juice, 
acetazolamide, amiodarone, amlodipine, amprenavir, bromocriptine, chloramphenicol, 
cimetidine, cisapride, clarithromycin, clotrimazole, danazol, diltiazem, erythromycin, 
ethinyl estradiol, metoclopramide, metronidazole, mibefradil, nefazodone, nelfinavir, 
tacrolimus, nifedipine, omeprazole, quinupristin/dalfopristin, ritonavir, saquinavir, 
theophylline, troleandomycin, verapamil (increases levels) 
Per the voriconazole package insert, when initiating therapy with voriconazole in patients 
already receiving cyclosporine, it is recommended that the cyclosporine dose be reduced to one-
half of the original dose and followed with frequent monitoring of the cyclosporine blood levels.  
Increased cyclosporine levels have been associated with nephrotoxicity.  When voriconazole is 
discontinued, cyclosporine levels should be frequently monitored and the dose increased as 
necessary (55). 
 
2.6.3.3. 
Tacrolimus 
 
The tacrolimus regimen for GVHD prophylaxis will initially employ an intravenous total daily 
dose of 0.03 mg/kg/day.  Subsequent tacrolimus doses are adjusted to target whole blood levels 
between 5 and 15 ng/mL.  When a patient is switched from intravenous to oral tacrolimus, the 
dose is increased by 3-4 fold to adjust for the lower bioavailability of oral compared to 
intravenous tacrolimus. 
 
Drugs that may affect tacrolimus levels are: 
1. Caspofungin, phenobarbital, phenytoin, rifampin, carbamazepine, rifabutin, St. John’s 
Wort (lowers levels); 
2. Glucocorticoids, fluconazole, voriconazole, ketoconazole, itraconazole, grapefruit juice, 
amprenavir, bromocriptine, chloramphenicol, cimetidine, cisapride, clarithromycin, 
clotrimazole, danazol, diltiazem, erythromycin, ethinyl estradiol, metoclopramide, 
metronidazole, 
mibefradil, 
nefazodone, 
nelfinavir, 
nifedipine, 
omeprazole, 
quinupristin/dalfopristin, ritonavir, saquinavir, theophylline, troleandomycin, verapamil 
(increases levels). 
 
Per the tacrolimus package insert, when initiating therapy with voriconazole in patients already 
receiving tacrolimus, it is recommended that the tacrolimus dose be reduced to one-third of the 
original dose and followed with frequent monitoring of the tacrolimus blood levels.  Increased 
tacrolimus levels have been associated with nephrotoxicity.  When voriconazole is discontinued, 
tacrolimus levels should be carefully monitored and the dose increased as necessary.(55) 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-11 
2.6.4. Methotrexate Treatment Regimen 
 
The regimen of methotrexate for GVHD prophylaxis will employ intravenous doses of 15 mg per 
m2 on Day 1 post-transplant, and 10 mg per m2 on Days 3, 6, and 11 post-transplant.  The dose of 
methotrexate may be decreased per institutional standard practice to no less than 5 mg per m2 on 
Days 1, 3, 6, and 11 post-transplant.  Third space syndromes with large accumulation of ascites 
or pleural effusions are a contraindication to the use of methotrexate.  Dose reductions should be 
made for renal, hepatic and mucosal toxicity.  Determinations of blood levels are indicated 24-72 
hours after administration in patients with impaired renal function.  Leucovorin rescue should be 
considered in patients with decreased clearance, severe toxicity or fluid accumulation/effusions. 
 
Drugs that may increase methotrexate levels are: 
1. Non-steroidal anti inflammatory drugs 
2. Penicillins 
3. Diuretics 
 
2.6.5. PBSC Mobilization and Collection 
 
2.6.5.1. 
G-CSF Administration to Donors 
 
G-CSF (filgrastim, Amgen) will be administered to the donor at a dose of ~10 mcg/kg/day 
subcutaneously for 5 consecutive days.  Daily dose shall not exceed 1200 mcg/day, and volume 
per injection site shall not exceed 2.0 mL.  G-CSF will be administered at approximately the 
same time each day for the first four days.  The fifth dose should be given at least one hour prior 
to apheresis.  There will be no additional, sixth dose of G-CSF in cases where a second PBSC 
collection is performed on Day 6.  See Donor Companion Manual for G-CSF dose calculation 
and dose modification. 
 
2.6.5.2. 
PBSC Collection and Evaluation 
 
Apheresis shall begin on Day 5 of G-CSF administration. 
 
Apheresis Devices and Central Catheters - Apheresis shall be accomplished using a continuous-
flow apheresis device.  Bilateral peripheral venous access will be used whenever possible.  
Donors with insufficient peripheral access may undergo placement of a central venous catheter.  
Central catheters should be inserted on the day of collection. 
 
Anticoagulation - A citrate based anticoagulant such as acid citrate dextrose formula A (ACD-
A) should be used unless there is a contraindication or sensitivity to this agent.  Mononuclear cell 
apheresis collections are generally performed using citrate: whole blood ratios of 1:12 to 1:13.  If 
a citrate to whole blood ratio of less than 1:13 is used, then additional ACD-A may be added to 
the component bag, either during apheresis or immediately after the procedure is completed. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-12 
CD34 Cell Dose - Typical requested CD34 cell doses are between 5-10 x 106 per kg recipient 
body weight.  Quantitation of the CD34 cell content of the product by the Apheresis Center on 
the day of apheresis is required. 
 
Volume Processed – The volume processed shall be linked to the actual weight of the recipient 
as follows.  For recipients weighing less than or equal to 35 kg, a single 12-liter apheresis shall 
be performed.  For recipients weighing greater than 35 kg, the volume processed shall be 15 to 
24 liters.   
 
Single larger volume procedures are encouraged whenever possible.  In a prospective 
randomized study, a single 25-liter PBSC collection yielded the same number of CD34 cells as 
two consecutive daily 15-liter procedures, and was associated with a marked reduction in 
inconvenience and discomfort for the donor (56).  The following table provides a guide to 
volume processed by weight of recipient.  Volume processed refers to true whole blood volume, 
not including anticoagulant (see Table 2.6.5). 
 
 
Table 2.6.5:  Blood Volume Processed in Relation to Recipient Weight 
 
Recipient 
Weight (kg) 
Volume 
Processed (L) 
Procedure 
≤ 35 
12 
Single 12-liter apheresis 
36 - 45 
15 
Single 15-liter apheresis 
46 -55 
18 
Single 18-liter apheresis or two 12-liter procedures 
56 - 65 
22 
Single 22-liter apheresis or two 12-liter procedures 
> 65 
24 
Single 24-liter apheresis or two 12-liter procedures 
 
 
Alternatively, centers may use an immediate pre-procedure blood CD34 cell count to determine 
the blood volume to be processed.  If such calculations are used, the transplant center requested 
CD34 cell dose should be targeted as the minimum dose.  If the requested dose is collected in the 
first apheresis procedure, a second collection will not be performed. 
 
Prevention of Citrate Toxicity - Apheresis procedures in which greater than 12 liters of blood 
are processed should incorporate a method to prevent severe citrate toxicity.  Such methods 
could include either (1) use of continuous infusion or intermittent bolus heparin administration, 
allowing use of lower citrate infusion rates, or (2) use of continuous infusion or bolus calcium 
salts (calcium chloride or calcium gluconate) (57).  Please refer to the Donor Companion Manual 
for suggested algorithms for heparin or calcium salt administration. 
 
Heparin should not be used in procedures requiring central venous catheter placement. 
 
Product Volume and Sampling - The product should have a minimal volume of 200 mL.  A 1.0 
mL sample for CBC should be obtained by the Apheresis Center from the long tubing tail 
attached to the bag. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-13 
Processing, Storage and Shipment - If more than one PBSC procedure is performed, the first 
collection will be stored at 2-8o C overnight.  No processing or freezing of the PBSC product 
shall be done by the apheresis facility.  The transportation of PBSC components shall be in 
accordance with NMDP Standards.  Products will be shipped in an NMDP-approved container 
that is charged with cold packs or similar material to provide an initial ambient temperature of  
2-8 o C.  Dry ice shall not be used. 
 
PBSC components will be infused within 12 hours of arrival at the Transplant Center. 
 
Sample Collection - Each collection will be separately evaluated by the central reference 
laboratory for cellular composition in keeping with Appendix C and the BMT CTN Manual of 
Procedures (MOP) for graft characterization. 
 
Records - Records of donation shall be maintained in accordance with NMDP Standards and 
shall include: 
1. Evaluation of donor health 
2. Dose of G-CSF administered per day 
3. Volume and type of anticoagulant administered 
4. Additional anticoagulant added to component 
5. Volume of blood processed, total cell and differential count in product 
6. Pre and post apheresis donor CBCs 
7. Details of storage and shipping 
 
2.6.6. Marrow Collection 
 
Donors randomized to the marrow arm will have marrow harvested on Day 0. 
 
Anesthesia - Either general or regional (epidural, spinal) anesthesia may be used. 
 
Anticoagulation of the Marrow Product - Reagents used, including salt solutions and 
anticoagulants, shall be approved by FDA or similar regulatory agency for human infusion.  
Recommended anticoagulation techniques are 10 U/mL of preservative-free heparin or 10% 
(volume/volume) ACD-A or a combination of both.  Anticoagulants to be used shall be agreed 
upon by the donor and transplant centers before initiation of the transplant conditioning regimen. 
 
Volume and Cell Dose - Requested marrow cell dose will be 4 x 108 nucleated cells per kg of 
recipient body weight.  This dose will be unattainable for many recipients because of donor 
and/or recipient factors, e.g., body size mismatches.  The volume of marrow shall not exceed  
20 mL per kg donor weight.  The estimated cell dose and a planned donor marrow volume shall 
be agreed upon by the donor and transplant centers before initiation of the transplant 
conditioning regimen. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-14 
Blood Product Support - Donors shall store blood for autologous use in accordance with existing 
NMDP Standards. 
 
The transfusion of autologous or homologous blood should be in accordance with appropriate 
medical practice.  Homologous blood, if used, shall be irradiated to 2500 cGy. 
 
Processing of Bone Marrow Products - No processing of bone marrow, other than 
anticoagulation, filtration, packaging, and labeling in preparation for transportation, shall be 
performed by the collection center.  Processing of bone marrow for reduction of volume, plasma, 
red blood cells, or fat, may be performed by the transplant center. 
 
Shipping of Bone Marrow - The transportation of bone marrow shall be in accordance with 
NMDP Standards.  Products will be shipped in an NMDP-approved container that is charged 
with cold packs or similar material to provide an initial ambient temperature of  
2-8 o C.  Dry ice shall not be used. 
 
The marrow will be infused within 12 hours of arrival at the Transplant Center. 
 
Sample Collection - Each collection will be separately evaluated by the central reference 
laboratory for cellular composition in keeping with Appendix C and the BMT CTN Manual of 
Procedures (MOP) for graft characterization. 
 
Records - Records of donation shall be maintained in accordance with NMDP Standards and 
include: 
1. Evaluation of donor health 
2. Volume and type of anticoagulant added to component 
3. Volume of marrow, total cell and differential count in product 
4. Pre and post marrow harvest donor CBCs 
5. Details of storage and shipping 
 
2.6.7. PBSC or Marrow Infusion 
 
All patients will receive unmodified G-CSF mobilized PBSC or marrow on Day 0 with the 
following exceptions: plasma and red cell depletion are allowed for volume reduction or ABO 
incompatibility.  CD34 cell selection or T cell removal are not allowed.  PBSC or marrow is 
infused via a central venous catheter using standard blood infusion tubing. 
 
There is no minimum cell dose for CD34 cells or nucleated cells in either arm.  Similarly, there 
is no maximum cell dose.  It is recommended that all products are infused entirely, but this is not 
required.  Non-infusion of portion of the products will be documented.  No portion of the donor 
marrow or PBSC should be cryopreserved if the CD34 cell count is < 5 x 106 per kg recipient 
weight. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-15 
In the case that there is an unexpected change in the recipient’s condition and the PBSC or 
marrow harvest cannot be cancelled, the transplant center is required to obtain an approval from 
the NMDP prior to cell cryopreservation.  The patient and donor remain on study even if the 
transplant does not occur.   
 
2.6.8. No Blinding of Marrow and PBSC Infusions 
 
Rationale for Blinding - There are at least theoretical concerns that knowledge of the type of the 
stem cell product infused may influence the decision-making process of clinicians and nurses at 
the participating transplant centers.  Patient knowledge may have an impact as well.  This can 
introduce bias in the evaluation of transplant outcomes of interest.  This could be avoided by 
stem cell manipulation (ordinarily at the collection center) aimed at making the two products 
indistinguishable upon infusion and asking recipients to agree via the consent form to refrain 
from asking about the product type.  This was seemingly accomplished in at least one single-
center study (58). 
 
Logistical Challenges - There are logistical challenges translating what was successfully carried 
out at a single center into procedures followed by many donor and transplant centers.  More 
importantly, blinding requires manipulation of the graft product and any additional stem cell 
manipulation introduces the potential for cell loss, clerical errors and infusion-related adverse 
events.  The related risks for patients are hard to justify.  Therefore, while acknowledging that 
blinding may be desirable, the decision was made not to pursue blinding in this Phase III study. 
 
2.6.9. PBSC Collection or Marrow Harvesting for Additional Stem Cell Products 
 
In the event of primary or secondary graft failure, additional PBSC collection or marrow 
harvesting from the original donor may be requested by transplant centers following established 
NMDP policies.  The selection of PBSC or marrow for the second transplant is not bound to the 
randomization arm; it is the choice of the transplant center physician, and requires donor consent.  
If the same donor is selected, no less than 21 days should elapse between the two donations.  If 
the donor is unwilling or unavailable for a second PBSC or marrow collection, alternative 
management strategies including transplantation from a second donor must be considered by the 
treating physician at the transplant center. 
 
2.6.10. Supportive Care 
 
All supportive care will be given in keeping with BMT CTN MOP and local institutional 
practice. 
 
2.6.11. Growth Factors 
 
It is recommended that patients not receive post-transplant growth factors before Day 21, except 
in the case of serious infection where hastening neutrophil recovery by 1-3 days may be critical 
for survival.  If a transplant center chooses to give growth factors prior to Day 21 post-transplant, 
they should be given to all patients, regardless of whether receiving bone marrow or peripheral 
blood stem cells.  After Day 21, G-CSF or granulocyte-macrophage colony stimulating factor 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-16 
(GM-CSF) should be given for severe neutropenia (ANC < 500/mcL), or as necessary to keep 
ANC > 1000/mcL. 
 
2.6.12. Blood Products 
 
Transfusion thresholds for blood product support will be consistent with BMT CTN MOP and 
standard institutional guidelines.  All cellular blood products will be irradiated.  Patients who are 
CMV negative will receive CMV negative or filtered blood products from study entry. 
 
2.6.13. Prophylaxis against Infections 
 
All patients will receive prophylaxis against bacterial, fungal and viral infections during the 
peritransplant period according to the BMT CTN MOP.  This will include: 
1. Anti-bacterial prophylaxis: In keeping with the BMT CTN MOP and local institutional 
standards for allogeneic transplants.  Prophylactic antibacterial antibiotics should be used 
for patients during the neutropenic (ANC < 500/mcL) period. 
2. Pneumocystis carinii: Prophylaxis will start at the time of engraftment or on Day 30 post-
transplant according to institutional preference.  Prophylaxis should be continued until 
immunosuppressive drugs are discontinued. 
3. Antifungal therapy: In keeping with the BMT CTN MOP and local institutional standards 
for allogeneic transplants. 
4. HSV/VZV: Prophylaxis will begin with conditioning therapy and continue up to one year 
post-allograft as directed by standard institutional practice. 
5. CMV: Monitoring and preemptive treatment strategy will be in accordance with the BMT 
CTN MOP and local institutional practice. 
 
2.6.14. Intravenous Immune Globulin (IVIG) 
 
IVIG administration will be left to local institutional standard practice. 
 
2.6.15. Failure to Engraft 
 
If the ANC has not reached 500/mcL by Day 21, G-CSF, GM-CSF or other cytokines may be 
utilized. If the ANC is < 100/mcL on Day 28 post-transplant, the patient should be considered for 
a second infusion of stem cells from the original donor or retransplantation from a different 
donor using appropriate Transplant Center protocols. 
 
2.6.16. Post-transplant Donor Leukocyte Infusions (DLI) 
 
DLI may be given to patients for a recurrent or a second malignancy according to institutional 
practice and in accordance with the NMDP policy, if the donor is available and provides consent.  
The use of DLI will be recorded and analyzed as a secondary endpoint. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
2-17 
2.6.17. Risks and Toxicities 
 
Recipients of marrow or PBSC transplants incur risks from pre-transplant conditioning, the graft 
itself, and post-transplant therapies.  All risks must be weighed against the risk of the malignancy 
for which the transplant is prescribed.  Major risks following transplantation include: 
1. Damage of any major organ may occur as a result of cumulative toxicity from anti-
neoplastic therapy, the conditioning regimen, drug toxicity, infection, or GVHD. 
2. Graft failure can result from genetic disparity between donor and recipient, insufficient 
immunosuppression of the recipient or poor cell dose. 
3. GVHD can be either acute or chronic; both types predispose to infection. 
4. Life-threatening infections may develop in patients with and without GVHD. These can 
be of a bacterial, viral, parasitic, or fungal nature. 
5. Relapse of the underlying disease may occur, especially in patients with far advanced 
disease status at time of transplant. 
6. All of these toxicities may be severe enough to result in death. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
3-1 
CHAPTER 3 
 
 
3. STUDY ENDPOINTS 
 
3.1. 
Primary Endpoint 
 
The primary endpoint is two-year survival from the time of randomization after two years of 
follow-up.  The event analyzed is death from any cause.  Patients alive at the time of last 
observation will be censored. 
 
3.2. 
Secondary Endpoints 
 
3.2.1. Two-Year Post-transplant Survival  
 
The endpoint is two-year survival from time of transplant.  Only patients who receive their 
transplant are included.  The event analyzed is death from any cause.  Patients alive at the time of 
last observation will be censored. 
 
3.2.2. Neutrophil Engraftment > 500/mcL 
 
This is defined as achieving ANC > 500/mcL for three consecutive measurements on different 
days.  The first of the three days will be designated the day of neutrophil engraftment.  This 
endpoint will be evaluated through 100 days. 
 
3.2.3. Primary Graft Failure 
 
This is defined by lack of neutrophil engraftment by 100 days in patients surviving a minimum 
of 14 days. 
 
3.2.4. Secondary Graft Failure 
 
This is defined by initial neutrophil engraftment followed by subsequent decline in neutrophil 
counts < 500/mcL unresponsive to growth factor therapy. 
 
3.2.5. Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent 
 
This is defined as achieving platelet counts > 20,000 and 50,000/mcL for consecutive 
measurements over seven days without requiring platelet transfusions.  The first of the seven 
days will be designated the day of platelet engraftment.  This endpoint will be evaluated through 
100 days. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
3-2 
3.2.6. Acute GVHD of Grades II-IV and III-IV 
 
Acute GVHD is graded according to the BMT CTN MOP.  The first day of acute GVHD onset at 
a certain grade will be used to calculate cumulative incidence curves for that GVHD grade (e.g., 
if the onset of grade I acute GVHD is on Day 19 post-transplant and onset of grade III is on Day 
70 post-transplant, time to grade III is Day 70).  This endpoint will be evaluated through 100 
days. 
 
3.2.7. Chronic GVHD 
 
Chronic GVHD is scored according to the BMT CTN MOP.  The first day of chronic GVHD 
onset will be used to calculate cumulative incidence curves. 
 
3.2.8. Current Immunosuppressive (IS) Free Survival 
 
This function is an estimate of the chance that a patient is alive and not receiving 
immunosuppressive therapy at a given point in time for any reason.  This outcome measure takes 
into account subsequent immunosuppressive therapy that may occur following discontinuation of 
initial immunosuppressive therapy.  Patients will be censored for this endpoint at the time of 
relapse.  A similar approach has been used in analyzing the role of DLI following allogeneic 
transplants for CML where relapse is expected to be frequent but subsequent disease control is 
also expected after treatment of relapse with DLI (59).  A multi-state model will estimate this 
with inputs being the patient’s immunosuppressive therapy and survival status at each potential 
examination time.  Immunosuppressive drugs include cyclosporine, tacrolimus, prednisone, 
methotrexate, azathioprine, mycophenolate mofetil, sirolimus, clofazimine, PUVA, anti-
thymocyte globulin, OKT3, daclizumab, basilixumab, visilizumab, infliximab and alemtuzumab. 
 
3.2.9. Relapse of the Original Malignancy 
 
Relapse of Malignancy - Testing for recurrent malignancy in the blood, marrow or other sites 
will be used to assess relapse after transplantation.  For the purpose of this study, relapse is 
defined by either morphological or cytogenetic evidence of AML, ALL, CML, MDS, CMML, 
Myelofibrosis or JMML consistent with pre-transplant features.   
 
Minimal Residual Disease - Minimal residual disease is defined by the sole evidence of 
malignant cells by flow cytometry, or fluorescent in situ hybridization (FISH), or Southern blot, 
or Western blot, or polymerase chain reaction (PCR), or other techniques, in absence of 
morphological or cytogenetic evidence of disease in blood or marrow.  Since the frequency of 
testing for minimal residual disease is highly variable among centers, and the sensitivity is highly 
variable among laboratory techniques, evidence of minimal residual disease will not be sufficient 
to meet the definition of relapse in the context of this study, even if transplant physicians will 
utilize the information to alter therapy.  Data on tapering immunosuppression, infusing donor T 
cells, administering chemotherapy or biological agents to attempt reducing the tumor load will be 
captured in the case report forms. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
3-3 
Acute Leukemia - Relapse will be diagnosed when there is: 
1. The reappearance of leukemia blast cells in the peripheral blood, or 
2. > 5% blasts in the marrow, not attributable to another cause (e.g., bone marrow 
regeneration), or 
3. The appearance of new dysplastic changes within the bone marrow, or 
4. No circulating blasts, but the marrow contains 5-20% blasts, a repeat bone marrow ≥ one 
week later with > 5% blasts is necessary to meet the criteria for relapse, or 
5. The development of extramedullary leukemia or leukemic cells in the cerebral spinal 
fluid. 
 
Chronic Myelogenous Leukemia (CML) -  
 
Hematologic relapse will be diagnosed when: 
1. Immature hematopoietic cells are persistently documented in the peripheral blood, 
or  
2. There is myeloid hyperplasia in the bone marrow in the presence of cytogenetics 
relapse. 
 
Cytogenetic relapse will be diagnosed when:  
1. 50% of the metaphases exhibit the characteristic 9;22 translocation with at least 
ten metaphases analyzed, or 
2. At least one metaphase exhibits the 9;22 translocation on each of two separate 
consecutive examinations at least one month apart, regardless of number of 
metaphases analyzed. 
Myelodysplastic (MDS) and Myeloproliferative Syndromes (include CMML, AMM or 
Idiopathic Myelofibrosis, and JMML) - Relapse will be diagnosed when there is: 
1. Reappearance of pre-transplant morphologic abnormalities, detected in two 
consecutive bone marrow specimens taken at least one month apart, or 
2. Satisfying above criteria for evolution into acute leukemia, or   
3. Reappearance of pre-transplant cytogenetic abnormalities in at least 50% of 
metaphases with at least ten methaphases examined, or 
4. Reappearance of pre-transplant cytogenetic abnormality in at least one metaphase 
on each of two separate consecutive examinations at least one month apart, 
regardless of the number of metaphases analyzed. 
Relapse will be defined to occur in the absence of the evidence above if specific therapy, 
such as infusion of donor lymphocytes, use of interferon, or second transplant, is initiated 
for relapse reversal. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
3-4 
 
3.2.10. Donor Lymphocyte Infusion (DLI) 
 
The indication for DLI will be collected, i.e., treatment of relapse of the original malignancy, 
treatment of a new malignancy, boost for immune reconstitution, reversal of graft failure, or 
others.  Pretreatment of the recipient with chemotherapy or irradiation will be recorded.  
Pretreatment of the donor with G-CSF will be recorded. 
 
3.2.11. Infections 
 
Microbiologically documented infections will be reported by site of disease, date of onset, 
severity and resolution, if any.  For definitions, see Chapter 6 and the BMT CTN MOP. 
 
3.2.12. Immune Reconstitution 
 
This will be measured in all patients by: 
1. The rate of peripheral blood repopulation by CD3, CD4, CD8 and  T cells, NK cells, 
DC1, DC2, monocytes and B cells. 
2. The rate of blood repopulation by EBV or CMV-specific T cells measured by tetramer 
staining, and response to CMV, tetanus and aspergillus antigens ex vivo. 
3. The rate of blood repopulation with recent thymus emigrants measured by T cell receptor 
excision circle-positive T cells. 
4. The serum levels of immunoglobulin G, A, and M and plasma levels of IL-2 and IL-7. 
5. Hepatitis B, Tetanus, Diphtheria and Pneumococcus antibody titers in response to 
immunization. 
 
3.2.13. Patient and Donor Quality of Life 
 
Details about these endpoints are given in Chapters 7 and 8. 
 
3.2.14. Three-year Survival 
 
The endpoint is three-year survival.  Two separate analyses will be conducted, one from time of 
randomization and one from time of transplant. 
 
3.2.15. Donor Recovery to Baseline Toxicity Scores 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
times will be employed for baseline toxicity recovery to baseline endpoints.  
 
3.2.16. Donor Recovery to Baseline CBC and WBC Differential Values 
 
Appropriate statistical methods to detect trends over the available spectrum of donor follow-up 
time will be employed for baseline CBC recovery to baseline endpoints. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-1 
CHAPTER 4 
 
 
4. PATIENT AND DONOR REGISTRATION, ENROLLMENT AND EVALUATION 
 
4.1. 
Donor Search Initiation 
 
Transplant centers will initiate the donor search by submitting patient demographics, HLA, and 
disease information to the NMDP coordinating center, using standard NMDP forms and 
additional data entry mechanisms developed for this trial.  It is anticipated that 50-90% of the 
patients will have suitable donors identified as defined by HLA type, transplant center donor 
matching preferences, patient age, disease risk, and financial coverage (see step (1) in Figure 
4.1).  It is anticipated that the duration of the search will vary between two months and more than 
one year with a median time of approximately four months. 
 
Figure 4.1 below highlights the event flow for recipients and donors in the trial.  The time scale 
is arbitrary beginning at the top and flowing downward.  Critical steps described in this Section 
are numbered (1) through (10). 
 
 
Figure 4.1 – Study Treatment 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-2 
4.2. 
Approaching Patients About the Study 
 
Typically, transplant physicians first interact with the patient in a consultation session either 
before or, more likely, after initiation of the donor search, and in rare cases after a suitable donor 
has been identified.  During the initial consultation session, physicians explain the risks and 
benefits of transplant approaches and alternative therapies.  They also explain transplant 
modalities including the potential sources of hematopoietic cells for transplantation.  In such a 
setting, it will be appropriate for transplant physicians to approach eligible patients about their 
potential interest in the randomized trial of PBSC versus marrow transplantation.  Since most 
patients are affected by serious, rapidly progressing diseases and must proceed to transplantation 
as soon as possible, approaching patients for study participation at this stage will avoid ‘last 
minute’ pressure to obtain patient informed consent, and allow the required donor and patient 
procedures to be scheduled as soon as a suitable donor is identified. 
 
4.3. 
Screening for Patient Eligibility 
 
Transplant center physicians will evaluate the patient eligibility for randomization onto this study 
(Section 2.3).  For patients who cannot be seen at the transplant center, data to satisfy eligibility 
criteria will be obtained through direct communication with the patient and the patient's 
physician.  Patients that are not eligible will proceed off study and no further follow-up will be 
obtained. 
 
4.4. 
Patient Consent to Randomization 
 
Eligible patients who would like to participate in the trial will sign the appropriate Institutional 
Review Board (IRB) approved form, providing evidence of informed consent to proceed to 
randomization to PBSC or marrow, contingent upon finding a suitable donor willing to 
participate in the trial (see step (2) in Figure 4.1).  Patients will be informed that participation is 
dependent upon donor willingness to be randomized and upon the patient meeting specified 
eligibility criteria immediately prior to start of conditioning.  Alternate approaches in the event 
that either of these criteria is not met will be explained.  Patients who cannot travel to the 
transplant center because of medical contraindications or other reasons will be counseled by 
phone and will be allowed to mail the signed consent form.   
 
4.5. 
Patient Refusal 
 
Patients who decline randomization on this study will proceed towards transplant off study.   
 
4.6. 
Donor Selection and Work-Up 
 
As suitably matched donors are identified, the transplant center is notified. The transplant 
physician selects the best donor for the patient and requests donor ‘work-up’. Donor ‘work-up’ 
consists of a physical evaluation and an information session (see step (3) in Figure 4.1).  
Selection of the best donor occurs before the donor is approached for participation in this study. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-3 
4.7. 
Donor Deferral 
 
If a candidate donor is found unsuitable to donate, an alternative donor will be sought. 
 
4.8. 
Donor Consent 
 
During the donor information session, the donor center physician explains the cell harvest 
procedures to the candidate donor.  Donors for patients who have consented to this study will be 
asked to participate in the study at this time (see step (4) in Figure 4.1).  Donors will express 
their consent to participate by signing an IRB-approved consent form.  Documentation of donor 
consent, as well as documentation of donor eligibility, will be recorded on the Donor Form in 
AdvantageEDC by NMDP staff. 
 
4.9. 
Donor Refusal 
 
If a donor refuses to participate in the study, the patient will be off study.  The donor will be 
asked to donate either marrow or PBSC, according to transplant physician preference and 
standard NMDP policies.  
 
4.10. Transplant Protocol Registration 
 
Before randomization occurs, the transplant center must state through AdvantageEDC which 
conditioning regimen and GVHD prophylaxis regimen will be used (see step (5) in Figure 4.1).  
Such a registration step will avoid potential biases that preferential association of a certain 
regimen with one treatment arm could confer to the study.  At this stage, the transplant center 
will also verify that the patient is still a candidate for transplantation, is eligible for the trial and 
has consented to participate in the trial.  This data will be entered on the Enrollment Form in 
AdvantageEDC. 
 
4.11. Randomization 
 
Once both patient and donor are deemed eligible and have given written informed consent, and 
the transplant center has confirmed patient eligibility and registered the patient’s conditioning 
and GVHD prophylaxis regimens, randomization occurs (see step (6) in Figure 4.1). 
 
4.12. Treatment Scheduling 
 
Once the randomization arm is known, a transplant calendar is negotiated between the search-
coordinating unit, donor center and transplant center, and the transplant date is scheduled (see 
step (7) in Figure 4.1).  It is anticipated that 2-3 weeks will elapse between the randomization 
and the day of cell harvest and transplant.  This period is necessary to schedule the marrow or 
PBSC harvest.  During this period, donors may donate and store up to 3 autologous red cell units, 
if randomized to marrow, or receive G-CSF injections, if randomized to PBSC.  During this 
period, transplant center physicians will complete the patient evaluation. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-4 
4.13. Patient Evaluation 
 
The patient pre-transplant evaluation will be completed within four weeks of initiation of 
conditioning (see steps (8) and (9) in Figure 4.1).  This step is necessary because patient organ 
function, infection status and status of malignancy may vary over time.  This evaluation will 
protect patients with a new contraindication to transplant from initiating transplant therapy at an 
unsafe time.  Results of the pre-transplant evaluations as outlined in Section 4.15.4.1 will be 
entered on the Baseline Form in AdvantageEDC. 
 
4.14. Patient Deferral 
 
Patients who meet exclusion criteria will be deferred.  One option is remaining on study and 
rescheduling the transplant when eligibility criteria are again met, for example after clearance of 
a serious infection.  Another option is proceeding to transplant or other treatment off study, if 
that is the best treatment option determined by the transplant physician for the patient.  Patients 
deferred will continue to be followed for the primary endpoint. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-5 
 
4.15. Study Monitoring 
 
A visit schedule based on transplant date is displayed for printing in AdvantageEDC and is 
referred to as ‘Follow-up Schedule.’ 
 
Table 4.15:  Follow-Up Schedule 
 
Study Visit 
Target Day Post-Transplant 
1 week 
7  2 days 
2 week 
14  2 days 
3 week 
21  2 days 
4 week 
28  2 days 
5 week 
35  2 days 
6 week 
42  2 days 
7 week 
49  2 days 
8 week 
56  2 days 
60 days 
60  2 days 
9 week 
63  2 days 
10 week 
70  2 days 
11 week 
77  2 days 
12 week 
84  2 days 
13 week 
91  2 days 
14 week 
98  2 days 
100 day 
100 2 days 
4 month 
120  28 days 
6 month 
180  28 days 
7 month 
210  28 days 
9 month 
270  days 
11 month 
330  28 days 
12 month 
365  28 days 
24 month 
730  28 days 
36 month 
1095  28 days 
 
 
4.15.1. Case Report Forms 
 
A description of the forms, the procedures required for forms completion and timeliness of 
submission can be found in the Data Management Handbook and User’s Guide.  Forms that are 
not received within the specified time are considered delinquent.  Transplant Centers can view 
submitted, past due, and expected forms via AdvantageEDC.  A missing form will continue to be 
requested either until the form is reported, or until an exception is granted. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-6 
4.15.2. Reporting Patient Deaths 
 
Recipient death while at the transplant center must be reported to the BMT CTN Data 
Coordinating Center (DCC) within 24 hours of the event.  Death after the patient has left the 
transplant center must be reported within 24 hours of the event notification but no more than 30 
days after the event.  If the cause of death is unknown, it need not be recorded at the time of 
initial reporting.  However, once the cause of death is determined, the form must be updated. 
 
4.15.3. Reporting Serious Adverse Events 
 
4.15.3.1. Patient SAEs 
 
Unexpected, grade 3-5 adverse events (AE) will be reported through an expedited AE reporting 
system.  Unexpected, grade 4-5 AEs must be reported within 24 hours of knowledge of the 
event.  Unexpected, grade 3 AEs must be reported within three business days of knowledge of 
the event.  All grade 3-5 adverse reactions to vaccines should be reported within three working 
days.  Expected AEs will be reported using NCI’s Common Terminology Criteria for Adverse 
Events (CTCAE), Version 3.0 at regular intervals as defined on the Form Submission Schedule. 
 
4.15.3.2. Donor SAEs 
 
Marrow Donors - Reporting of SAEs following marrow donation will be consistent with 
standard BMT CTN procedures.  Serious and unexpected adverse events should be reported 
within three working days, and will include unexpected or life-threatening complications of 
anesthesia, and severe pain, debility, or incapacitation related to mechanical injury during 
marrow harvest.  Other SAEs, including prolonged hospitalization or hospital readmission, will 
be tracked, staged according to CTCAE, and reported on appropriate systems. 
 
PBSC Donors - Reporting of SAEs following G-CSF administration and apheresis donation will 
be consistent with NMDP policies and procedures.  Serious and unexpected adverse events 
should be reported within three working days, and will include complications of central line 
placement, and severe or life-threatening reactions to G-CSF administration or apheresis.  The 
Data and Safety Monitoring Board will receive summary reports of all adverse donor 
experiences on at least an annual basis. 
 
4.15.4. Patient Assessments 
 
Table 4.15.4 summarizes patient clinical assessments over the course of the study. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-7 
 
Table 4.15.4:  Summary of Patient Clinical Assessments 
 
Study Assessments/ 
Testing 
Baseline 
Days Post-Transplant 
7 
14 
21 
28 
35 
42 
49 
56 
63 
70 
77 
84 
91 
98 
180 
210 
270 
330 
365 
730 
1095 
1825 
History, physical exam, 
weight, height, and 
Karnofsky/Lansky 
performance status 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
X 
X 
X 
 
CBC1, differential, platelet 
count, and blood 
chemistries2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
X 
 
 
 
X 
X 
X 
 
Infectious disease titers3 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EKG 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DLCO, FEV1 and FVC 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone marrow aspirate for 
pathology and cytogenetics 
X 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
X 
 
Bone marrow biopsy for 
pathology 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
X 
 
Patient anti-donor 
lymphocyte cross match (in 
mismatched transplants 
only) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chest X-ray 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ß-HCG serum pregnancy 
test (females only) 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GVHD and other morbidity 
assessments4 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
 
 
X 
X 
X 
 
5 mL sample from allograft 
for graft characterization 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5 mL heparinized blood for 
HLA typing 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Blood samples for immune 
reconstitution assays5 
 
 
 
 
0 
 
 
 
 
 
 
 
0 
 
 
0 
 
 
 
0 
0 
 
 
Plasma samples for IL-7 
and IL-2 levels 
 
 
 
 
 
 
 
 
 
 
 
 
0 
 
 
0 
 
 
 
0 
0 
 
 
dT vaccination6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
X 
 
 
 
 
PCV7 vaccination6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-8 
Study Assessments/ 
Testing 
Baseline 
Days Post-Transplant 
7 
14 
21 
28 
35 
42 
49 
56 
63 
70 
77 
84 
91 
98 
180 
210 
270 
330 
365 
730 
1095 
1825 
PPV23 vaccination6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
 
 
 
 
Hepatitis B vaccination6 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
X 
X 
 
X 
 
 
 
 
Serum sample for 
immunoglobulin and 
antibody titers7, 8 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
 
 
0 
0 
0 
 
 
Blood sample for natural 
killer cell receptors 
acquisition ancillary study 
0 
 
 
 
 
 
 
 
 
 
 
 
0 
 
 
0 
 
 
 
0 
 
 
 
Peripheral blood T-cell 
chimerism9 
X 
 
 
 
X 
 
 
 
 
 
 
 
X 
 
 
 
 
 
 
X 
X 
 
 
Patient quality of life 
interviews 
0 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
 
 
 
0 
0 
 
010 
 
1  CBC performed three times weekly from Day 0 until ANC >500 mcL for three days after nadir.  CBC performed twice weekly until Day 28. CBC performed weekly 
after Day 28 until 12 weeks post-transplant. 
2  Blood chemistries include: creatinine, bilirubin, alkaline phosphatase, AST, and ALT.  Blood chemistries performed twice weekly until Day 28. Blood chemistries 
performed weekly after Day 28 until 12 weeks post-transplant. 
3  Infectious disease titers include: CMV,  Hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab),  herpes simplex virus, varicella zoster virus, syphilis, HIV 
and HTLV ½ antibody. 
4  GVHD and other morbidity assessments performed weekly until Day 100 post-transplant. 
5  Immune reconstitution assays include: FACS analysis, tetramer assay, TREC analysis,  and T-cell responses to tetanus, CMV, and Aspergillus antigens, and CBC with 
differential. 
6  Vaccinations should be given ± 1 week of the scheduled date. 
7  Sample for antibody titers should be drawn just before vaccination.  Includes dT antibody titer, S. pneumoniae antibody and opsynophagoctyic titer, Hepatitis B antibody 
titer, and H. influenzae antibody titer. 
8  Quantitative Ig to include IgG, IgM, and IgA. 
9  Recommended, but not mandatory. 
10  Will not be analyzed as part of the randomized trial. 
 
X = Generally performed for transplant patients. 
0  = Required for this study. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-9 
 
4.15.4.1. Pre-Transplant Evaluations 
 
The following evaluations, which are generally performed for transplant eligibility, should be 
determined < 4 weeks before initiation of conditioning therapy: 
1. History, physical examination, height and weight. 
2. Karnofsky or Lansky performance status. 
3. CBC with differential and platelet count, creatinine, bilirubin, alkaline phosphatase, AST, 
ALT. 
4. CMV antibody test, Hepatitis panel (HepB SAb, HepB SAg, HepB Core Ab, HepC Ab), 
herpes simplex virus, varicella zoster virus, syphilis, HIV and HTLV1/2 antibody. 
5. EKG. 
6. DLCO, FEV1, and FVC. 
7. Bone marrow aspirates for pathology and cytogenetics. 
8. If the donor is HLA mismatched, patient anti-donor lymphocyte cross match must be 
performed to rule out donor-directed sensitization (60, 61). 
9. Chest X-ray. 
10. -HCG for serum pregnancy test (for women of childbearing potential). 
11. Heparinized blood sample for post-transplant chimerism assay (recommended but not 
mandatory). 
12. Heparinized blood sample for retrospective HLA typing to the NMDP repository. A 
separate NMDP consent form is used for blood sample acquisition for the NMDP 
repository and HLA typing. 
13. Sample from the marrow or PBSC allograft for graft characterization. 
 
The following evaluations, which are required for this study, should be determined < 4 weeks 
before initiation of conditioning therapy: 
1. Serum for quantification of IgG, IgM and IgA, and antibody titers to diphtheria and 
tetanus. 
2. Blood sample for natural killer cell receptors acquisition ancillary study. 
3. Quality of life survey. 
 
4.15.4.2. Post-Transplant Evaluations 
 
The following evaluations are generally performed for transplant recipients: 
1. History and physical exam to assess GVHD and other morbidity weekly until Day 100 
post-transplant, then at six months, one year and then yearly until three years post-
transplant. GVHD evaluation and grading to be in keeping with BMT CTN MOP. 
2. Data on occurrence of infections will be collected as specified in Chapter 6. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-10 
3. CBC at least three times a week from Day 0 until ANC > 500 mcL for 3 days after nadir 
reached. Thereafter CBC twice per week until Day 28, then weekly until 12 weeks, then 
six months, one year and then yearly until three years post-transplant. 
4. Creatinine, bilirubin, alkaline phosphatase, ALT, AST, twice a week until Day 28 (or 
four weeks) and then weekly until 12 weeks, six months, one year and then yearly until 
three years post-transplant. 
5. Bone marrow aspirate and biopsy to pathology, aspirate to cytogenetics at 12 weeks, one 
year and then yearly until three years post transplant. 
6. dT vaccine at 6 and 11 months post-transplant, Hepatitis B vaccine at 6, 7, and 11 months 
post transplant, PCV7 vaccine at 7 and 9 months post-transplant, and PPV23 vaccine at 
11 months post-transplant.  Vaccinations should be given ±1 week of scheduled date. 
7. Quantification of peripheral blood T cell chimerism at 1, 3, 12, and 24 months post-
transplant (recommended but not mandatory – see Appendix C). 
 
The following evaluations are required for this study: 
1. Heparinized blood for quantification of peripheral blood immune reconstitution at 1, 3, 6, 
12, and 24 months post-transplant. 
2. Serum for quantification of IgG, IgM and IgA, and antibody titers to diphtheria, tetanus, 
and pneumococcus at 6, 11, 12 and 24 months post-transplant.  Serum for antibody titers 
to H. influenzae type B and Hepatitis B at 6, 12, and 24 months post-transplant.  
Antibody titers should be drawn just before vaccination. 
3. Blood sample for natural killer cell receptors acquisition ancillary study at 3, 6, and 12 
months post-transplant. 
4. Quality of life surveys at 6 months, 1 year and 2 years. 
 
4.15.5. Required Observations for Donor  
 
Routine pre-allografting work-up in keeping with NMDP guidelines (see Donor Companion 
Manual for this protocol).  Work-up to include the following evaluations, which are generally 
performed for transplant donors: 
 
Pre-collection Evaluations: 
1. Complete history and physical examination. 
2. HLA typing of heparinized peripheral blood sample to determine compatibility. 
3. Serologic testing for Hepatitis B and C (HBsAg, anti-HBc, anti-HCV), CMV, syphilis, 
HIV1/2 and HTLV I/II. Molecular testing for HIV, HCV, and West Nile virus as 
recommended by the FDA. 
4. Sickle cell trait testing. 
5. ABO Rh blood typing.  In the case of donor-recipient ABO incompatibility, the graft 
should be manipulated according to institutional practices. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
4-11 
6. Heparinized blood samples for HLA typing to NMDP repository.  A separate NMDP 
consent form is used. 
7. Heparinized blood sample for Chimerism assays, if requested by the transplant center 
(not mandatory but recommended). 
8. Baseline toxicity scores, and CBC and WBC differential. 
9. Toxicity scores on each day of G-CSF administration. 
10. Number of autologous units collected prior to marrow donation. 
 
Collection Day Evaluations: 
11. Type and duration of anesthesia, volume of marrow collected, pre- and post-marrow 
donation CBC and WBC differential, and number of autologous units infused. 
12. Pre- and post-leukapheresis CBC and WBC differential and volume of whole blood 
processed. 
13. Toxicity scores on day of collection. 
14. Product CBC. 
 
Post-collection Evaluations: 
15. Toxicity scores post-donation at two days, weekly until donor reports recovery from 
donation, one month, six month, and annually for a minimum of three years. 
16. CBC post-donation at one month, six months, and annually for a minimum of three years. 
 
The following evaluations are required for this study: 
1. Serum for Hepatitis B antibody titer. 
2. Quality of life assessments as specified in Chapter 8. 
3. Blood sample for natural killer cell receptors acquisition ancillary study pre-donation 
(prior to G-CSF if PBSC). 
4. Product sample for cellular composition testing. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-1 
CHAPTER 5 
 
 
5. STATISTICAL CONSIDERATIONS 
 
5.1. 
Study Design 
 
The study is designed as a Phase III, randomized, multicenter, prospective comparative study of 
G-CSF mobilized PBSC versus marrow transplantation in HLA compatible unrelated donors.  
The target enrollment is initially 550 patients, with a provision to increase enrollment to 652 
patients depending on the observed rate of patients dropping out without receiving a transplant. 
 
5.1.1. Accrual 
 
It is estimated that three years of accrual will be necessary to enroll the targeted sample size.  
Both Core and non-Core Centers will enroll patients on this study.  Details of accrual estimates 
follow in the sample size section. 
 
5.1.2. Randomization 
 
All patient-donor pairs who have consented to the randomization as detailed earlier will be 
randomized once the donor has been cleared for donation.  Randomization will be performed in a 
1:1 ratio using random block sizes for the PBSC and marrow arms.  Randomization will be 
stratified by transplant center and by disease risk (see Table 5.4). 
 
5.1.3. Primary Endpoint 
 
The primary endpoint is the two-year survival probability. 
 
5.1.4. Primary Hypothesis 
 
The primary comparison of interest in this study is the two-year survival with PBSC 
transplantation as compared to marrow transplantation.  However, because this is a long-term 
endpoint, a monitoring rule comparing six-month survival between the two arms was put into 
place, to protect patients against unexpected (>10%) differences in six month mortality.  
Therefore, the primary hypothesis, accounting for both the primary comparison of two-year 
mortality as well as the stopping rule for six-month mortality, is a composite hypothesis which 
can be formally stated as: 
 
There will not be a difference in two-year survival with PBSC transplantation as compared to 
marrow transplantation AND the difference in six-month survival between PBSC transplantation 
and marrow transplantation will be ≤ 10%.   
 
The alternative statistical hypothesis is that two-year survival after PBSC versus marrow 
transplantation will differ OR six-month survival after PBSC versus marrow transplantation will 
differ by more than 10%. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-2 
 
5.2. 
Analysis of the Primary Hypothesis 
 
Because the primary hypothesis is a composite hypothesis, the analysis will split the overall type 
I error rate of 5% into 4.5% for the comparison of two-year survival and 0.5% for the 
comparison of six-month mortality.  This weighting reflects the primary interest on the two-year 
comparison.  The resulting procedure will control the overall type I error rate at 5% when there is 
no difference in two-year mortality and the true difference in six-month mortality is  ≤ 10%. 
 
5.2.1. Comparison of Two-year Survival 
 
The standard and experimental therapy arms will be compared using the stratified binomial 
comparison (Mantel-Haenszel test).  All patients who are randomized will be included in the 
analysis based on an intention to treat.  Survival times will be based on time since randomization, 
so that those patients who drop out of the study after randomization but before transplant can still 
be included.  The final analysis will be performed after all patients have been followed for a 
minimum of two years post-transplant.  In addition to this pointwise comparison, Kaplan-Meier 
survival curves will be constructed for each group.  Estimates of the difference between these 
survival curves and confidence bands for these differences will be constructed using the method 
of Zhang and Klein (62).  In the event that there are no significant differences between the two 
arms, a post hoc power analysis will be performed. 
 
5.2.2. Comparison and Interim Monitoring of Six-month Mortality 
 
There will be periodic interim analyses approximately every six months beginning nine months 
after the study opens to test whether the difference in six-month mortality rates is ≤ 10% against 
the alternative that the difference is > 10%.  An allowable difference, for which we would not 
stop early, of 10% is used because NMDP Phase II data indicates a potential for early survival 
differences between PBSC and marrow to dissipate by two years.  For example, Table 1.6.2 
gives an estimated relative risk of PB relative to marrow of 0.6 for the first 100 days followed by 
an estimated relative risk of 1.2 after 100 days.  This would result in a difference of 6.5% at six 
months, which is approximately 0% at two years; the allowable difference of 10% is chosen to 
reflect uncertainty in the Phase II data.   
 
A significance level of 0.5% is allocated to these interim analyses.  The stopping rule will only 
be applied to the estimated 495 patients who actually receive the randomized transplant, rather 
than the intent-to-treat population.  Because there are multiple looks at the data, a Pocock 
stopping boundary will be applied to control the type I error rate.  Therefore, at each interim 
analysis the hypothesis that the difference in six-month mortality rates is less than or equal to 
10% will be tested against the alternative that it is greater than 10%, using a two-sided 
alpha=0.005 level Pocock critical value with interim analysis schedule given in Table 5.2.  This 
test will be done by comparing the Kaplan-Meier estimates of six-month mortality, and using 
Greenwood’s formula for the variance in each group.   
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-3 
The final interim analysis procedure is to stop if  
 
.
222
.3
)
ˆ
ˆ
(
10
.0
|)
6
(
ˆ
)
6
(
ˆ
|
005
.0
2
1
2
1
1






c
p
p
SE
mo
p
mo
p
Z
 
where 
222
.3
005
.0

c
 is the Pocock two-sided stopping boundary with significance level 0.005 
and stopping points given in Table 5.2.   
 
If this hypothesis is rejected, all analyses will be sent to the DSMB for expedited review.  
Operating characteristics of this interim analysis for safety are given below, as a function of the 
true difference in six-month survival (Delta), assuming an exponential survival curve with 55% 
or 55% + Delta survival at six months in the marrow or PB arms, respectively, and assuming 
uniform accrual over three years.  All estimates are based on 10,000 simulations.  As shown, this 
stopping rule will have good power to detect a large difference of 25-30% in six-month 
mortality, but will not stop often for smaller differences that may dissipate by two years. 
 
 
Table 5.2:  Probability of Stopping 
 
Interim Analysis 
1 
2 
3 
4 
5 
  
Accrual Month 
9 
15 
21 
27 
33 
  
Patients Enrolled 
124 
206 
289 
371 
454 
  
Delta 
Probabilities of Stopping 
Total 
15% 
0.6% 
0.5% 
0.8% 
0.8% 
0.9% 
3.6% 
20% 
1.5% 
3.0% 
4.4% 
4.9% 
5.7% 
19.5% 
25% 
4.2% 
11.1% 
14.4% 
15.5% 
14.6% 
59.8% 
30% 
10.7% 
28.1% 
26.8% 
17.9% 
9.5% 
93.0% 
 
 
5.3. 
Sample Size and Power Considerations 
 
Sample size calculations are based on the analysis of the primary endpoint of two-year survival, 
conducted at the 4.5% significance level.  Based on the eligibility criteria, the estimated survival 
for the marrow transplant arm at two years is 35% as detailed in Table 5.3 below.  The study is 
powered to detect a 12.5% difference in the two-year survival of 35% among patients who 
actually receive a transplant.  Because randomization takes place prior to determination of a 
patient’s eligibility for transplant, NMDP experience indicates that between 5-15% of the 
randomized patients in each arm will never receive a transplant.  These patients are typically 
high risk and are assumed to all die within six months.  Therefore, the intent-to-treat populations 
to be compared in the primary analysis are assumed to be a mixture of 85-95% who receive the 
randomized stem cell source, and 5-15% who never receive a transplant.  The resulting two-year 
survival rates for the intent-to-treat populations are given in the table below, as well as the 
powers to detect these differences, for sample sizes of 275 per group (550 total) and 326 per 
group (652 total), and for differences of Delta=10%, 12.5%, and 15%.  A total sample size of 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-4 
550 patients will have 80% power to detect the targeted difference of 12.5% in two-year survival 
rates for a 5% dropout rate using a two-sided binomial comparison with alpha=0.045. 
 
 
Table 5.3:  Power to Reject the Null Hypothesis under Various Scenarios1 
 
 
 
 
Transplanted 
Intention to Treat Population 
Delta 
Source 
  
Population 
5% Dropout 10% Dropout 15% Dropout 
  
Marrow 
2 Yr. Survival 
35.0% 
33.3% 
31.5% 
29.7% 
12.5% 
PB 
2 Yr. Survival 
47.5% 
45.1% 
42.8% 
40.4% 
 
 
Power (N=550) 
80% 
76% 
72% 
  
  
Power (N=652) 
86% 
83% 
80% 
10% 
PB 
2 Yr. Survival 
45.0% 
42.8% 
40.5% 
38.3% 
 
 
Power (N=550) 
61% 
57% 
53% 
  
  
Power (N=652) 
69% 
65% 
61% 
15% 
PB 
2 Yr. Survival 
50.0% 
47.5% 
45.0% 
42.5% 
 
 
Power (N=550) 
92% 
89% 
86% 
 
 
Power (N=652) 
95% 
94% 
91% 
1The table has been simplified for interpretability.  Power calculations are based on a two-sided test. 
 
 
5.4. 
Accrual 
 
This study will accrue patients from U.S. and Canadian Transplant Centers and donors from 
U.S., Canadian, and German Donor Centers, according to the eligibility criteria described in 
Chapter 2.  According to data from NMDP (based on 2002 numbers), there are approximately 
350 patients who would be potentially eligible for this protocol transplanted in 14 non-Pediatric 
Blood and Marrow Transplant Consortium (PBMTC) Core Centers per year.  Assuming an 
enrollment rate of 40%, the Network plans to accrue 140 patients annually from these Core 
Centers.  Among the PBMTC Centers doing at least 6 pediatric or at least 15 total unrelated 
donor peripheral blood or bone marrow transplants a year (N=9 centers), NMDP data indicate 
that there are about 125 potentially eligible for this study a year (70 under the age of 20 years).  
Assuming an enrollment rate of 40%, the Network plans to accrue an additional 50 patients 
annually.  The Network plans to accrue an additional 40 patients a year from non-Core NMDP 
Centers.  In summary, we estimate accruing 190 patients annually from 23 Core Centers and 40 
from 5-8 non-Core centers.  These estimates were corroborated by surveys of Core Centers and 
non-Core Centers asking for the number of unrelated donor transplants done in the 12-month 
period from March 2001-March 2002.  Although, this survey indicated a somewhat higher 
anticipated accrual, we chose to plan the study based on the conservative estimates given above 
because: 1) they are based on real data on actual numbers of NMDP-facilitated transplants in 
these centers; 2) participants may be lost based on either patient unwillingness to participate or 
donor unwillingness to participate; and, 3) about 20% of NMDP-facilitated transplants in the 
U.S. use donors from non-U.S. donor centers.   
 
Given these conservative estimates, it is anticipated that the accrual goal of 550 patients will be 
met in three years (see Figure 5.4 below).  Accrual will be closely monitored.  If necessary, the 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-5 
DCC will identify additional U.S. and Canadian non-Core NMDP Centers that can contribute a 
minimum of three patients per year to the study.  Accrual will also be monitored to ascertain that 
enrolled patients reflect women, minorities and children in proportion to the numbers expected 
based on available NMDP data regarding general unrelated donor transplant recipients.  In 
addition, the rate of patients enrolling in the study and not receiving a transplant will be closely 
monitored and compared with our target rate of 5%.  If the observed rate appears to be as high as 
15%, increasing accrual to up to 652 patients will be considered.   
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-6 
 
Table 5.4:  Outcome of U.S. Unrelated Donor Blood or Marrow Transplants – 1996-2001 
 
Risk 
Stratum 
Disease / 
Stage^ 
N 
100-day 
survival 
1-year 
survival 
2-year 
survival 
3-year 
survival 
4-year 
survival 
5-year 
survival 
# Tx’s 
2001* 
NMDP 
 
 
 
 
 
 
 
 
 
 
Good 
CML-CP 
1097 
75±3 
59±3 
53±3 
50±3 
47±3 
42±4 
61 (10%) 
 
CML-AP/ 
CP2+ 
401 
67±5 
41±5 
31±5 
28±5 
26±5 
22±6 
44 (7%) 
 
AML-CR1 
357 
67±5 
43±5 
36±6 
32±6 
32±6 
32±6 
83 (13%) 
 
AML-CR2 
381 
74±4 
47±5 
40±5 
38±6 
34±6 
33±7 
67 (11%) 
 
ALL-CR1 
287 
73±5 
54±6 
44±6 
41±6 
38±7 
38±7 
42 (7%) 
 
ALL-CR2 
431 
74±4 
46±5 
37±5 
34±5 
33±5 
31±5 
77 (12%) 
 
ALL-CR3 
125 
70±8 
43±9 
33±9 
29±9 
29±9 
25±11 
15 (2%) 
 
MDS-RA 
121 
69±8 
45±9 
42±9 
36±10 
25±11 
25±11 
17 (3%) 
 
MDS-RAEB 
143 
60±8 
36±8 
30±8 
29±8 
27±8 
27±8 
30 (5%) 
 
JCML 
(JMML) 
25 
68±18 
48±20 
43±20 
43±20 
34±22 
34±22 
0 (0%) 
 
MFMM 
37 
59±16 
45±16 
41±17 
41±17 
41±17 
41±17 
7 (1%) 
 
Total Good 
Risk 
3405 
72±2 
50±2 
42±2 
39±2 
37±2 
34±2 
443 (70%) 
 
Poor 
CML-BP 
72 
56±12 
25±10 
15±9 
13±8 
13±8 
9±9 
10 (2%) 
 
AML-CR>2 
38 
45±16 
26±14 
18±12 
18±12 
18±12 
18±12 
6 (1%) 
 
AML-Not in 
CR 
648 
57±4 
23±3 
15±3 
14±3 
12±3 
11±4 
100 (16%) 
 
ALL-Not in 
CR 
275 
48±6 
18±5 
10±4 
9±4 
7±3 
6±3 
50 (7%) 
 
MDS-
RAEBT 
114 
69±9 
39±9 
24±8 
23±8 
21±8 
17±10 
18 (3%) 
 
CMML 
34 
73±15 
25±18 
25±18 
25±18 
25±18 
25±18 
9 (1%) 
 
Total Poor 
Risk 
1199 
56±3 
24±3 
15±2 
14±2 
12±2 
11±3 
193 (30%) 
 
TOTAL 
4604 
68±1 
43±1 
35±1 
33±1 
31±2 
28±2 636 (100%) 
* Includes all NMDP centers, U.S. and non-U.S., core and non-core centers. 
^ Abbreviations: CP = chronic phase; AP = accelerated phase; CR = complete remission; RA = 
refractory anemia; RAEB = refractory anemia with excess blasts; BP = blast phase; RAEBT = 
refractory anemia with excess blast in transformation. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-7 
0
100
200
300
400
500
600
6 mos
12 mos
18 mos
24 mos
30 mos
36 mos
Core
PBMTC
Other
Total
 
Figure 5.4 – Anticipated Patient Accrual 
 
 
5.5. 
Interim Analyses  
 
Interim analyses will be conducted for safety at times coincident with regularly scheduled 
meetings of the National Heart, Lung, and Blood Institute (NHLBI)-appointed Data and Safety 
Monitoring Board (DSMB).  Policies and composition of the DSMB are described in the BMT 
CTN MOP. 
 
Toxicity, adverse experiences, and other safety endpoints will be monitored regularly and 
reported to the DSMB at each interim analysis.  Treatment will be coded for all analyses unless 
the DSMB requests that the code be revealed. 
 
5.6. 
Demographic and Baseline Characteristics 
 
Demographics and baseline characteristics will be summarized for all patients, and for all 
patients who actually receive a transplant.  Between group comparisons will be performed for 
continuous variables via a t-test and for categorical variables, via the chi-square test. 
 
5.7. 
Analysis of Secondary Endpoints 
 
Transplant-related event data will only be collected on patients who actually receive a transplant 
and will use event times calculated from the time of transplantation.  Therefore, these 
comparisons will be made using the actually transplanted populations.  Because of the potential 
for unequal drop out between the two arms, adjustment for covariates will be used to make these 
groups comparable, if necessary.  Covariates to be considered are transplant center, year of 
transplant, preparative regimen, GVHD prophylaxis, recipient characteristics (age, sex, body 
mass index [BMI], race, performance status, diagnosis, disease stage, time from diagnosis to 
transplant, CMV status, comorbid diseases) and donor characteristics (age, sex, BMI, race, CMV 
status and parity), and HLA match.  
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-8 
5.7.1. Two-year Survival among Transplanted Patients 
 
The two-year survival will be compared between patients actually receiving the randomized 
transplant stem cell source, using a stratified Mantel-Haenzel test.  In addition, logistic 
regression may be used to adjust for patient characteristics, which are unbalanced in the actually 
transplanted arms. 
 
5.7.2. Neutrophil Engraftment > 500/mcL 
 
Rates of neutrophil engraftment over time, treating death prior to engraftment as a competing 
risk, will be compared between the two groups using a stratified log-rank test, and the 
cumulative incidence curves will be estimated for each group.  Cox regression will be performed 
to compare the groups after adjusting for covariates, which may be imbalanced due to patient 
dropout. 
 
5.7.3. Platelet Engraftment > 20,000 and 50,000/mcL Transfusion Independent 
 
Rates of platelet engraftment over time, treating death prior to engraftment as a competing risk, 
will be compared between the two groups using a stratified log-rank test, and the cumulative 
incidence curves will be estimated for each group.  Cox regression will be performed to compare 
the groups after adjusting for covariates that may be imbalanced due to patient dropout. 
 
5.7.4. Acute GVHD of Grades II-IV and III-IV 
 
The stratified log-rank test will be used to compare the cumulative incidence of acute GVHD of 
grades II-IV or III-IV by Day 100 between the treatment groups considering death as a 
competing risk.  Cox regression will be performed to compare the groups after adjusting for 
covariates, which may be imbalanced due to patient dropout. 
 
5.7.5. Chronic GVHD 
 
Rates of chronic GVHD, treating death prior to occurrence of chronic GVHD as a competing 
risk, will be compared between the two groups using a stratified log-rank test, and the 
cumulative incidence curves will be estimated for each group.  Cox regression will be performed 
to compare the groups after adjusting for covariates, which may be imbalanced due to patient 
dropout. 
 
5.7.6. Current Immunosuppressive (IS) Free Survival 
 
Patients on either arm may go off IS therapy, and then need to subsequently reinitiate therapy.  
The current immunosuppressive free survival is an estimate of the likelihood that a patient will 
be alive and not on immunosuppressive therapy at any given point in time.  Patients will be 
censored for this endpoint at the time of relapse. 
 
These survival curves will be compared between the two arms of the study across all time points 
using a technique found in Klein et al (63). 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-9 
 
The probability that a patient is alive and off IS therapy at 2, 6, 9, 12, 15, 18, 21, 24, 30 and 36 
months will be estimated.  In the analysis at K months, the numerator for this estimate counts 
patients alive and off IS therapy, and the denominator counts all patients followed to K months, 
regardless of survival status.  These probabilities will be compared using standard tests for 
binomial proportions. 
 
5.7.7. Relapse of the Original Malignancy 
 
Rates of relapse, treating death prior to relapse as a competing risk, will be compared between 
the two groups using a stratified log-rank test, and the cumulative incidence curves will be 
estimated for each group.  Cox regression will be performed to compare the groups after 
adjusting for covariates that may be imbalanced due to patient dropout. 
 
5.7.8. Donor Lymphocyte Infusion 
 
The use of DLI will be recorded and analyzed as a secondary endpoint. DLI will be a competing 
risk for evaluation of acute and chronic GVHD. 
 
5.7.9. Bacterial, Viral and Invasive Fungal Infection 
 
Infectious complications will be analyzed in relation to patients’ clinical risk with comparison of 
the two treatment cohorts (PBSC versus marrow) and adjusted by other relevant clinical risk 
factors.  These may include, but will not be limited to: pre-transplant infectious history and 
serostatus, time to neutrophil engraftment, and acute and chronic GVHD.  Analysis of infection 
incidence (by cumulative incidence) and infection density (number of infections over time for 
patients with repeated infections), especially during later time periods, will be performed.  
Multivariate regression analysis will be performed to test for the contribution of stem cell source 
(PBSC versus marrow) and other relevant covariates to the incidence of infections.  Specific 
analyses using these techniques will be performed for bloodstream infections (bacteremia), 
systemic fungal infections, and viral infections (CMV, HSV, respiratory viruses), and infections 
that lead to added isolation precautions in the hospital setting (e.g., resistant enterococcus, 
Clostridium difficile, varicella zoster, adenovirus, rotavirus, respiratory viruses). 
 
5.7.10. Patient and Donor Quality of Life 
 
Details about these analyses will be given in the separate sections on quality of life. 
 
5.7.11. Three-Year Survival 
 
Same as for the primary and secondary two-year endpoints. 
 
5.8. 
Safety Analysis 
 
All entered patients will be included in the safety analysis. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-10 
5.8.1. Adverse Events 
 
All reported serious treatment related adverse events will be carefully examined with respect to 
the severity and relationship to study treatment.  Adverse events will be graded according to the 
NCI Common Terminology Criteria for Adverse Events, Version 3.0.  The incidence for each 
reported study group associated adverse experience delineated in Section 4.15 will be presented 
for each group. 
 
5.9. 
Laboratory Tests 
 
Graft Characterization - Descriptive statistics will be computed on the cellular constituents of 
the graft, separately for each graft type.  These will be compared between graft types using 
nonparametric Wilcoxon rank sum tests.  Counts of the immune cells of different types in the 
graft (including donor CD34 and dendritic cells) as well as the graft type will be used to model 
post-transplant GVHD, relapse, and various measures of immune reconstitution through Cox 
regression, treating death prior to immune reconstitution, GVHD, or relapse as a competing risk. 
 
Immune Reconstitution - Descriptive statistics will be computed on the cellular constituents and 
Ig types separately by treatment arm.  These will be compared between treatment arms using 
nonparametric Wilcoxon rank sum tests.  Levels of IL-2 and IL-7 will be correlated using 
nonparametric measures with the levels of T cells in the blood.  Response to vaccinations will be 
compared between treatment arms using the binomial comparison of proportions.   
 
Chimerism - Chimerism results will be compared between the treatment arms using 
nonparametric Wilcoxon rank sum tests. 
 
5.10. Donor Recovery 
 
Donor Recovery to Baseline Toxicity Scores - Appropriate statistical methods to detect trends 
over the available spectrum of donor follow-up time will be employed for baseline toxicity 
recovery to baseline endpoints.  Such methods may include, but not necessarily be limited to: 
analysis of variance with repeated measures techniques, non-parametric paired comparisons, or 
other methods suitable for comparisons of correlated data. 
 
Donor Recovery to Baseline CBC and WBC Differential Values - Appropriate statistical 
methods to detect trends over the available spectrum of donor follow-up time will be employed 
for baseline CBC recovery to baseline endpoints.  Such methods may include, but not necessarily 
be limited to: analysis of variance with repeated measures techniques, non-parametric paired 
comparisons, or other methods suitable for comparisons of correlated data. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
5-11 
5.11. Subgroup Analyses 
 
Subgroup analyses will be performed on the following subgroups: pediatric patients (<16), 
disease risk (High vs. low, as defined in Table 5.4), and HLA matching status (matched on HLA-
A, B, C, DRB1 vs. mismatched).  First the direction and magnitude of the treatment effect in the 
subgroup will be compared with the rest of the sample to look for qualitative differences.  In 
addition, statistical hypothesis testing will be performed on endpoints of interest to look for 
significant interactions between the treatment and each subgroup of interest.  However, because 
of the greatly reduced sample sizes in such subgroups, these tests are underpowered and not 
anticipated to reach statistical significance in most cases.  They will be used only to note very 
strong interactions and to generate hypotheses.   
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
6-1 
CHAPTER 6 
 
 
6. INFECTIOUS COMPLICATIONS OF TRANSPLANTATION 
 
The early neutropenia, 
mucocutaneous 
barrier disruption and extended period 
of 
immunodeficiency after allogeneic transplantation leave patients vulnerable to serious and life-
threatening infections.  Because engraftment as well as immune reconstitution rates may differ 
following PBSC versus marrow transplantation, in this trial individual infectious complications 
will be prospectively monitored and compared.  The primary question asked in this protocol 
component is whether there will be a significant difference in the incidence, severity and case-
fatality rate of microbiologically documented infections between the PBSC and the marrow arms 
of the trial. 
 
Regimens to prevent and treat infectious complications of transplantation have evolved over the 
last three decades and continue to evolve, as have diagnostic and monitoring tools.  Specific 
prophylactic, monitoring and therapeutic regimens also vary from center to center.  While the 
study randomization will be stratified by center, in part for this reason, knowledge of prevention 
regimens used at each center will assist with the interpretation of putative relationships between 
study arm and infectious complications on this trial. 
 
Infection prophylaxis and complication monitoring forms and instructions for completion of the 
forms are included in the Data Management Handbook and User's Guide. 
 
6.1. 
Required Data Elements for Collection 
 
6.1.1. Pre-transplant Infections that may have an Impact on the Transplant by Recurrence 
 
Information regarding clinically significant fungal infections that occurred before transplant will 
be obtained based on the expected possibility of their reactivation during transplantation.  In 
addition, cytomegalovirus (CMV) serostatus of the donor and recipient, and herpes simplex 
(HSV) and varicella zoster virus (VZV) serostatus of the recipient will be collected.  The 
presence of fungal, bacterial and viral infections requiring treatment will also be captured as part 
of the pre-treatment eligibility screening form, as these infections are grounds for delaying or 
deferring the transplant. 
 
6.1.2. Infectious Disease Prophylaxis 
 
To determine what infection preventive measures were used, centers will be surveyed annually to 
report their infection prophylaxis protocols applicable to patients enrolled on this trial.  These 
center-defined, rather than patient-specific, data will be compiled for analysis.  The survey will 
include questions on: systemic bacterial, viral, fungal and pneumocystis prophylaxis, pre-
emptive therapy for positive CMV pp65 antigen or PCR tests.  Infection prophylaxis varies by 
time period post-transplant.   
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
6-2 
The center infection prophylaxis survey will include the following periods: 
1. Early neutropenia combined with mucocutaneous barrier disruption, weeks –1 through 
week + 4 post-transplant; 
2. Resolution of early neutropenia combined with continuing recovery from mucocutaneous 
barrier disruption, from 4-12 weeks post-transplant; 
3. Extended period of immunodeficiency from 12-26 weeks post-transplant; and 
4. Extended period of immunodeficiency from 26-52 weeks post-transplant. 
 
Centers should indicate varying practices over time in their survey responses. 
 
6.1.3. Specific Reporting of Individual Infections 
 
6.1.3.1. 
Data of interest 
 
The objective of this protocol component is to capture microbiologically defined opportunistic 
infections.  These will include the following etiologies: 
1. Viruses 
2. Fungi 
3. Bacteria 
4. Protozoa 
5. Others 
 
For the case definition for each infectious syndrome please refer to the BMT CTN Infectious 
Diseases MOP.  Case definitions specify clinical manifestations of disease and microbiological 
data.  Microbiological data will be captured from evidence of microbiology isolates, as well as 
genetic or antibody probes tested on fluid or tissue samples.  Clinical manifestations specific for 
each infectious disease syndrome will be captured by the case report forms using data from 
clinical source documents. 
 
Specific microbiology information about Candida and Aspergillus species will be included in the 
MOP, as this emerging and serious infection class is now being managed with multiple alternate 
antifungal agents. 
 
6.1.3.2. 
Tempo of data acquisition and reporting 
 
To enhance the reporting of all individual infections, infections forms should be filed as soon as 
possible after diagnosis.  Patient charts should be reviewed on Days 28, 100, 180, 365 and 730 to 
ensure that all clinically significant infections were captured between these reporting time 
periods.  If no clinically significant infections have occurred, that negative information will be 
reported. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-1 
CHAPTER 7 
 
 
7. PATIENT QUALITY OF LIFE 
 
7.1. 
Background and Significance 
 
7.2. 
Overview and Rationale 
 
Quality of life (QOL) refers to every dimension of life except for its length, and includes 
physical abilities, symptoms, social well-being, psycho-emotional status, and spiritual/existential 
qualities.  It reflects how well people feel, what they can accomplish, how satisfied they are with 
their lives, and whether their lives have meaning and purpose.  Within this broad concept, health-
related quality of life (HRQOL) refers to aspects of QOL that are attributable to health, disease 
or medical treatment (for simplicity, the abbreviation QOL will be used in this protocol).  
Following hematopoietic stem cell transplantation (HSCT), QOL can range from perfect, with no 
physical, emotional or social sequelae and a greater appreciation for life, to severely 
compromised with physical disability, pain and psychological despair.  Of course, most patients 
who have undergone HSCT fall within this spectrum. 
 
The figure below shows an example of QOL taxonomy. Global QOL (“Overall, how is your 
quality of life?”) is made up of several domains such as physical symptoms and functioning, 
emotional well-being, social relationships etc.  HSCT survivors generally report high global 
quality of life following HSCT, but many specific symptoms (64, 65, 66, 67, 68, 69, 70) and 
limitations on their daily activities (71).  However, despite many problematic long-term 
complications, almost all patients indicate they would undergo the procedure again given similar 
circumstances (72, 73, 74, 75).  In addition, for some common problems after HSCT such as 
fatigue, sleep and sexual functioning, documented dissatisfaction is also high in the general 
population and chemotherapy-treated patients (76, 77). 
 
 
 
 
The purpose of the QOL component of this trial comparing unrelated PBSC versus marrow as a 
stem cell source is to understand the long-term QOL implications of one graft source versus 
another.  While the trial is powered with survival as the primary endpoint, QOL will be an 
especially important secondary endpoint if survival is not statistically different, or if the 
incidence of chronic GVHD is higher in one group.  It is also possible that immunologic 
recovery, peri-transplant experiences and complications, speed of physical recovery, and 
expectations may influence ultimate QOL. 
 
 
PHYSICAL 
fatigue 
pain 
SOCIAL 
family 
friends 
EMOTIONAL 
anxiety 
depression 
FUNCTIONAL 
work 
sleep 
Global QOL 
SPIRITUAL
religion 
meaning 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-2 
It is very important that data collection is centralized, patients’ response burden is minimized and 
QOL assessments are fully integrated into the trial to maximize the chance of complete data 
collection.  With this goal in mind, the number of data instruments will be minimized and 
focused on answering the research question, assuming that other psychological, social etc. 
factors are balanced by the randomization process.  Specifically, associations between QOL and 
specific clinical events or patient characteristics will not be investigated.  Other ongoing studies 
fully address those issues. 
 
7.3. 
Preliminary Work 
 
NHLBI has sponsored a randomized trial of T cell depletion vs. immunosuppressive medications 
for acute GVHD prophylaxis in unrelated donor marrow transplantation (TCD).  Accrual and 
follow-up are complete.  Dr. John Wingard and the International Bone Marrow Transplant 
Registry (IBMTR) have concluded a large, cross-sectional study of QOL and relationships 
incorporating patients, spouses and controls.  Both these studies have shown the feasibility of a 
centralized, telephone data collection strategy using mailed surveys followed by phone 
interviews.  Overall and item completion rates were excellent, and anecdotally, the personal 
contact was much appreciated by the patients.  Results are not yet available from these studies, 
but completion rates in the NHLBI trials were excellent (baseline – 91%, 100 days – 59%, 6 
months – 64%, one year – 73%, 3 years – 84%).  However, compliance varied and improved as 
the study progressed.  In addition, a pediatric component was planned but closed early due to 
poor compliance.  In order to facilitate comparison of the current study with the NHLBI and 
IBMTR studies, every effort has been made to include similar instruments and assessment times. 
 
7.4. 
Specific Aims 
 
The overall aim is to compare the QOL of patients undergoing unrelated donor marrow 
transplantation with that of patients undergoing unrelated donor PBSC transplantation.  Other 
aims include: 
1. To compare chronic GVHD symptom burden (as measured by the chronic GVHD 
symptom scale) between the two treatment groups. 
2. To compare physical, functional, and transplant-specific QOL modules (as measured by 
the Trial Outcome Index [TOI] of the Functional Assessment of Chronic Illness Therapy 
[FACT-BMT] and the rate of return to work) between the two groups. 
3. To compare the positive and negative psycho-emotional aspects of transplantation (as 
measured by the Mental Health Inventory) between the two groups. 
 
7.5. 
Hypotheses 
1. There will be greater chronic GVHD symptom burden in recipients of PBSC transplants 
at one-year post-transplantation. 
2. There will be no difference in the physical, functional, and transplant-specific QOL 
between the two groups over time through two years post-transplantation.  
3. There will be no difference in rate of return to work at two years. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-3 
4. There will be no difference in the positive and negative psycho-emotional aspects of 
transplantation, as measured by the Mental Health Inventory. 
 
7.6. 
Eligibility and Exclusion Criteria 
 
7.6.1. Inclusion Criteria 
1. Enrollment in the randomized clinical trial. 
2. At least 16 years of age. 
3. Signed informed consent. 
 
7.6.2. Exclusion Criteria 
1. Inability to communicate in English or Spanish. 
2. Inability to participate in interviews due to cognitive, linguistic or emotional difficulties. 
3. Current uncontrolled psychiatric illness. 
4. No telephone or access to a telephone. 
5. This study will not be offered to children and their parents based on the experience with 
the NHLBI TCD study.  In addition, QOL considerations and instruments differ between 
adult and pediatric patients necessitating a separate analysis.  It is anticipated that 
minority representation will mirror that in the randomized study. 
 
7.7. 
Study Procedures 
 
7.7.1. Study Design 
 
Patients will be enrolled in the QOL study at the time they provide first consent for the 
randomized trial.  Once a donor is confirmed, the patient will be sent a QOL study packet 
including a cover letter, copy of the QOL interview, and information to schedule the time for a 
pre-transplant interview. Interviews will be conducted in either English or Spanish.  
 
Interviewers will read the verbatim questions to the subject, who will indicate their answers.  
Interviewers will record those answers.  If a patient wishes to stop and continue later or another 
day, that is permissible.  Three contacts with the patient will be allowed with his/her permission 
to obtain complete data at each time point.  In addition, a toll-free line will be established for 
patient questions or in case it is easier for the patient to complete the surveys at another phone 
(e.g., at a clinic appointment or a friend’s house). 
 
Patients will be surveyed prior to transplantation (within 1 month of admission), and at 6 months, 
1 year and 2 years.  Post-transplant interviews may occur +/- 1 month from the scheduled time 
point.  Permission will also be sought for QOL assessment at 5 years post-transplantation, 
although these data will not be analyzed as part of the randomized controlled trial. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-4 
7.7.2. Study Endpoints 
 
The four study endpoints of the QOL component will be: 
1. The chronic GVHD symptom scale. 
2. The Trial Outcome Index of the FACT-BMT. 
3. Occupational functioning. 
4. The Psychological Distress and Psychological Well-Being Subscales of the Mental 
Health Inventory. 
 
7.7.3. Instruments 
 
Table 7.7.3:  Description of Instruments 
 
Instrument 
Domains 
Rationale 
Sociodemographics 
Race/ethnicity, Age, 
Gender, Education, 
Income 
 
Global quality of life 
Karnofsky 
performance status 
Perception of 
overall health, 
Perception of 
overall QOL, Rating 
scale 
Assesses patient self-perceived global quality of life 
and functioning. 
FACT-BMT 
Physical, 
Emotional, Social 
Functional, 
Transplant-specific 
Collected in NHLBI TCD and IBMTR QOL study. 
Allows comparison with other cancer populations. 
Mental Health Inventory 
(MHI) 
MHI Index, 
Psychological 
distress, 
Psychological well-
being 
Measures depression, anxiety, positive affect, 
emotional ties and loss of behavioral and emotional 
control.  Includes the mental subscale from the SF36. 
Occupational functioning 
Occupational 
functioning 
Only about 75% of surviving patients return to work, 
and return to work is associated with better QOL.  
This instrument was used in NHLBI study. 
Chronic GVHD module 
Chronic GVHD 
summary score 
Anticipated rates of cGVHD are 50-90%.  Measures 
cGVHD problems with skin, energy, lung, nutrition, 
psychological, eye, and mouth. 
Alternative contacts 
 
Contact information for two alternative individuals. 
Distress assessment 
 
Measures distress caused by survey administration. 
 
Sociodemographics: Eight standardized questions will assess ethnicity (Hispanic/Non-
Hispanic), race (White, Black, Asian, American Indian/Alaskan Native, Native Hawaiian or 
other Pacific Islander, Multiracial), age, sex, education, work status and occupation, and family 
income. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-5 
Global Quality of Life: Four standard questions will assess patient self-assessed Karnofsky 
performance status, overall health and overall quality of life (excellent, very good, good, fair, 
poor), and a rating scale for overall quality of life (where 0 equals death and 100 equals perfect 
quality of life). 
 
FACT-BMT: The FACT-BMT is a 37-item instrument composed of the FACT-G and 
transplant-specific subscale.  The FACT-G is comprised of 4 domains, physical (7 items), social 
(7 items, including sexual satisfaction), emotional (6 items) and functional (7 items, including 
work, sleep and leisure activities).  The transplant-specific module (10 scored items) includes 
appetite, appearance, mobility and fatigue (78,79).  Higher scores indicate better functioning.  
The Trial Outcome Index (TOI) is composed of the physical, functional, and transplant-specific 
modules (80).  Data from 132 observations in unrelated donor recipients post-transplantation (6-
60 months) showed a mean of 66.76, SD 19.53, range 11.8-96.0. 
 
Mental Health Inventory (MHI): Thirty-eight items divided into two summary scores and five 
subscales measure anxiety, depression, positive affect, emotional ties, and loss of behavioral and 
emotional control (this instrument includes the entire mental subscale of the SF36).  As 
transplantation has been associated with both positive and negative psycho-emotional sequelae, it 
is important that the instrument detects both.  Psychological well-being is measured by 14 items 
with a reported mean of 59.16 and SD 12.16 in a general population sample of 5,000 individuals.  
Cronbach’s alpha is 0.92, one year test-retest 0.63, and higher scores indicate better functioning. 
On the 24 item psychological distress scale, mean is 47.54, SD 15.39, Cronbach’s alpha 0.94, 
one-year test-retest 0.62, and higher scores indicate more distress (81, 82).  The MHI was 
sensitive to changes associated with azacytidine treatment in MDS patients, and baseline scores 
were very similar to that of the general population. 
 
Occupational Functioning: Occupational functioning was measured in the NHLBI TCD trial 
using 6 items that assess current job status, type of work (will be captured using Hollingshead 
categories), number of hours of paid and unpaid work, school, importance of work and change in 
work goals. 
 
Chronic GVHD Symptom Scale: The 30 item cGVHD symptom scale measures degree of 
bother of cGVHD manifestations in skin, energy, lung, nutrition, psychological, eye and mouth.  
Responses are captured on a five-point Likert scale (“no symptoms, or not bothered at all”, 
“slightly bothered,” “moderately bothered,” “bothered quite a bit,” or “extremely bothered”).  
Scores for each domain are converted to a 0-100 scale where higher scores indicate more bother.  
Mean (SD) was 12 (9) for patients with mild (N=55), 18 (13) for patients with moderate (N=39), 
and 34 (13) for patients with severe (N=13) disease.  Although the SF-36 and FACT-BMT were 
sensitive to changes in overall health, only the chronic GVHD symptom scale was sensitive to 
changes in patient-perceived chronic GVHD severity (83).  
 
Alternative Contact Information: The names of two people who do not live with the subject, 
but would be able to locate the patient in case of phone number change, move etc. will be 
obtained.  Names, addresses and phone numbers of these alternative contacts will be collected. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-6 
Distress Assessment: Two items will assess distress at the conclusion of each survey 
administration.  One question measures level of comfort with the questions (very comfortable, 
comfortable, a little uncomfortable, very uncomfortable) and degree of stress caused by the 
questions (a great deal, a lot, some, a little, none).  These questions were modified from studies 
of bereaved family members.  Responses of “very uncomfortable” with questions or “a great 
deal” or “a lot” of stress caused by the survey leads to follow-up questions and an offer of 
referral.  Actual referral or the need to notify the transplant center Principal Investigator due to 
distress caused by the survey administration will constitute an unexpected serious adverse event. 
 
7.7.4. Required Data 
 
Table 7.7.4:  Required Data 
 
Instrument 
N 
items 
Pre 
6 mos 
1 & 2 
yrs 
5 years 
Sociodemographics 
8 
X 
 
 
 
Global quality of life 
4 
X 
X 
X 
X 
FACT-BMT 
37 
X 
X 
X 
X 
Mental Health Inventory (MHI) 
38 
X 
X 
X 
X 
Occupational functioning 
6 
X 
 
X 
X 
Chronic GVHD module 
30 
 
X 
X 
 
Alternative contacts 
2 
X 
X 
X 
 
Distress assessment 
2 
X 
X 
X 
X 
TOTAL N ITEMS 
 
97 
114 
120 
87 
ANTICIPATED TIME 
 
20 min 
20 min 
25 min 
15 min 
 
 
7.8. 
Description of Study Process 
 
7.8.1. Identification of Eligible Patients 
 
Upon provision of informed consent for participation in the randomized clinical trial, patients 
will also complete a Patient Contact Form to allow the QOL interviewer to reach them.  This 
form will capture name, address, home phone number, email address, alternative contact 
information, preferred language, and preferred time to be contacted.  Site coordinators will 
provide transplant center name, type of transplant, date of admission, date of transplant, 
transplant center and patient NMDP identification numbers and patient’s study number.  This 
information will be faxed to the QOL coordinating center and entered into a password-protected 
database.  Upon receipt of this information, patients will be mailed a packet of information 
including a cover letter explaining more about the QOL survey procedures, the first survey for 
their review, and contact information for more questions. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-7 
7.8.2. Informed Consent 
 
Consent for QOL data collection is contained in the informed consent document for the trial.  
Procedures between the QOL coordinating center and the BMT CTN Data Coordinating Center 
(DCC) will ensure that a copy of the informed consent is on file before collection of the QOL 
data. 
 
7.8.3. Collection of QOL Data 
 
QOL interviewers will call the patient at a day and time that is convenient for them, or patients 
may call a toll-free number at a predetermined time.  Baseline data will be collected within one 
month prior to graft infusion and after an admission date is scheduled.  For each subsequent 
contact, the QOL coordinator will call or email the clinical contact person associated with the 
patient within a month of contact in order to prevent contact attempts with deceased patients.  
Once confirmation of survival is obtained, the QOL coordinator will mail the patient a packet of 
information, and call the patient to schedule the QOL interview.  The post-transplant interviews 
may occur +/- 1 month from the scheduled time.  At the conclusion of each survey 
administration, patients will be reminded of the next date of contact and the procedures that will 
be followed. 
 
7.8.4. Location of Missing Patients 
 
If patients cannot be located through the contact information provided, or through the transplant 
center, then the alternative contacts will be used to locate the patient.  With the patient’s 
permission, updated contact information will be forwarded to the transplant center for their 
records. 
 
7.8.5. Withdrawal of Consent for QOL Data Collection 
 
If patients wish to discontinue participation in the QOL study, the QOL interviewer will notify 
the Principal Investigator at the transplant center immediately.  In approximately one week, the 
Principal Investigator will call the patient back to make an attempt to keep the patient in the 
study by explaining the goals of the study and the required data needs.  Should the patient still 
wish to drop out of the QOL study, no further contact will be attempted.  However, QOL data 
will be removed from the database only when specifically requested by the patient. 
 
7.8.6. Fifth Year Contact 
 
Although the fifth year will not be officially part of the randomized controlled study or the 
analysis, consenting patients for long-term follow-up allows important long-term data to be 
collected.  Similar procedures as for the two-year survey will be followed. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-8 
7.8.7. Letter of Appreciation and Communication of Findings 
 
At the conclusion of the study, a letter of appreciation will be sent to all surviving patients 
thanking them for their participation.  If a patient dies, a letter will NOT be sent to the next of 
kin.   
 
7.8.8. Management of Adverse Reactions 
 
Patients enrolled in this study will undergo up to five interviews.  At the start of each interview, 
patients will be told clearly that they may skip over any interview questions they wish and may 
withdraw from the study at any time.  Despite our best efforts, it is conceivable that some 
patients may find the process upsetting.  Names and phone numbers of local people to contact 
will be listed in the consent form and provided at the end of each interview.  Notification of the 
transplant center Principal Investigator based on distress caused by participation in the study will 
be considered an unexpected, serious adverse event and will be reported to the Principal 
Investigator, the IRB and the DCC.  However, distress incidentally detected will be reported to 
physicians and noted in the research file, but will not be considered an adverse event.  Section 
7.11.1 details study procedures in case distress is detected with potential to cause injury to self or 
others. 
 
7.9. 
Statistical Considerations 
 
7.9.1. Sample Size 
 
As quality of life is a secondary endpoint for the randomized clinical trial, the available sample 
size is predetermined by the primary endpoint of survival.  Thus, statistical considerations will 
focus on the power to detect differences given the enrollment and likely survival of the treatment 
arms. 
 
The available sample size at two years will be 60 for marrow and 81 for PBSC, based on 
expected accrual and the following additional assumptions: 
1. 90% of patients are adults (age > 18 years) who communicate in English or Spanish. 
2. Compliance with QOL assessments is 80%. 
3. Survival is 45% in the PBSC and 35% in the marrow group at two years. 
 
The hypothesis related to chronic GVHD symptoms pertains only to the one-year time point, and 
return to work applies to the two-year assessment.  All other hypotheses address differences 
between the two groups (marrow versus PBSC) over four potential time points: pre-transplant, 
six months, one year and two years.  For illustrative purposes, there is 64% power to detect a 0.5 
SD difference in the scores of interest at the two year time point (assuming 81 PBSC and 60 
marrow eligible survivors) and with a Bonferroni correction p=0.01 and two-sided testing. These 
detectable differences are presented in Table 7.9.1. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-9 
Table 7.9.1:  Detectable Differences 
 
Outcome 
Raw scores 
0.5 SD 
CGVHD Symptoms 
12 vs. 18.5 
6.5 
Trial Outcome Index 
60 vs. 70 
10 
Psychological Well-Being 
56 vs. 62 
6 
Psychological Distress 
44 vs. 52 
8 
 
 
Differences in QOL between the two groups will be assessed in two main ways.  First, the 
marginal QOL scores given that a patient is alive will be compared at the specific time points 
described above using simple t-tests/confidence intervals.  Each of these time point comparisons 
will be done using the patients alive at that time.  Additionally, a second analysis will be done 
using the Integrated Quality Adjusted Survival to compare the two treatments on an aggregated 
assessment of QOL over the entire period of observation.  This second analysis will account for 
potential differences in the survival rates between the two groups. 
 
7.9.2. Missing Data 
 
Missing data is a common problem in survey and/or longitudinal studies.  Reasons of missing 
data are multifold: death, relapse, drop-out, early termination, or missing assessments.  Death 
rates are expected to be substantial based on the underlying disease states and the nature of 
unrelated donor transplantation, and will be accounted for by the Quality Adjusted Survival, as 
discussed above.  For comparison of QOL among survivors, every effort will be made to collect 
all measurements from all eligible patients to minimize missing data from survivors.  However, 
as experience with the TCD trial suggests, there appear to be fewer problems with missing data 
at later time points because initial toxicity has diminished.  If missing data occur, we will 
diagnose the mechanism and pattern of missing data based on information provided by the site 
and we will perform missing data analysis.  Since prior studies suggest that missing data in 
HSCT studies is associated with poor QOL (84) (i.e., informative right censoring, non-ignorable 
missing), we will explore the generalized Schlucter model (85), which is a joint model for 
longitudinal and survival data, where the survival component of the model acts as a missing data 
mechanism using software developed at the Dana-Farber Cancer Institute (86).  This model 
essentially allows missing QOL measurements at a specific time point of interest to be imputed 
based on how soon after that time the patient dies.  Note that use of subsequent survival 
information to input the QOL scores is primarily useful when comparing QOL at earlier time 
points, because the survival times will be observed until two years for each patient, while at later 
time points there may be less additional time for which the patient’s survival status is recorded.  
Therefore this should be a reasonable approach to dealing with the missing data related to QOL. 
 
7.9.3. Modified Intent-to-Treat 
 
A modified intent-to-treat analysis is planned using all randomized patients who are transplanted 
according to their randomization assignment. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-10 
7.10. Risks and Discomforts 
 
No medical treatment will be delivered as part of the QOL component.  Participation is limited to 
completion of the surveys.  It is possible that some of the questions may be upsetting, although 
they are all validated instruments used on thousands of patients.  Patients will be reminded 
before every survey administration that they may skip items if they wish.  Distress will be 
assessed at the completion of each survey, and distress attributable to participation in the study 
(as opposed to distress detected incidentally) will be considered a severe adverse event 
reportable to the IRB. 
 
7.10.1. Potential Risks to Research Subjects 
 
As this is an observational study, there are no associated physical risks.  It is possible that the 
survey questions could cause emotional distress, but the risk is likely to be minimal.  Distress 
will be assessed after every contact with patients, and if we detect a high level of distress, the 
transplant center Principal Investigator will be notified. 
 
7.10.2. Adequacy of Protection Against Risks 
 
The informed consent document clearly outlines the QOL procedures, assessment points, time 
commitment and goals of this portion of the trial and must be signed by the patient.  Study 
participants may withdraw their consent to participate at any time or may refuse to participate in 
any aspect of the study.  This withdrawal will not compromise their medical care in any way. 
 
Confidential and emotionally sensitive material will be collected from the patients.  These data 
will be kept in locked research areas.  Access to all data will be limited to study personnel.   
 
7.10.3. Sources of Research Materials 
 
For the QOL component, potentially identifiable information on patients will consist of 
completed surveys.  Patient sociodemographics, quality of life, functional status, employment 
status, mental health and chronic GVHD symptoms will be measured.  Permission to collect all 
data will be obtained through the informed consent document, and will be obtained specifically 
for research purposes.  However, if a high level of emotional distress is detected, the transplant 
center Principal Investigator will be notified. 
 
7.10.4. Potential Benefits 
 
Patients participating in this study are not expected to obtain any direct benefit although some 
patients do report feeling better after participation in other QOL studies. 
 
7.10.5. Potential Benefits of the Proposed Research to the Subjects and Others 
 
This study will involve minimal risk to participants.  No benefits to the patients, as a result of 
participation in the study, are anticipated.  However it is hoped that future patients will benefit.  

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
7-11 
The risks of the study to participants are minimal whether measured absolutely or relative to 
what will be learned to benefit future patients. 
 
7.11. Monitoring and Quality Assurance 
 
7.11.1. Patient Tracking 
 
Patient tracking will be accomplished through a master file maintained by the QOL interviewers.  
Every four months, a progress report with total number of contacts attempted, total number of 
surveys successfully collected, and barriers to complete data collection will be produced.  In this 
way, response rates will be constantly monitored with the ability to enhance data collection 
procedures if inadequate QOL participation is detected. 
 
If serious distress is detected (suicidal, homicidal or psychotic features), the Principal 
Investigator at the patient’s transplant center will be notified for the patient’s own protection.  
This safeguard will be clearly outlined in the patient consent form, “Your answers to the quality 
of life interviews will be kept private and not included in your medical records nor shared with 
your physicians or other caregivers.  Your answers will be coded with a study number only and 
kept in password-protected electronic files or locked in file cabinets.  Only study personnel will 
have access to your information.  However, if any of your answers lead us to believe you are 
seriously depressed or in danger of hurting yourself, your physician will be notified.” 
 
7.11.2. Oversight of Project Staff 
 
Prior to patient contact, all study staff will be able to: 
1. Administer QOL surveys over the phone under appropriate supervision 
2. Demonstrate basic knowledge about the medical procedures under study and know where 
to refer patients who have questions about their medical conditions 
3. Explain and answer questions about the standardized instruments 
4. Know how to recognize and refer patients experiencing distress to the study investigators 
 
Ongoing quality will be maintained through random monitoring of interviews and additional 
training provided as necessary. 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-1 
CHAPTER 8 
 
 
8. DONOR QUALITY OF LIFE 
 
8.1. 
Background and Significance 
 
Although both bone marrow harvest and PBSC collection are fairly well tolerated by donors (see 
Chapter 1), there may be significant differences between the procedures in terms of their impact 
on donor quality of life (QOL).  In a French study (87), researchers performed a prospective 
evaluation of anxiety, pain, and inconvenience.  Patients were randomly assigned to apheresis or 
bone marrow harvest for collection of stem cells in preparation for an autologous hematopoietic 
cell transplant.  Marrow donor patients experienced more anxiety and pain than PBSC patients.  
Patients undergoing PBSC collection experienced more positive judgments toward the collection 
procedure than bone marrow donor patients.  Patients who had a venous catheter placed for 
collection of stem cells experienced more pain than those from whom stem cells were collected 
by peripheral venous access. 
 
A group in Norway (88) also conducted a randomized study of safety and complaints of PBSC or 
marrow donation of stem cells.  They found a striking difference in the total burden of 
complaints, duration of hospital stay, and sick leave in the two groups of donors, favoring PBSC 
donors.  Interestingly, they found that PBSC donors used more analgesics than marrow donors.  
They hypothesized that these differences may have been due to the nature of the discomfort and 
the expectation that PBSC donors would continue to work during their daily injections of growth 
factor.  They indicated that the method used for informing donors may have influenced 
expectations, possibly impacting the post-procedure assessment.  However, they do not elaborate 
this point. 
 
Switzer et al., (89) compared the physical and psychosocial experiences of marrow and PBSC 
donors donating cells a second time.  Although the study was cross-sectional and retrospective, 
examination of quality of life outcomes from donors who have experienced both procedures 
makes this study unique.  Results were similar to the aforementioned studies; a greater 
proportion of marrow donors reported post-donation physical side effects as compared to PBSC 
donors.  A greater proportion of marrow donors reported using pain medications.  Individuals 
who donated marrow for their first donation and PBSCs for their second reported PBSC donation 
as less physically difficult, time-consuming, and inconvenient as compared to marrow donation. 
 
Rowley et al., (90) compared the experiences of marrow and PBSC donors participating in a 
randomized trial, and did not find significant differences in symptom burden or emotional status 
between collection methods.  They found that pain levels and duration were similar for the two 
groups, although they peaked at different times.  Both marrow and PBSC donors reported 
minimal fluctuations in emotional status.  However, as emotional status was measured with only 
a single, global item, these results should be interpreted with caution. The most significant 
difference between the groups was that recovery time was shorter for PBSC donors. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-2 
Given the few studies conducted and their somewhat contradictory results, further investigation 
is warranted to better describe the potential differences in quality of life following marrow versus 
PBSC donation. 
 
8.2. 
Specific Aims and Hypotheses 
 
Our overall goal is compare the QOL of marrow donors with PBSC donors.  We are interested in 
knowing if the physical and psychosocial symptom burdens, recovery time, inconvenience, 
concerns, and satisfaction levels of marrow and PBSC donors differ depending on the donation 
method.  Specific aims include: 
1. To compare the physical side effects, functional ability, and recovery time of donors 
randomized to PBSC or marrow donation. 
2. To compare the psychosocial side effects between the two donation methods. 
3. To compare the inconvenience and restriction of activities between the two groups. 
4. To compare the level of concern about donation of each group. 
5. To compare levels of satisfaction reported by each type of donor. 
 
8.2.1. Hypotheses 
1. PBSC donors will report fewer numbers of side effects and greater functional ability 
overall, but a greater degree of bone pain, than marrow donors.  PBSC donors will 
recover to baseline functioning faster than marrow donors. 
2. PBSC donors will report less anxiety about donation than marrow donors. 
3. PBSC donors will report lower levels of inconvenience and restriction of daily activities 
than marrow donors. 
4. PBSC donors will report fewer concerns about donation than marrow donors. 
5. PBSC donors will report greater satisfaction levels than marrow donors. 
 
8.3. 
Eligibility and Exclusionary Criteria 
 
Potential study participants will be the 550 donors (~275 each of PBSC and marrow) recruited to 
participate in the randomized clinical trial (RCT).  Donors must (a) meet the standard NMDP 
requirement for donor eligibility, (b) be selected for participation in the RCT, (c) meet the 
inclusion and exclusion criteria listed below, and (d) give signed informed consent to participate 
in both the RCT and the Donor Quality of Life study. 
 
8.3.1. Inclusion criteria 
1. Enrollment in the parent randomized clinical trial. 
2. Signed informed consent. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-3 
8.3.2. Exclusion Criteria 
1. Inability to read and speak in English, because the instruments to be used in the Quality 
of Life study have not all been validated in other languages. 
2. Inability to complete telephone interview due to cognitive or linguistic difficulties. 
3. Lack of telephone access. 
4. Age less than 18 years. 
 
8.4. 
Study Procedures 
 
8.4.1. Study Design 
 
Pre-donation.   Donors will be enrolled upon completion of their evaluations and agreement to 
the study randomization.   
 
Within four weeks prior to marrow donation or initiation of G-CSF administration for PBSC 
donors, participants will complete the baseline interview.  Every attempt will be made to 
administer the baseline interview as close to donation or G-CSF administration.  PBSC donors 
will have an additional assessment at Day 4 of G-CSF administration, since the preparatory 
procedures for PBSC donation are considered part of the donation process and include 
experiences that likely affect QOL. 
 
Post-donation.   Donors will be surveyed within 48 hours after donation, then weekly until they 
indicate normal functioning for a period of three consecutive weeks.  Long-term assessment will 
occur at 6 and 12 months.  All questionnaires will be administered by telephone by an 
independent interviewer.  Basic medical information will be obtained directly from donors by the 
donor center following standard NMDP procedures and forms.  Information will include the need 
for central venous catheter placement, hospitalization and reason, and any serious adverse event.   
 
Permission will be sought for repeated QOL and satisfaction assessment yearly for five years.  
These data will not be included as part of this randomized trial. 
 
8.4.2. Study Endpoints 
 
Study endpoints include physical recovery, including symptoms, functioning, and recovery time, 
psychological and social functioning, degree of inconvenience experienced, concerns about 
donation, and satisfaction with donation. 
 
8.4.3. Measures 
 
Sociodemographic Questions: Age, sex, marital status, education level, and work status will be 
assessed. Race/ethnicity will be identified using NIH categories. 
 
Physical Recovery: Physical side effects will be measured by a series of questions used by 
Switzer et al., in their 2001 study of second-time donors.  These questions include assessment of 
fever, overall pain, and specific side effects.  These questions will be supplemented with similar 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-4 
questions contained on the standard NMDP forms, which assess side effects, complications, 
medication use, and discomfort in specific parts of the body, as well as evaluation of return to 
baseline functioning.  Four additional items will assess highest pain intensity, average pain, 
amount of pain, and pain’s effect on sleep using visual analog scales used previously by Rowley 
et al., (90).  Functional status will be measured by toxicity criteria, which is standard on the 
NMDP forms. 
 
General Physical, Social, and Emotional Functioning: Global physical, social, and emotional 
functioning will be assessed with the 12-item Medical Outcomes Survey Short-Form 12v2 (91).  
The SF-12v2 is widely used, reliable and a well-validated instrument that is appropriate for 
individuals with a broad range of functional limitations.  It has the advantage of being linked to a 
substantial body of normative data. 
 
Psychological Functioning: Psychological status will be measured by the Profile of Mood 
States-Short Form (92).  This is a 30-item measure that produces an overall distress score, as 
well as scores on six subscales: depression, anxiety, anger, confusion, fatigue, and vigor.  This 
scale has been shown to have good reliability and validity (92) and has been used extensively in 
the assessment of psychological aspects of quality of life. 
 
Convenience: The degree to which the procedure interferes with daily activities, and requires 
that special arrangements be made for coverage of work or domestic responsibilities, the number 
of days off from work, and the restriction of leisure activities will be assessed with items from 
the standard NMDP forms and items used in previous studies (89). 
 
Concerns about Donation: The degree to which donors are concerned about short- and long-
term health effects of donation will be assessed with questions used in previous studies (89). 
 
Satisfaction with Donation: Donors’ level of satisfaction with their donation experience will be 
assessed with questions used in previous studies (89). 
 
Clinical Data: Number of blood transfusions given, requirement for a central line and the 
number and duration of leukapheresis procedures will also be assessed via NMDP forms. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-5 
Table 8.4.3:  Data Collection Timeline 
 
Measures 
N items 
Pre 
Day 4-
PBSC only 
Within 48 
hours 
donation 
Weekly 
until 3 
weeks 
after full 
recovery 
Final 
weekly 
assessment 
after full 
recovery 
6 & 12 
mos 
Sociodemographics and 
Background Information 
13 
X 
 
 
 
 
 
Influence of Others 
4 
X 
 
 
 
X 
 
Concerns about Donation 
5 
X 
(7 items) 
X 
X 
 
X 
X 
Preparedness 
5 
X 
 
 
 
X 
 
Physical Symptom Scale 
12 
X 
X 
X 
X 
X 
X 
Physical/Emotional Function: 
SF-12 
12 
X 
 
X 
 
X 
X 
Pain 
4 
X 
X 
X 
X 
X 
X 
Profile of Mood States 
30 
X 
 
X 
 
X 
X 
Satisfaction and Feelings 
about Donation 
9 
 
 
X 
 
X 
X 
Response of Others 
3 
 
 
X 
 
X 
X 
Side Effects 
7 
 
X 
(6 items) 
X 
X 
X 
X 
Inconvenience 
5 
 
X 
(4 items) 
 
 
X 
X 
Concerns about the Recipient 
5 
 
 
X 
X 
X 
X 
TOTAL N ITEMS 
105 
87 
35 
87 
28 
92 
88 
ANTICIPATED TIME 
 
20 min 
10 min 
20 min 
5 min 
25 min 
20 min 
 
 
8.5. 
Description of Study Process 
 
8.5.1. Contact Information 
 
Refer to Donor Center Companion Manual. 
 
8.5.2. Informed Consent 
 
A copy of the signed informed consent will be kept in a secure location to ensure confidentiality. 
 
8.5.3. Collection of QOL Data 
 
All interviews will be administered by telephone by a trained interviewer.  If donors wish, they 
can receive a mailed copy of the interviewer’s questionnaire to review before the telephone 
interview.  Medical information will be obtained by the donor center following standard NMDP 
procedures and forms. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-6 
8.5.4. Withdrawal of Consent for QOL Data Collection 
 
If a donor wishes to discontinue participation, every attempt will be made to ascertain the reason 
for discontinuation.  In general, the project coordinator or the study Principal Investigator will 
briefly review the procedures to make certain that the cause of withdrawal is not 
misunderstanding of study procedures. 
 
8.5.5. Letter of Appreciation and Summary of Results 
 
At the close of the study, thank you letters will be sent to each participant.  A summary of study 
results will be made available upon request. 
 
8.6. 
Statistical Considerations 
 
8.6.1. Sample Size 
 
As donor quality of life is a secondary endpoint for this randomized trial, the sample size is 
predetermined by the primary endpoint of patient survival.  A total sample size of 550 will 
provide more than adequate power to examine group-level differences between PSBC and 
marrow donors. 
 
8.6.2. Group Comparisons 
 
All demographic variables will be summarized and the PBSC and marrow groups will be 
compared with chi-squared tests as appropriate.  All outcome variables will be compared 
between the two groups at each time point using t-tests for continuous outcomes, nonparametric 
Wilcoxon tests for ordinal outcomes, chi-square tests for nominal categorical variables, and chi-
square trend tests for ordinal categorical variables, as appropriate.  A significance level of 0.01 
will be used as protection against multiplicity due to a large number of outcome variables and 
time points examined.  In addition, because physical recovery and psychological functioning are 
assessed both at baseline and subsequent times, adjustment for baseline measurements will be 
considered.  Symptom reporting (three categories) will be compared between the two groups at 
each time point using chi-squared tests, and may be adjusted for baseline symptom levels by 
treating them as strata variables.  Pain and psychological functioning will be compared between 
the two groups using mixed models for repeated measures data.  Clinical data will be compared 
between the two groups using nonparametric Wilcoxon tests or chi-squared tests as appropriate. 
 
8.6.3. Missing Data 
 
Missing data will initially be assumed to be missing at random, requiring no adjustment to the 
mixed models analysis across time.  If this is the case, separate tests performed at each time point 
will be done with the complete data at that time.  However, missing cases will be examined to 
determine whether data are missing systematically by key sociodemographic indicators. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
8-7 
8.7. 
Risks and Discomforts 
 
QOL data collection involves non-invasive survey procedures that pose no risk to the 
participants.  It is possible, although highly improbable, that completion of the survey items 
could elicit distress.  However, participants are instructed not to answer any questions that make 
them uncomfortable.  Donors also are informed that they may withdraw from study participation 
at any time without penalty.  Should high levels of distress be detected during donor contacts, the 
interviewer will attempt to determine the nature and intensity of the distress, and will ask the 
donor if they wish to receive a follow up call from their local donor coordinator, Principal 
Investigator of the RCT, or from a member of the Donor Services Staff at the NMDP.  If the 
donor says yes, the interviewer will contact the appropriate individual within 12 hours.  That 
individual, in turn, will make every attempt to contact the donor by telephone within 24 hours. 
 
8.8. 
Potential Benefits 
 
There are no direct benefits to participating in this study.  However, participants may experience 
positive feelings associated with sharing their experiences and/or contributing to research that 
may help others in the future. 
 
8.9. 
Monitoring and Quality Assurance 
 
The QOL data is confidential and will be kept in secure areas accessible only to study personnel.  
The study will be approved by the IRBs of all participating centers.  Standard operating 
procedures to respond to any adverse event are delineated above.   
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
A-1 
 
 
APPENDIX A 
 
RATIONALE FOR THE STUDY DESIGN 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
A-2 
APPENDIX A – RATIONALE FOR THE STUDY DESIGN 
 
 
In creating this study, the protocol team held extensive discussions about the proper approach to 
donor and recipient enrollment.  The study is complicated because two research subjects, the 
hematopoietic stem cell (HSC) donor and the HSC recipient, must be managed 
contemporaneously.  Between these two, the recipients are inherently more unstable and more 
likely to shift in their eligibility status over short periods of time. 
 
The selected management schema is depicted in Figure 1.  Here the recipient eligibility is 
divided into two components, eligibility for randomization and eligibility for transplantation.  
The donor will be selected, enrolled and cleared for donation prior to randomization.  The 
recipient should be confirmed eligible for randomization prior to donor work-up (using the 
somewhat abbreviated criteria described in Section 2.3, with information that can be obtained by 
phone or mail for patients remote from the transplant center), but must be confirmed eligible on 
full evaluation at the transplant center after randomization but before conditioning therapy is 
initiated. 
 
Once the pair is randomized, the recipient will undergo work-up to determine final eligibility for 
transplantation.  Simultaneously, the donor will be prepared for the assigned donation, bone 
marrow or mobilized peripheral blood.  The donor’s preparation will require 2 – 3 weeks, during 
which time the recipient will be confirmed eligible for transplantation (Figure 1). 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
A-3 
 
 
 
The major disadvantage of this approach is that a certain proportion of recipients will be found 
ineligible for transplant after randomization.  Based upon NMDP data, this is expected to be 15% 
or less, and has led to appropriate adjustment in the sample size (see Section 5.3).  The intent to 
treat analysis is discussed in the protocol. 
 
Several alternative approaches were considered.  The first of these involved performing work-up 
of both the donor and recipient prior to randomization (Figure 2).  

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
A-4 
 
 
 
This schema has the advantage of ensuring that the recipient is fully eligible for the study and 
transplantation prior to randomization.  The problem here is that following randomization the 
donor must still be prepared for donation.  During this 2 - 3 week preparation, the recipient will 
have ample time to change in status.  Complete or partial rework-ups would be needed for some 
recipients.  Also a consideration, long-distance recipients, i.e., those living far from the 
transplant center, would need to travel back and forth or stay in the transplant center city for 
several weeks before transplant. 
 
A modified version of schema II was also considered at the request of some donor center medical 
directors (Figure 3).  It was reasoned that donor enrollment would be greatly simplified if the 
randomization assignment was known at the time of donor work-up request. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
A-5 
 
 
 
Thus, the recipient would be randomized to a treatment arm and the donor invited to participate 
in the study by agreeing to provide the assigned product.  This model was discarded because it 
further aggravated the time delay for recipients between randomization and transplantation.  In 
addition, there were concerns because it could be argued (strongly) that donors were being 
randomized prior to their enrollment. 
 
The ideal randomization schema would place randomization as close as possible to the start of 
therapy.  This model is shown in Figure 4.  This model, unfortunately, would require that donors 
be prepared for both PBSC and marrow donation during the days prior to randomization.  Thus it 
would be necessary to schedule collection time in both the operating room and apheresis center.  
In all likelihood, donors eventually randomized to PBSC would still need to provide autologous 
blood before the randomization.  This model was rejected because it is too complex, it ties up 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
A-6 
resources that do not belong to the donor centers (operating room and apheresis time) and it 
would be prohibitively costly (Figure 4). 
 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-1 
 
 
APPENDIX B-1 
 
RECIPIENT CONSENT FORM and ATTACHMENTS 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-2 
 
 
Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell 
with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Institution  
Name/Title/Phone number/ 
 
3. Contact information for Emergencies after Hours or on Weekends or Holidays 
Name/Phone number/ 
 
4.  Sponsors and Source of Funding or Other Material Support 
The research in this study is paid for by the National Institutes of Health (NIH) and the National Marrow 
Donor Program ® (NMDP).  The NMDP and the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN) will direct the research study.  This study will be done at many different medical centers, 
including [Center Name/Location]. 
 
5. Introduction 
This is a consent form for a research study.  You are being invited to participate in this study because 
you have a disease that may be treated with a transplant of either bone marrow or peripheral blood 
stem cells (PBSC).  This form is intended to give you information to help you decide if you want to 
participate in this study.  You should read this form and ask any questions you may have before 
agreeing to be in the study. 
 
Doctors have been successfully treating blood disorders such as leukemia and myelodysplasia with a 
transplant of blood stem cells from either the bone marrow or the peripheral blood.  The goal of this 
study is to see if patients receiving a transplant from an unrelated donor have better results using 
blood stem cells from: 1) bone marrow or 2) peripheral blood.  The study may find that patients have 
similar results with either type of transplant.   
 
Important results of this study will include: 
 
Survival 
 
Quality of life 
 
Blood counts after transplant 
 
Number and severity of infections 
 
Graft-versus-host disease (GVHD) 
 
Relapse of disease (return of disease) 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-3 
Other information about the study: 
 
You will not be paid to be in this study. 
 
You or your insurance company will pay the bills for your medical treatment. 
 
You will not be charged for research tests. 
 
You will face the same risks and benefits as any other bone marrow or peripheral blood stem 
cell (PBSC) transplant patient. 
 
It is your choice whether or not to participate in this study.  You and the medical staff at your 
transplant center will discuss other treatment options before you make your decision about 
participating in this study. 
 
6. Purpose of the Study 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cell (PBSC), and their side effects.  At this time, doctors use both types of blood stem cells for 
transplant.  Previous studies have compared the survival of patients who received an unrelated donor 
transplant from bone marrow with patients who received an unrelated donor transplant from PBSCs.  
In these studies there was no difference in survival between the bone marrow transplant patients and 
PBSC transplant patients.  This may have been because the patients in each group did not have the 
same characteristics (for example, different diseases, different ages). 
 
In this study, the patient and donor will be randomly assigned (much like the toss of a coin) to either 
the bone marrow or the PBSC transplant study group.  By randomly assigning the patients to receive 
either a bone marrow or PBSC transplant, the characteristics of each study group should be similar.  
The primary goal is to see which type of blood stem cell transplant (bone marrow or PBSC) has better 
survival results.  With similar patient characteristics in each study group, researchers should be able to 
find out if one type of blood stem cell transplant (bone marrow or PBSC) has better survival results 
for patients, or if both types of blood stem cell transplants have similar survival results.   
 
An important part of this study will look at how well you feel after your transplant.  Researchers want to 
know the effects from each type of stem cell used for the transplant and how long they last. 
 
Good effects might include: 
Bad effects might include: 
 
Quick recovery of blood counts after 
transplant 
 
Slow recovery or no recovery of 
blood counts after transplant 
 
No relapse of disease 
 
Relapse of disease 
 
High cure rates 
 
Severe graft-versus-host disease 
(GVHD) 
 
Few infections 
 
Serious infections 
 
Able to return to important activities in life 
 
Not able to return to important 
activities in life 
 
The information collected from this study will help doctors and future patients make better treatment 
choices.  About 550 patients will take part in this study at many centers around the country. 
 
7. Study Procedures 
If you agree to participate in the study, the transplant process has many steps.  A matched donor must 
be found.  Both you and the donor will need to to give permission to participate in this study.  A 
donor could refuse to participate in this study, but continue to be available for your transplant.  In that 
case, you may decide to have a transplant using this donor, but not participate in this study or another 
donor may be found who does want to participate in this study. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-4 
Since this study looks at the results of two different kinds of transplants, bone marrow and peripheral 
blood stem cell (PBSC), the kind of transplant you will receive will be decided randomly, like a coin 
toss.  Neither you nor your doctor chooses the type of transplant; the type of transplant you will 
receive is determined by a computer program.  Half of the patients in the study will have a bone 
marrow transplant.  The other half will receive a PBSC transplant.  Participation in the study means 
that you are willing to accept either type of transplant. 
 
One part of the study will involve collecting your medical information.  Your medical information 
will be collected for three years.  The study coordinators at your center will collect information from 
your medical record chart every week for 100 days, then at 6 months, 1 year, 2 years, and 3 years. 
 
Another part of the study will ask questions about your physical and emotional health.  This 
information will be collected for five years.  A trained interviewer will contact you by telephone 
before your transplant, then 6 months, 1 year, 2 years and 5 years after your transplant.  These 
interviews will last approximately 15-25 minutes and will be done at a convenient time for you.  They 
will include questions about side effects, health problems and how well you can do things that are 
important to you.  When you are contacted, you may skip any questions you don’t want to answer. 
 
As part of the standard transplant procedure, you will need to take many medications and have other 
medical treatments.  The medical staff will explain these during discussion of your medical care. 
 
8. Possible Discomforts and Risks 
You will face risks from the transplant itself, and from treatments given before and after the 
transplant.  Your doctor thinks these risks are less than the risk from the disease for which you are 
receiving a transplant.  
 
The bone marrow and PBSCs from the donor contain blood stem cells, which allow your blood 
counts (red blood cells, white blood cells, and platelets) to recover.  Blood stem cells make all the 
blood cells in the bone marrow and serve the entire body.  It is possible that even after the transplant 
your bone marrow will not work well enough, and you will be at an increased risk of infections and 
even death.  Infections after transplant can be from bacteria, viruses, parasites, or fungi.  Early after 
transplant, the risk of getting an infection might be less after a PBSC transplant, because the blood 
counts return faster than with bone marrow.  Later, the risk of infections might be increased in PBSC 
transplants, because graft-versus-host disease (GVHD) might be worse and last longer.  Blood counts 
will be done often to track recovery of the bone marrow.  You will get platelets and red cells as 
needed to keep your counts at a healthy level. 
 
There is a risk that stem cells may not grow after being given to you.  This is called graft failure.  
Graft failure can be fatal unless you have a second transplant.  Failure of the donor cells to grow 
(graft failure) may result from a mismatch with the donor, infection, a reduced effect of pre-transplant 
drugs on your body, or not enough cells in the product.  This risk may be less with PBSCs, since 
PBSCs contain more blood stem cells than bone marrow. 
 
Graft-versus-host disease (GVHD) is a frequent problem after unrelated donor transplantation.  After 
the cells in the product begin to grow, there is a risk that the donor cells may react against your body.  
GVHD may show up as a skin rash, or liver or stomach problems.  GVHD may cause nausea (feeling 
sick to your stomach), vomiting (throwing up), lack of appetite, stomach cramps, diarrhea (loose 
stools), and bleeding of the gut.  Chronic GVHD may occur later after transplantation and may 
involve problems with the eyes, mouth, lips, throat and liver.  Early (acute) or late (chronic) GVHD 
may be bad enough to cause death.  GVHD is treated with drugs that weaken the body’s defense 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-5 
system, and thus make you more likely to get an infection.  The chance of getting GVHD may be 
increased with PBSCs, since PBSC transplants contain more donor cells. 
 
Relapse of your disease might occur after transplant, especially in patients with advanced disease.  
This risk may be decreased by PBSC transplantation. 
 
If one type of transplant does have better results, and you are not randomly assigned to that study 
group, you may not receive the same benefits as those in the study group with overall better results. 
 
Completion of the quality of life interviews will not cause you any physical discomfort, although it is 
possible that you will find some of the questions or topics upsetting.  If you do, there will be someone 
available to speak with you.  They will be able to refer you to appropriate counselors or other support 
people. 
 
Refer to Appendix A, B, C or D for additional risks and toxicities toxicities related to the specific 
transplant conditioning regimen you will receive, the drugs you will receive to help prevent graft-
versus-host disease (GVHD) and risks and toxicities related to the transplant procedure itself. 
 
9. Unknown or Unexpected Side Effects  
As with any treatment, there may be unknown and/or unexpected side effects from a bone marrow or 
PBSC transplant.  We may learn new things about bone marrow or PBSC transplants that might make 
you want to stop being in the study.  We will let you know if this happens and you can decide if you 
want to continue in the study. 
 
10. Alternative Treatments Available if You Don’t Want to be in the Study 
Participation in this study is entirely voluntary.  You don't have to be in this study.  What you decide 
will not affect current or future health care you receive at this institution.  Before you decide to be in 
this study, you and the medical staff will discuss other options available to you, including: 
 
No treatment 
 
Chemotherapy 
 
A transplant using your own bone marrow or PBSCs 
 
A transplant of bone marrow or PBSCs from a relative 
 
A transplant of cord blood cells 
 
A bone marrow or PBSC transplant from an unrelated donor without participation in this study 
 
11. Possible Benefits to Participating in the Study 
This research study is comparing the treatment results of bone marrow and PBSC transplants.  At this 
time doctors do not know if one type of transplant has better results than the other, or if they both 
have the same results.  If one type of transplant does have better results, and you are randomly 
assigned to that study group, you may benefit from participating in the study.  The knowledge gained 
from this study may help future patients who need a blood stem cell transplant, but there is no 
expectation that you will benefit from participating in the study. 
 
As a result of the bone marrow or PBSC transplant your disease may be put in remission or continue 
in remission. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-6 
12. Cost of Participating in the Study 
You and/or your insurance company will pay all medical expenses relating to, or arising from 
transplantation of either bone marrow or PBSC.  Research tests described in Section 20 will be paid 
by the NIH and the NMDP.  
 
For questions about your costs, financial responsibilities, and/or medical insurance coverage for your 
transplant and this study, please contact /Center/ Financial Counselor at /Number/. 
 
13. Reimbursement for Participating in the Study 
You will not be paid for participating in this study. 
 
14. In the Event of Injury While Participating in the Study 
If you are injured or become ill while taking part in this study, medical care will be provided at this 
center.  No funds have been set aside to pay you if you are injured.  You or your insurance company 
will be charged for ongoing medical care and/or hospitalization. 
 
Contact your doctor or one of the people listed at the start of this form if you are concerned about a 
research-related injury. 
 
15. Withdrawing from the Study 
You may decide to withdraw at any time, for any reason, without notice from this study that compares 
bone marrow transplant with PBSC transplant.  If you wish, you may withdraw from the study but 
still receive a blood stem cell transplant.  If you withdraw from the study after you have had some or 
all of the pre-transplant treatments and decide to have no transplant at all, then your blood counts may 
not return and you could die. 
 
If you decide to withdraw from the study, we ask that you tell [the Principal Investigator] in writing 
(his/her address is on the front page of this form).  If you withdraw, there will be no penalty or loss of 
benefit to which you are entitled and you will continue to receive medical care. 
 
If you withdraw from the study, the medical staff will continue to tell us about your progress for three 
years after your transplant.  If you do not want this, you must specifically tell your doctor. 
 
If you have any questions about your rights as a study subject, you may contact the Institutional Review 
Board (IRB) office at /number/. 
 
16. Reasons Your Doctor May Take You off the Study 
You can be taken off the study (with or without your consent) for any of these reasons: 
 
You would be harmed by staying in the study. 
 
You need treatment not allowed in this study. 
 
You do not follow directions that are important to participating in the study. 
 
The study is cancelled.  
 
17. Protection of your Privacy and Confidentiality of Your Research Records  
Your participation in this research study will be kept private and confidential.  All your medical, 
demographic (such as race and ethnicity, gender and household income) and quality of life 
information will be kept private and confidential. (Name of Transplant Center) and the organizations 
listed below will not disclose your participation by any means of communication to any person or 
organization, except by your written request, or permission, or unless required by federal, state or 
local laws, or regulatory agencies.  

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-7 
 
Individuals authorized by the organizations below will have access to your research and medical 
information for inspections or audits.  In agreeing to participate, you consent to such inspections and 
to the copying of excerpts from these records, if required by these authorized representatives. 
 
Organizations with access to your research and medical information:  
 
/Institution/ 
 
The National Institutes of Health (NIH) 
 
Office of Human Research Protection (OHRP) 
 
The Food and Drug Administration (FDA)  
 
Institutional Review Boards (IRBs) responsible for this study 
 
Data and Safety Monitoring Board (DSMB), not part of /Institution/ 
 
The National Marrow Donor Program (NMDP) 
 
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 
 
Quality of Life staff at Center on Outcomes, Research, and Education at Evanston Northwestern 
Healthcare 
 
Laboratory staff at Dr. Edmund Waller’s laboratory at Emory Unversity, Esoterix, Inc., Dr. 
Jeffrey Miller’s laboratory at the Univerity of Minnesota 
 
Scientific and medical findings resulting from a study may be presented at meetings and published so 
that the information can be useful to others.  You would not be identified in these presentations and 
publications.  
 
For questions about access to your medical records, please contact /name / at/number/. 
 
18. Expiration Date for Keeping Your Records 
Study records will be kept indefinitely by the transplant center for re-analysis and follow-up. 
 
If you have questions about the keeping of your research records or access to your files, please call 
/name/at /number/. 
 
19. Benefit to Doctors for Your Participation in this Study 
Your doctors have no money invested in this study.  Presenting research results may help the career of a 
doctor.  Therefore, the doctors running this research study may benefit when the results are presented at 
scientific meetings or in the scientific press.  In addition, the hospital where you will receive your 
transplant is paid for participating in the study. 
 
20. Blood Samples for Research Purposes 
You will be asked to provide blood samples to see if infection-fighting cells are working and to help 
better understand tissue matching between donors and recipients in this study.  You do not have to 
participate in this part of the study. 
 
If you agree, you will provide blood samples up to 7 times (10-100 mL each time or approximately 1-
7 tablespoons) between the time transplant is initiated and two years after (up to a total for all 7 blood 
draws of 430 mL or approximately 2 cups).  The samples will be saved for future testing.  The blood 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-8 
can usually be drawn from your central line at the time of other blood collections.  If this is not 
possible, then it will be drawn directly from a vein. 
 
As a standard part of the transplant procedure you will receive vaccinations for diphtheria, tetanus, 
Hepatitis B and pneumococcus.  The research studies on infection-fighting cells will include studies 
to look at how well these vaccinations are working.  You may still receive the vaccinations as part of 
your standard medical care even if you decide not to participate in the research on infection-fighting 
cells. 
 
The doctors conducting this study may choose to do some additional research tests on the blood 
samples.  These tests would only be done if the groups overseeing the safety and protection of 
subjects participating in this study approved these additional tests.  These tests would only be 
performed on blood samples that were left-over after the tests on infection-fighting cells, 
vaccinations, and tissue matching were done; no additional blood would be drawn for these tests.  
This research may include tests to determine and evaluate other factors that affect transplant outcome 
in this study. 
 
Any of your blood samples drawn for research purposes will be sent to laboratories that have a 
contract with the NMDP to conduct these research tests.  Your blood will be labeled with a unique 
code that contains no information that could identify you.  A link to this code does exist.  The link is 
stored at the Data Coordinating Center for the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN).  The staff at the laboratory where your blood is being tested does not have a link to this 
code.  Your blood will be stored at these laboratories until the entire sample has been used for the 
research tests or until the end of the study. 
 
If any of your blood samples are left over after the research studies are completed, these samples will 
either be destroyed or be sent to the National Heart Lung and Blood Institute (NHLBI) sample 
repository in Maryland.  If your left-over blood samples are sent to the repository, they will be given 
an anonymous code.  These left-over blood samples stored at the repository can never be linked to 
you.  Any research performed on these left-over blood samples must first be approved by an advisory 
panel at the NHLBI. 
 
You are free to not take part in this research and still participate in the other parts of the study.  
There will be no change in your care if you choose not to give blood samples for research purposes.  
Please mark your choice below (check only one box): 
 
 I agree to have blood drawn for research purposes. 
 
 I do not agree to have blood drawn for research purposes. 
 
 
 ______________________________________   ______________________________  
Signature 
Date 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-9 
21. Subject’s Consent  
 
I have been informed about this study’s purpose, procedures, possible benefits and risks.  I have been 
given a chance to ask questions and have had them answered to my satisfaction.  I understand that I 
can ask more questions at any time. 
 
I voluntarily agree to participate in this study. 
 
By signing this consent form, I have not given up any of the legal rights, which I otherwise would 
have as a subject in a research study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Subject 
 
 
 
 
Date 
 
 
 ______________________________________  
Print Name of Subject 
 
 
Certification of Counseling Healthcare Professional 
 
 
I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions about 
this information have been answered. 
 
 
 ______________________________________   ______________________________  
Counseling Healthcare Professional 
Date 
 
  Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to  
  obtain consent: 
 
  Print name of interpreter:  _______________________  Date: _____________________  
 
  Signature of interpreter:  ________________________   
 
  An oral translation of this document was administered to the donor in ________________ (state  
  language) by an individual proficient in English and __________________ (state language).  See the  
  attached short form addendum for documentation. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-10 
 
Attachment A 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Total Body Irradiation and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications and irradiation therapy you will receive as part of the conditioning for the 
transplant, and risks related to the transplant itself.  Most of these risks and side effects are listed below, 
but they will vary from person to person.  There may be more risks involved with transplantation, and 
there may be more side effects.  Your doctor may give you medications to lessen some of the side-effects.  
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause you to have diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-term 
bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder damage and 
bleeding for a longer time.  You will be given large amounts of a sterile solution through your central line 
to protect your bladder.  A bladder catheter (thin plastic tube) may be inserted into your bladder, if your 
physician thinks that it can help you.  Cyclophosphamide slows the making of new red blood cells, white 
blood cells, and platelets.  This causes a risk of infection and/or severe bleeding until the transplanted 
donor cells begin to work in you.  You will get blood transfusions as needed.  Cyclophosphamide also 
lowers your defense system.  As a result, you may have more infections for several months after 
transplant.  In a small number of patients, cyclophosphamide can damage the heart muscle causing heart 
failure.  Sometimes cyclophosphamide causes abnormal heart function.  If this occurs you may have 
shortness of breath and have fluids build-up in your body.  This medication can also cause the lungs to 
become scarred. If scarring of the lungs occurs it will usually happen three to six months after you receive 
the medication.  Scarring of the lungs can cause you to die.  Cyclophosphamide can damage the male 
(testes) or female (ovaries) sex glands.  In men, the number of sperm may be reduced but you would still 
be able to have intercourse.  Women who are still menstruating may have irregular periods or may no 
longer have any periods.  Whether you are a man or woman, this medication will likely greatly decrease 
your chances of being able to have a child.  It is not known whether the use of cyclophosphamide will 
cause more side effects or problems with your health in the future. 
 
Total Body Irradiation (TBI):  TBI may cause you to have diarrhea (loose stools), nausea (feeling sick 
to your stomach), vomiting (throwing up), and painful swelling of the saliva gland for a few days.  You 
may also experience short-term hair loss.  TBI kills both sick and normal marrow, leading to a lack of red 
blood cells, white blood cells, and platelets.  The short-term loss of these blood cells could cause you to 
become anemic, develop an infection, and/or bleeding.  This will continue until the transplanted donor 
cells begin to work in you.  You will get blood transfusions as needed.  There is a risk that cataracts 
(cloudiness) may develop in your eyes.  This may mean partial loss of vision, and you may need contact 
lenses or surgery to remove the cataracts.  The TBI dose used will probably result in sterility (not being 
able to have children.)  It is not known whether the use of TBI will cause more side effects or problems 
with your health in the future. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-11 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cell (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness).   
 
 
Risks Related to the Medications Used to Help Prevent Graft-versus-host Disease (GVHD) 
 
Cyclosporine or Tacrolimus:  These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience include nausea 
(feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  Other 
side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects, 
they generally go away when the dose of the medication is decreased.  A few patients have had a seizure 
while on these medications.  You may experience a change of liver or kidney function, in which case the 
medication dose will be reduced or possibly even withheld.  The effect on kidneys seems to increase 
when other medications, which might cause kidney problems, are given at the same time, especially 
antibiotics.  Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate:  This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare you for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate and Steriods:  These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant.  
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-12 
more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets and may be at serious risk for bleeding.  
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, irradiation 
therapy, or both.  VOD causes severe damage to the liver.  Symptoms include jaundice (yellowing of the 
skin and eyes), weight gain, and extra fluid build-up in the abdominal cavity and other parts of the body.  
It can often be managed successfully, and completely resolve.  However, complications can arise that may 
be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines and irradiation cause irritation in the lining of 
the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth 
sores you will be given medicine to help control the pain.  If your mouth sores are severe you may not be 
able to eat normally until the sores are healed.  Mouth sores get better when the white blood count starts 
to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy and irradiation therapy.  The 
blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You 
may gain water weight and not go to the bathroom as often as you normally do.  Capillary leak syndrome 
can be difficult to manage if extra fluid enters the lungs and causes difficulty breathing.  You may die if 
there is continued fluid collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  Occasionally, the high 
doses of chemotherapy and radiation cause severe lung damage that cannot always be treated.  If this 
happens, you may need to use oxygen or even a respirator.  The lung damage may get worse and be life-
threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  As a result of irradiation, cataracts may occur earlier in life compared to a person who had 
not had a transplant.  If you develop cataracts (cloudiness in the eyes) they may require treatment.  It is 
rare, but your kidneys could be affected, causing anemia (low red blood cell count) or high blood 
pressure.  There is also a risk you may develop a second cancer as a result of the chemotherapy, 
irradiation and/or underlying disease.  If secondary cancers occur they generally do not occur until 10 to 
15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-13 
 
Attachment B 
 
Additional Risks and Toxicities Related to the Standard Transpant Procedure 
Busulfan and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications you will receive as part of the conditioning for the transplant, and risks 
related to the transplant itself.  Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your doctor may give you medications to lessen some of the side-effects.  
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause you to have diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-term 
bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder damage and 
bleeding for a longer time.  You will be given large amounts of a sterile solution through your central line 
to protect your bladder.  A bladder catheter (thin plastic tube) may be inserted into your bladder, if your 
physician thinks that it can help you.  Cyclophosphamide slows the making of new red blood cells, white 
blood cells, and platelets.  This causes a risk of infection and/or severe bleeding until the transplanted 
donor cells begin to work in you.  You will get blood transfusions as needed.  Cyclophosphamide also 
lowers your defense system.  As a result you may have more infections for several months after 
transplant.  In a small number of patients, cyclophosphamide can damage the heart muscle causing heart 
failure.  Sometimes cyclophosphamide causes abnormal heart function.  If this occurs you may have 
shortness of breath and have fluids build-up in your body.  This medication can also cause the lungs to 
become scarred.  If scarring of the lungs occurs it will usually happen three to six months after you 
receive the medication.  Scarring of the lungs can cause you to die.  Cyclophosphamide can damage the 
male (testes) or female (ovaries) sex glands.  In men, the number of sperm may be reduced but you would 
still be able to have intercourse.  Women who are still menstruating may have irregular periods or may no 
longer have any periods.  Whether you are a man or woman, this medication will likely greatly decrease 
your chances of being able to have a child.  It is not known whether the use of cyclophosphamide will 
cause more side effects or problems with your health in the future. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
you most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases your risk of infection, lower platelet count that 
increases your risk of bleeding, hair loss, stopping of menstrual periods in women, temporary reduced or 
no sperm production in men.  Less likely side effects that you may experiene are fatigue, sores in the 
mouth or on the lips, fever, rash, loss of appetite, changes in color of the skin, seizure.  Rare side effects 
that you may experience are damage to your lungs, which may cause you to cough, be short of breath and 
have trouble breathing.  It is rare, but busulfan can also cause changes in your liver function.  
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cell (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-14 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience include nausea 
(feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  Other 
side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects 
they generally go away when the dose of the medication is decreased.  A few patients have had a seizure 
while taking these medications.  You may experience a change of liver or kidney function, in which case 
the medication dose will be reduced or possibly even withheld.  The effect on kidneys seems to increase 
when other medications, which might cause kidney problems, are given at the same time, especially 
antibiotics.  Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare you for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant.  
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but 
more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets and may be at serious risk for bleeding. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-15 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth sores you will 
be given medicine to help control the pain.  If your mouth sores are severe you may not be able to eat 
normally until the sores are healed.  Mouth sores get better when the white blood count starts to rise, and 
engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You may gain water weight and 
not go to the bathroom as often as you normally do.  Capillary leak syndrome can be difficult to manage 
if extra fluid enters the lungs and causes difficulty breathing.  You may die if there is continued fluid 
collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  Occasionally, the high 
doses of chemotherapy cause severe lung damage that can not always be treated.  If this happens, you 
may need to use oxygen or even a respirator.  The lung damage may get worse and be life-threatening.  
Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  It is rare, but your kidneys could be affected, causing anemia (low red blood cell count) or 
high blood pressure.  There is also a risk you may develop a second cancer as a result of the 
chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur until 10 
to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-16 
 
Attachment C 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Melphalan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications you will receive as part of the conditioning for the transplant, and risks 
related to the transplant itself.  Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your doctor may give you medications to lessen some of the side effects.  
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects you may experience are low white 
blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects you may experience 
include confusion or coma, trouble seeing or problems with your eyes, trouble breathing, diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), pneumonia, agitation, numbness 
and tingling of the fingertips and toes, and kidney problems. 
 
Melphalan: This medication disrupts the growth of cancer cells and destroys them.  Side effects you 
most likely will experience include nausea (feeling sick to your stomach), hair loss, and low white blood 
cell count, which may lead to infection.  Less likely side effects you may experience include diarrhea 
(loose stools), mouth ulcers, and low platelet count with increased risk of bleeding.  It is rare, but you 
may experience a severe allergic reaction.  Symptoms of a severe allergic reaction include itching, hives 
(bumps on your skin), flushing (redness), wheezing, chest tightness, skin rashes, fever, chills, muscle 
stiffening, severe breathing problems, and loss of appetite. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cell (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness).   
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience may include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects 
they generally go away when the dose of the medication decreased.  A few patients have had a seizure 
while taking these medications.  You may experience a change of liver or kidney function, in which case 
the medication dose will be reduced or possibly withheld.  The effect on kidneys seems to increase when 
other medications that might cause kidney problems are given at the same time, especially antibiotics.  

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-17 
Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by-mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is a medication used to try to prevent GVHD.  Methotrexate causes damage to cells, 
and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth sores 
or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare ou for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all.   
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and as a result bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but more 
serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets, and may be at serious risk for bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It may often be managed 
successfully, and completely resolve.  However, complications can arise that can be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth sores you will 
be given medicine to help control the pain.  If your mouth sores are severe you may not be able to eat 
normally until they are healed.  Mouth sores get better when the white blood count starts to rise, and 
engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You may gain water weight and 
not go to the bathroom as often as you normally do.  Capillary leak syndrome can be difficult to manage 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-18 
if extra fluid enters the lungs and causes difficulty breathing.  You may die if there is continued fluid 
collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of this the transplant.  Occasionally, the 
high doses of chemotherapy cause severe lung damage that can not always be treated.  If this happens, 
you may need to use oxygen or even a respirator.  The lung damage may get worse and be life-
threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  It is rare, but your kidneys could be affected, causing anemia (low red blood cell count) or 
high blood pressure.  There is also a risk you may develop a second cancer as a result of the 
chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur until 10 
to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating all of this fluid.  Furosemide is a medication that is often given to help eliminate 
this excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium 
and sodium. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-19 
 
Attachment D 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Busulfan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications you will receive as part of the conditioning for the transplant, and risks 
related to the transplant itself.  Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your doctor may give you medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects you may experience are low white 
blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects you may experience 
include confusion or coma, trouble seeing or problems with your eyes, trouble breathing, diarrhea (loose 
stools), nausea (feeling sick to your stomach), vomiting (throwing up), pneumonia, agitation, numbness 
and tingling of the fingertips and toes, and kidney problems. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
you most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases your risk of infection, lower platelet count that 
increases your risk of bleeding, hair loss, stopping of menstrual periods in women, temporary reduced or 
no sperm production in men.  Less likely side effects that you may experience are fatigue, sores in the 
mouth or on the lips, fever, rash, loss of appetite, changes in color of the skin, seizure.  Rare side effects 
that you may experience are damage to your lungs, which may cause you to cough, be short of breath and 
have trouble breathing.  It is rare, but busulfan can also cause changes in your liver function.  
 
Antithymocyte Globulin (ATG): This medication is given pre-transplant with the conditioning regimen 
medications to try and prevent both acute and chronic graft-versus-host disease.  While taking ATG you 
most likely will have, a fever and chills, a lower white blood cell count that increases your risk of 
infection, a lower platelet count that increases your risk of bleeding, and a skin rash.  Less likely side 
effects you may experience are fatigue, diarrhea, vomiting, muscle aches and headaches.  Rare side 
effects that you may experience are changes in your blood pressures (either higher or lower blood 
pressure), rapid heart beat, be short of breath and have trouble breathing, chest pain and retention of 
fluids. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-20 
Risks Related to the Medications Used to Help Prevent Graft versus Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus:  These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects you may experience include nausea 
(feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  Other 
side effects you may experience include high blood pressure (hypertension), shaking of the hands 
(tremor), increased hair growth and possibly an effect on mental function.  If you experience these effects, 
they generally go away when the dose of the medication is decreased.  A few patients have had a seizure 
while on these medications.  You may experience a change of liver or kidney function, in which case the 
medication dose will be reduced or possibly even withheld.  The effect on kidneys seems to increase 
when other medications, which might cause kidney problems, are given at the same time, especially 
antibiotics.  Occasionally, the kidney damage caused may require the use of an artificial kidney machine 
(hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate:  This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which you may have already developed from the procedures and 
medications used to prepare you for the transplant.  Methotrexate may slow down the recovery of blood 
cells after transplantation.  Methotrexate can cause kidney damage.  If your kidneys are already damaged 
for other reasons, it can worsen kidney function.  If kidney damage does occur, the methotrexate dose 
may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate and Steroids:  These medications interfere with the body’s 
defense system (the immune system).  This may cause you to have more infections (especially viral 
infections and pneumonia) for several months after transplant.  
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help your blood to clot.  Your platelets will be low until the new bone marrow grows 
and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, but 
more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains low.  
Usually, there is success in preventing major bleeding problems with transfusions of platelets.  However, 
some patients may not respond well to transfused platelets and may be at serious risk for bleeding.  
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, irradiation 
therapy, or both.  VOD causes severe damage to the liver.  Symptoms include jaundice (yellowing of the 
skin and eyes), weight gain, and extra fluid build-up in the abdominal cavity and other parts of the body.  

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-21 
It can often be managed successfully, and completely resolve.  However, complications can arise that may 
be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines and irradiation cause irritation in the lining of 
the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If you have severe mouth 
sores you will be given medicine to help control the pain.  If your mouth sores are severe you may not be 
able to eat normally until the sores are healed.  Mouth sores get better when the white blood count starts 
to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy and irradiation therapy.  The 
blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  You 
may gain water weight and not go to the bathroom as often as you normally do.  Capillary leak syndrome 
can be difficult to manage if extra fluid enters the lungs and causes difficulty breathing.  You may die if 
there is continued fluid collection in the lungs.  
 
Unexpected Organ Damage and Other Side Effects: It is possible you may experience unexpected, 
life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  Occasionally, the high 
doses of chemotherapy and radiation cause severe lung damage that cannot always be treated.  If this 
happens, you may need to use oxygen or even a respirator.  The lung damage may get worse and be life-
threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is often fatal. 
 
Late Effects: You may experience side effects that occur several months to many years after your 
transplant.  You may experience poor function of the thyroid gland, requiring you to take thyroid 
medication.  It is rare, but your kidneys could be affected, causing anemia (low red blood cell count) or 
high blood pressure.  There is also a risk you may develop a second cancer as a result of the 
chemotherapy, irradiation and/or underlying disease.  If secondary cancers occur they generally do not 
occur until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are 
unknown. 
 
Fluid Build-up: You will receive intravenous fluids during the transplant process and you may have 
difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-22 
 
Legal Guardian Informed Consent to Participate in Research 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell 
with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Child’s Institution 
Name/Title/Phone number/ 
 
3. Contact Information for Emergencies after Hours or on Weekends or Holidays: 
Name/Phone number/ 
 
4. Sponsors and Source of Funding or Other Material Support 
The research in this study is paid for by the National Institutes of Health (NIH) and the National Marrow 
Donor Program® (NMDP).  The NMDP and the Blood and Marrow Transplant Clinical Trials Network 
(BMT CTN) will direct the research study.  This study will be done at many different medical centers, 
including [Center Name/Location]. 
 
5. Introduction 
This is a consent form for a research study.  Your child is being invited to participate in this study 
because he/she has a disease that may be treated with a transplant of either bone marrow or peripheral 
blood stem cells (PBSC).  This form is intended to give you information to help you decide if you 
want your child to participate in this study.  You should read this form and ask any questions you may 
have before allowing your child to participate in the study. 
 
Doctors have been successfully treating blood disorders such as leukemia and myelodysplasia with a 
transplant of blood stem cells from either the bone marrow or the peripheral blood.  The goal of this 
study is to see if patients receiving a transplant from an unrelated donor have better results using 
blood stem cells from: 1) bone marrow or 2) peripheral blood.  The study may find that patients have 
similar results with either type of transplant.  
 
 
Important results of this study will include: 
 
Survival 
 
Quality of life  
 
Blood counts after transplant 
 
Number and severity of infections 
 
Graft-versus-host disease (GVHD) 
 
Relapse of disease (return of disease) 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-23 
 
 
Other information about the study: 
 
Your child will not be paid to be in this study. 
 
You or your child’s insurance company will pay the bills for your child’s medical treatment. 
 
You will not be charged for research tests. 
 
Your child will face the same risks and benefits as any other bone marrow or peripheral blood 
stem cell (PBSC) transplant patient. 
 
You and your child have a choice whether or not to participate in this study.  The medical staff at 
your child’s transplant center will discuss other treatment options before you make a decision about 
allowing your child to participate in this study. 
 
6. Purpose of the Study 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cell (PBSC), and their side effects.  At this time, doctors use both types of blood stem cells for 
transplant.  Previous studies have compared the survival of patients who received an unrelated donor 
transplant from bone marrow with patients who received an unrelated donor transplant from PBSCs.  
In these studies there was no difference in survival between the bone marrow transplant patients and 
PBSC transplant patients.  This may have been because the patients in each group did not have the 
same characteristics (for example, different diseases and different ages).  
 
In this study, the patient and donor will be randomly assigned (much like the toss of a coin) to either 
the bone marrow or the PBSC transplant study group.  By randomly assigning the patients to receive 
either a bone marrow or PBSC transplant, the characteristics of each study group should be similar.  
The primary goal is to see which type of blood stem cell transplant (bone marrow or PBSC) has better 
survival results.  With similar patient characteristics in each study group, researchers should be able to 
find out if one type of blood stem cell transplant (bone marrow or PBSC) has better survival results 
for patients, or if both types of blood stem cell transplants have similar survival results. 
 
An important part of this study will look at how patients recover after transplant.  Researchers want to 
know what the effects are from each type of blood stem cells used for the transplant and how long they 
last. 
 
Good effects might include: 
 Quick recovery of blood counts after 
transplant 
 No relapse of disease 
 High cure rates 
 Few infections 
 Able to return to important activities in life 
 
Bad effects might include: 
 Slow recovery or no recovery of blood 
counts after transplant 
 Relapse of disease 
 Severe graft-versus-host disease (GVHD) 
 Serious infections 
 Not able to return to important activities in 
life 
 
The information collected from this study will help doctors and future patients make better treatment 
choices.  About 550 patients will take part in this study at many centers around the country. 
 
7. Study Procedures 
If you allow your child to participate in this study, the transplant process has many steps.  A matched 
donor must be found.  You will need to give permission for your child to participate in the study and 
the donor will also need to give permission to participate in this study.  A donor could refuse to 
participate in this study, but continue to be available for your child’s transplant.  In that case, you may 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-24 
decide that your child will have a transplant using this donor, but not participate in this study, or 
another donor who does want to participate in this study may be found. 
Since this study looks at the results of two different kinds of transplants, bone marrow and peripheral 
blood stem cell (PBSC), the kind of transplant your child will receive will be decided randomly, like a 
coin toss.  Neither you, nor your child’s doctor, choose the type of transplant; the type of transplant 
your child will receive is determined by a computer program.  Half of the patients in the study will 
have a bone marrow transplant. The other half will receive a PBSC transplant.  Participation in the 
study means that you are willing to accept either type of transplant for your child. 
One part of the study will involve collecting your child’s medical information.  Your child’s medical 
information will be collected for three years.  The study coordinators at your child’s center will 
collect information from your child’s medical record chart every week for 100 days, then at 6 months, 
1 year, 2 years and 3 years. 
 
If your child is 16 or 17 years old, another part of the study will ask questions about his/her physical 
and emotional health.  This information will be collected for five years.  A trained interviewer will 
contact your child by telephone before his/her transplant, then 6 months, 1 year, 2 years and 5 years 
after the transplant.  These interviews will last approximately 15-25 minutes and will be done at a 
convenient time for your child.  They will include questions about side effects, health problems and 
how well your child can do things that are important to him/her.  When your child is contacted, your 
child may skip any questions he/she doesn’t want to answer. 
 
As part of the standard transplant procedure, your child will need to take many medications and have 
other medical treatments as part of the transplant.  The medical staff will explain these during 
discussion of your child’s medical care. 
 
8. Possible Discomforts and Risks 
Your child will face risks from the transplant itself and from treatments given before and after the 
transplant.  Your child’s doctor thinks these risks are less than the risk from the disease for which 
your child is receiving a transplant. 
 
The bone marrow and PBSCs from the donor contain blood stem cells, which allow your child’s 
blood counts (red blood cells, white blood cells, and platelets) to recover.  Blood stem cells make all 
the blood cells in the bone marrow and serve the entire body.  It is possible that even after the 
transplant your child’s bone marrow will not work well enough and he/she will be at an increased risk 
of infections and even death.  Infections after transplant can be from bacteria, viruses, parasites, or 
fungi.  Early after transplant, the risk of getting an infection might be less after a PBSC transplant, 
because the blood counts return faster than with bone marrow.  Later, the risk of infections might be 
increased in PBSC transplants, because graft-versus-host disease (GVHD) might be worse and last 
longer.  Blood counts will be done often to track recovery of the bone marrow.  Your child will get 
platelets and red cells as needed to keep his/her counts at a healthy level. 
 
There is a risk that stem cells may not grow after being given to your child.  This is called graft 
failure.  Graft failure can be fatal unless your child has a second transplant.  Failure of the donor cells 
to grow (graft failure) may result from a mismatch with the donor, infections, a reduced effect of pre-
transplant medications on your child’s body, or not enough cells in the product.  This risk may be less 
with PBSCs, since PBSCs contain more blood stem cells than bone marrow. 
 
Graft-versus-host disease (GVHD) is a frequent problem after unrelated donor transplantation.  After 
the cells in the product begin to grow, there is a risk that the donor cells may react against your 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-25 
child’s body. GVHD may show up as a skin rash, or liver or stomach problems.  GVHD may cause 
nausea (feeling sick to your stomach), vomiting (throwing up), lack of appetite, stomach cramps, 
diarrhea (loose stools), and bleeding of the gut.  Chronic GVHD may occur later after transplantation 
and may involve problems with the eyes, mouth, lips, throat and liver.  Early (acute) or late (chronic) 
GVHD may be bad enough to cause death.  GVHD is treated with drugs that weaken the body’s 
defense system, and thus makes your child more likely to get an infection.  The chance of getting 
GVHD may be increased with PBSCs, since PBSC transplants contain more donor cells. 
 
Relapse of your child’s disease might occur after transplant, especially in patients with advanced 
disease.  This risk may be decreased by PBSC transplantation. 
 
If one type of transplant does have better results, and your child is not randomly assigned to that study 
group, your child may not receive the same benefits as those children in the study group with overall 
better results. 
 
Completion of the quality of life interviews will not cause your child any physical discomfort, 
although it is possible that your child will find some of the questions or topics upsetting.  If this 
occurs, there will be someone available to speak with your child.  They will be able to refer your child 
to appropriate counselors or other support people. 
 
Refer to Appendix A, B, C or D for additional risks and toxicities related to the specific transplant 
conditioning regimen your child will receive and the specific drugs your child will receive to help 
prevent graft-versus-host disease (GVHD). 
 
9. Unknown or Unexpected Side Effects 
As with any treatment, there may be unknown and/or unexpected side effects from a bone marrow or 
PBSC transplant.  We may learn new things about bone marrow or PBSC transplants that might make 
you or your child want to stop being in the study.  We will let you know if this happens and you can 
decide if you want to continue to allow your child to be in the study. 
 
10. Alternative Treatments Available if You Don’t Want Your Child to be in the Study 
Participation in this study is entirely voluntary.  You don’t have to allow your child to be in this 
study. What you and your child decide will not affect current or future health care your child receives 
at this institution.  Before you decide to allow your child to be in this study, you and the medical staff 
will discuss other options available to your child, including: 
 
No treatment 
 
Chemotherapy 
 
A transplant using your child’s own bone marrow or PBSCs 
 
A transplant of bone marrow or PBSCs from a relative 
 
A transplant of cord blood cells 
 
A bone marrow or PBSC transplant from an unrelated donor without participation in this study 
 
11. Possible Benefits to Participating in the Study  
This research study is comparing the treatment results of bone marrow and PBSC transplants.  At this 
time doctors do not know if one type of transplant has better results than the other, or if they both 
have the same results.  If one type of transplant does have better results, and your child is randomly 
assigned to that study group, he/she may benefit from participating in the study.  The knowledge 
gained from this study may help future patients who need a blood stem cell transplant, but there is no 
expectation that your child will benefit from participating in this study. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-26 
 
As a result of the bone marrow or PBSC transplant your child’s disease may be put in remission or 
continue in remission. 
 
12. Cost of Participating in the Study 
You and/or your child's insurance company will pay all medical expenses relating to, or arising from 
transplantation of either bone marrow or PBSC.  Research tests described in Section 20 will be paid 
by the NIH and the NMDP. 
 
For questions about your costs, financial responsibilities, and/or medical insurance coverage for your 
child’s transplant and this study, please contact /Center/ Financial Counselor at /Number/. 
 
13. Reimbursement for Participating in the Study 
You or your child will not be paid for participating in this study. 
 
14. In the Event of Injury While Participating in the Study 
If your child is injured or becomes ill while taking part in this study, medical care will be provided at 
this center.  No funds have been set aside to pay you or your child if injury occurs.  You or your 
insurance company will be charged for ongoing medical care and/or hospitalization. 
 
Contact your child’s doctor or one of the people listed at the start of this form if you are concerned about 
a research-related injury. 
 
15. Withdrawing from the Study 
You may decide to withdraw your child at any time, for any reason, without notice, from this study 
that compares bone marrow transplant with PBSC transplant.  If you wish, you may withdraw your 
child from the study but he/she may still receive a blood stem cell transplant.  If you decide to 
withdraw your child from the study after your child has had some or all of the pre-transplant 
treatments and decide to have no transplant at all, then your child’s blood counts may not return and 
he/she could die. 
 
If you decide to withdraw your child from the study, we ask that you tell [the Principal Investigator] 
in writing (his/her address is on the front page of this form).  If you withdraw your child, there will be 
no penalty or loss of benefit to which your child is entitled, and he/she will continue to receive 
medical care. 
 
If you withdraw your child from the study, the medical staff will continue to tell us about your child’s 
progress for three years after his/her transplant.  If you do not want this, you must specifically tell your 
child’s doctor. 
 
If you have any questions about your child’s rights as a study subject, you may phone the Institutional 
Review Board (IRB) office at /number/. 
 
16. Reasons Your Child’s Doctor May Take Your Child off the Study 
Your child can be taken off the study (with or without your consent) for any of these reasons: 
 
Your child would be harmed by staying in the study. 
 
Your child needs treatment not allowed in this study. 
 
Your child does not follow directions that are important to participating in the study. 
 
The study is cancelled. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-27 
17. Protection of Your Child’s Privacy and Confidentiality of Your Child’s Research Records 
Your child’s participation in this research study will be kept private and confidential.  All your child’s 
medical, demographic (such as race and ethnicity, gender and household income) and quality of life 
information will be kept private and confidential. (Name of Transplant Center) and the organizations 
listed below will not disclose your child’s participation by any means of communication to any 
person or organization, except by your written request, or permission, or unless required by federal, 
state or local laws, or regulatory agencies. 
 
Individuals authorized by the organizations below will have access to your child’s research and 
medical information for inspections or audits.  In allowing your child to participate, you consent to 
such inspections and to the copying of excerpts from your child’s records, if required by these 
authorized representatives. 
 
Organizations with access to your child’s research and medical information: 
 
/Institution/ 
 
The National Institutes of Health (NIH) 
 
Office of Human Research Protection (OHRP) 
 
The Food and Drug Administration (FDA) 
 
Institutional Review Boards (IRBs) responsible for this study 
 
Data and Safety Monitoring Board (DSMB), not part of /Institution/ 
 
The National Marrow Donor Program (NMDP) 
 
Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 
 
Quality of Life staff at Center on Outcomes, Research, and Education at Evanston 
Northwestern Healthcare 
 
Laboratory staff at Dr. Edmund Waller’s laboratory at Emory Unversity, Esoterix, Inc., and 
Dr. Jeffrey Miller’s laboratory at the Univerity of Minnesota 
 
Scientific and medical findings resulting from a study may be presented at meetings and published so 
that the information can be useful to others.  Your child would not be identified in these presentations 
and publications. 
 
For questions about access to your child’s medical records, please contact /name/ at /number/. 
 
18. Expiration Date for Keeping Your Child’s Records 
Study records will be kept indefinitely by the transplant center for re-analysis and follow-up.   
 
If you have questions about the keeping of your child’s research records or access to your child’s 
files, please call /name/ at /number/. 
 
19. Benefit to Doctors for Your Child’s Participation in the Study 
Your child’s doctors have no money invested in this study.  Presenting research results may help the 
career of a doctor.  Therefore, the doctors running this research study may benefit when the results are 
presented at scientific meetings or in the scientific press. In addition, the hospital where your child will 
receive his/her transplant is paid for participating in the study. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-28 
20. Blood Samples for Research Purposes 
You will be asked to allow your child to provide blood samples to see if infection-fighting cells are 
working and to help better understand tissue matching between donors and recipients in this study.  
You do not have to allow your child to participate in this part of the study. 
 
If you agree, your child will provide blood samples up to 7 times (10-100 mL each time or 
approximately 1-7 tablespoons) between the time transplant is initiated and two years after (up to a 
total for all 7 blood draws of 430 mL or approximately 2 cups).  The samples will be saved for future 
testing.  The amount of blood drawn will never be more than what is safe for your child to provide.  
The blood can usually be drawn from your child’s central line at the time of other blood collections.  
If this is not possible, then it will be drawn directly from a vein. 
 
As a standard part of the transplant procedure your child will receive vaccinations for diphtheria, 
tetanus, Hepatitis B and pneumococcus.  The research studies on infection fighting-cells will include 
studies to look at how well these vaccinations are working.  Your child may still receive the 
vaccinations as part of his/her standard medical care even if your child does not participate in the 
research on infection-fighting cells. 
 
The doctors conducting this study may choose to do some additional research tests on the blood 
samples.  These tests would only be done if the groups overseeing the safety and protection of 
subjects participating in this study approved these additional tests.  These tests would only be 
performed on blood samples that were left over after the tests on infection-fighting cells, 
vaccinations, and tissue matching were done; no additional blood would be drawn for these tests.  
This research may include tests to determine and evaluate other factors that affect transplant outcome 
in this study. 
 
Any of your child’s blood samples drawn for research purposes will be sent to laboratories that have a 
contract with the NMDP to conduct these research tests.  Your child’s blood will be labeled with a 
unique code that contains no information that could identify him/her.  A link to this code does exist. 
The link is stored at the Data Coordinating Center for the Blood and Marrow Transplant Clinical 
Trials Network (BMT CTN).  The staff at the laboratory where your child’s blood is being tested does 
not have a link to this code.  Your child’s blood will be stored at these laboratories until all the sample 
has been used for the research tests or until the end of the study. 
 
If any of your child’s blood samples are left over after the research studies are completed, these 
samples will either be destroyed or be sent to the National Heart Lung, and Blood Institute (NHLBI) 
sample repository in Maryland.  If your child’s left-over blood samples are sent to the repository, they 
will be given an anonymous code.  These left-over blood samples stored at the repository can never 
be linked to your child.  Any research performed on these left-over blood samples must first be 
approved by an advisory panel at the NHLBI. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-29 
You are free to not allow your child to take part in this research and still allow your child to 
participate in the other parts of the study.  There will be no change in your child’s care if you 
choose not to allow your child to give blood samples for research purposes.  Please mark your 
choice below (check only one box): 
 
 I agree to have blood drawn from my child for research purposes. 
 
 I do not agree to have blood drawn from my child for research purposes. 
 
 ________________________________________   _____________________________  
Signature of Parent/Legal Guardian 
Date 
 
 ________________________________________   _____________________________  
Signature of Parent/Legal Guardian 
Date 
 
The signatures of both parents (or legal guardians) are required. 
 
 
21. Parental/Legal Guardian Consent 
The signatures of both parents (or legal guardians) are required. 
 
I have been informed about this study’s purpose, procedures, possible benefits and risks.  I have been 
given a chance to ask questions and have had them answered to my satisfaction.  I understand that I 
can ask more questions at any time. 
 
I voluntarily agree to allow my child to participate in this study. 
 
By signing this consent form, I have not given up any of the legal rights, which I or my child 
otherwise would have as a subject in a research study. 
 
 
 ________________________________________   _____________________________  
Signature of Parent/Legal Guardian 
Date 
 
 ________________________________________  
Print Name of Parent/Legal Guardian 
 
 
 ________________________________________   _____________________________  
Signature of Parent/Legal Guardian 
Date 
 
 ________________________________________  
Print Name of Parent/Legal Guardian 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-30 
Certification of Counseling Healthcare Professional 
 
I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions about 
this information have been answered. 
 
 ________________________________________   _____________________________  
Counseling Healthcare Professional 
Date 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to 
obtain consent: 
 
Print name of interpreter:  ________________________  Date: _____________________  
 
Signature of interpreter:  _________________________   
 
An oral translation of this document was administered to the donor in ______________________ (state 
language) by an individual proficient in English and _____________________ (state language).  See the 
attached short form addendum for documentation. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-31 
 
Attachment A 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Total Body Radiation and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications and irradiation therapy your child will receive as part of the conditioning 
for the transplant and risks related to the transplant itself.  Most of these risks and side effects are listed 
below, but they will vary from person to person.  There may be more risks involved with transplantation, 
and there may be more side effects.  Your child’s doctor may give your child medications to lessen some 
of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause your child to have diarrhea 
(loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-
term bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder 
damage and bleeding for a longer time.  Your child will be given large amounts of a sterile solution 
through his/her central line to protect the bladder.  A bladder catheter (thin plastic tube) may be inserted 
into your child’s bladder, if your child’s physician thinks that it can help him/her.  Cyclophosphamide 
slows the making of new red blood cells, white blood cells, and platelets.  This causes a risk of infection 
and/or severe bleeding until the transplanted donor cells begin to work in your child.  Your child will get 
blood transfusions as needed.  Cyclophosphamide also lowers the defense system.  As a result your child 
may have more infections for several months after transplant.  In a small number of patients, 
cyclophosphamide can damage the heart muscle causing heart failure.  Sometimes cyclophosphamide 
causes abnormal heart function.  If this occurs your child may have shortness of breath and have fluids 
build-up in his/her body.  This medication can also cause the lungs to become scarred.  If scarring of the 
lungs occurs it will usually happen three to six months after your child receives the medication.  Scarring 
of the lungs can cause your child to die.  Cyclophosphamide can adversely affect the production of 
hormones responsible for the onset and completion of puberty and the number and function of eggs (girls) 
and sperm (boys) leading to decreased fertility and even sterility.  The onset of puberty can be delayed in 
your child and your child’s ultimate height can be decreased.  Since it is not possible to predict in a 
specific child the extent of these effects, it is important that your child has continuing, careful follow-up 
after the transplant.  It is not known whether the use of cyclophosphamide will cause more side effects or 
problems with your child’s health in the future. 
 
Total Body Irradiation (TBI): TBI may cause your child to have diarrhea (loose stools), nausea (feeling 
sick to your stomach), vomiting (throwing up), and painful swelling of the saliva glands for a few days.  
Your child may also experience short-term hair loss.  TBI kills both sick and normal marrow, leading to a 
lack of red blood cells, white blood cells, and platelets.  The short-term loss of these blood cells could 
cause your child to become anemic, develop an infection, and/or bleeding.  This will continue until the 
transplanted donor cells begin to work in your child.  Your child will get blood transfusions as needed.  
There is a risk that cataracts (cloudiness) may develop in your child’s eyes.  This may mean partial loss of 
vision, and your child may need contact lenses or surgery to remove the cataracts. TBI can adversely 
affect the production of hormones responsible for the onset and completion of puberty and the number 
and function of eggs (girls) and sperm (boys) leading to decreased fertility and even sterility.  The onset 
of puberty can be delayed in your child and your child’s ultimate height can be decreased.  Since it is not 
possible to predict in a specific child the extent of these effects, it is important that your child has 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-32 
continuing, careful follow-up after the transplant.  It is not known whether the use of TBI will cause more 
side effects or problems with your child’s health in the future. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects they generally go away when the dose of the medication is decreased. A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your child’s body.  It may cause or can worsen the 
mouth sores or inflammation of the mouth which your child may have already developed from the 
procedures and medications used to prepare him/her for the transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation.  Methotrexate can cause kidney damage.  If your child’s 
kidneys are already damaged for other reasons, it can worsen kidney function.  If kidney damage does 
occur, the methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-33 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low.  Usually, there is success in preventing major bleeding problems with transfusions of platelets. 
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy, irradiation 
therapy, or both.  VOD causes severe damage to the liver. Symptoms include jaundice (yellowing of the 
skin and eyes), weight gain, and extra fluid build-up in the abdominal cavity and other parts of the body. 
It can often be managed successfully, and completely resolve.  However, complications can arise that may 
be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines and irradiation cause irritation in the lining of 
the mouth and intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe 
mouth sores he/she will be given medicine to help control the pain.  If your child’s mouth sores are 
severe, he/she may not be able to eat normally until the sores are healed.  Mouth sores get better when the 
white blood count starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy and irradiation therapy.  The 
blood vessels may become ‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your 
child may gain water weight and not go to the bathroom as often as he/she normally does.  Capillary leak 
syndrome can be difficult to manage if extra fluid enters the lungs and causes difficulty breathing.  Your 
child may die if there is continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy and irradiation cause severe lung damage that cannot 
always be treated.  If this happens, your child may need to use oxygen or even a respirator. The lung 
damage may get worse and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney 
failure) may occur, which is often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication.  As a result of irradiation, cataracts (cloudiness of the eyes) may occur earlier in life 
as compared to a person who had not had a transplant.  If your child develops cataracts they may require 
treatment. It is rare, but your child’s kidneys could be affected, causing anemia (low red blood cell count) 
or high blood pressure.  There is also a risk your child may develop a second cancer as a result of the 
chemotherapy, irradiation and/or underlying disease.  If secondary cancers occur they generally do not 
occur until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are 
unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-34 
 
Attachment B 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Busulfan and Cyclophosphamide Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications your child will receive as part of the conditioning for the transplant, and 
risks related to the transplant itself. Most of these risks and side effects are listed below, but they will vary 
from person to person.  There may be more risks involved with transplantation, and there may be more 
side effects.  Your child’s doctor may give your child medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Cyclophosphamide (Cytoxan): This is a common medication used to treat cancer.  This medication kills 
cancer cells by stopping them from growing.  Cyclophosphamide may cause your child to have diarrhea 
(loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), short-term hair loss, short-
term bladder problems, and, at times, bleeding from the bladder.  A few patients may have bladder 
damage and bleeding for a longer time.  Your child will be given large amounts of a sterile solution 
through the central line to protect his/her bladder.  A bladder catheter (thin plastic tube) may be inserted 
into your child’s bladder, if your child’s physician thinks that it can help him/her.  Cyclophosphamide 
slows the making of new red blood cells, white blood cells, and platelets.  This causes a risk of infection 
and/or severe bleeding until the transplanted donor cells begin to work in your child.  Your child will get 
blood transfusions as needed. Cyclophosphamide also lowers the defense system.  As a result your child 
may have more infections for several months after transplant. I n a small number of patients, 
cyclophosphamide can damage the heart muscle causing heart failure.  Sometimes cyclophosphamide 
causes abnormal heart function.  If this occurs your child may have shortness of breath and have fluids 
build-up in his/her body.  This medication can also cause the lungs to become scarred.  If scarring of the 
lungs occurs it will usually happen three to six months after your child receives the medication.  Scarring 
of the lungs can cause your child to die.  Cyclophosphamide can adversely affect the production of 
hormones responsible for the onset and completion of puberty and the number and function of eggs (girls) 
and sperm (boys) leading to decreased fertility and even sterility.  The onset of puberty can be delayed in 
your child and your child’s ultimate height can be decreased.  Since it is not possible to predict in a 
specific child the extent of these effects, it is important that your child has continuing careful follow-up 
after the transplant.  It is not known whether the use of cyclophosphamide will cause more side effects or 
problems with your child’s health in the future. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
your child most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases the risk of infection, lower platelet count that 
increases the risk of bleeding, hair loss, stopping of menstrual periods in girls who have reached puberty, 
temporary reduced or no sperm production in boys who have reached puberty.  Less likely side effects 
that your child may experience are fatigue, sores in the mouth or on the lips, fever, rash, loss of appetite, 
changes in color of the skin, seizure.  Rare side effects that your child may experience are damage to the 
lungs, which may cause him/her to cough, be short of breath, and have trouble breathing.  It is rare, but 
busulfan can also cause changes in your child’s liver function. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-35 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects they generally go away when the dose of the medication is decreased.  A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your child's body.  It may cause or can worsen the 
mouth sores or inflammation of the mouth which your child may have already developed from the 
procedures and medications used to prepare him/her for the transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation. Methotrexate can cause kidney damage.  If your child’s 
kidney is already damaged for other reasons, it can worsen kidney function.  If kidney damage does 
occur, the methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one drug or the transplanted donor cells, but they are 
risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-36 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low. Usually, there is success in preventing major bleeding problems with transfusions of platelets.  
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe mouth sores 
he/she will be given medicine to help control the pain.  If your child’s mouth sores are severe, he/she may 
not be able to eat normally until the sores are healed.  Mouth sores get better when the white blood count 
starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your child may gain water weight 
and not go to the bathroom as often as she/she normally does.  Capillary leak syndrome can be difficult to 
manage if extra fluid enters the lungs and causes difficulty breathing.  Your child may die if there is 
continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy cause severe lung damage that can not always be treated.  
If this happens, your child may need to use oxygen or even a respirator.  The lung damage may get worse 
and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is 
often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication.  It is rare, but your child’s kidneys could be affected, causing anemia (low red blood 
cell count) or high blood pressure.  There is also a risk your child may develop a second cancer as a result 
of the chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-37 
 
Attachment C 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Melphalan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell PBSC) transplant.  There 
are risks from the medications your child will receive as part of the conditioning for the transplant and 
risks related to the transplant itself.  Most of these risks and side effects are listed below, but they will 
vary from person to person.  There may be more risks involved with transplantation, and there may be 
more side effects.  Your child’s doctor may give your child medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects your child may experience are low 
white blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects your child may 
experience include confusion or coma, trouble seeing or problems with your child’s eyes, trouble 
breathing, diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
pneumonia, agitation, numbness and tingling of the fingertips and toes, and kidney problems. 
 
Melphalan: This medication disrupts the growth of cancer cells and destroys them.  Side effects your 
child most likely will experience include nausea (feeling sick to stomach), hair loss, and low white blood 
cell count, which may lead to infection.  Less likely side effects your child may experience include 
diarrhea (loose stools), mouth ulcers, and low platelet count with increased risk of bleeding.  It is rare, but 
your child may experience a severe allergic reaction.  Symptoms of a severe allergic reaction include 
itching, hives (bumps on the skin), flushing (redness), wheezing, chest tightness, skin rashes, fever, chills, 
muscle stiffening, severe breathing problems, and loss of appetite. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 
 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects, they generally go away when the dose of the medication is decreased.  A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-38 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes away when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your body.  It may cause or can worsen the mouth 
sores or inflammation of the mouth which your child may have already developed from the procedures 
and medications used to prepare him/her for the transplant.  Methotrexate may slow down the recovery of 
blood cells after transplantation.  Methotrexate can cause kidney damage.  If your child’s kidneys are 
already damaged for other reasons, it can worsen kidney function.  If kidney damage does occur, the 
methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one medication or the transplanted donor cells, but they 
are risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low.  Usually, there is success in preventing major bleeding problems with transfusions of platelets.  
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe mouth sores 
he/she will be given medicine to help control the pain.  If your child’s mouth sores are severe, he/she may 
not be able to eat normally until the sores are healed.  Mouth sores get better when the white blood count 
starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your child may gain water weight 
and not go to the bathroom as often as he/she normally does.  Capillary leak syndrome can be difficult to 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-39 
manage if extra fluid enters the lungs and causes difficulty breathing.  Your child may die if there is 
continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy cause severe lung damage that can not always be treated.  
If this happens, your child may need to use oxygen or even a respirator.  The lung damage may get worse 
and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is 
often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication. It is rare, but your child’s kidneys could be affected, causing anemia (low red blood 
cell count) or high blood pressure.  There is also a risk your child may develop a second cancer as a result 
of the chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating all of this fluid.  Furosemide is a medication that is often given to help 
eliminate this excess fluid.  This medication may cause hearing loss and loss of body chemicals such as 
potassium and sodium. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-40 
 
Attachment D 
 
Additional Risks and Toxicities Related to the Standard Transplant Procedure 
Fludarabine and Busulfan Conditioning Regimen 
There are certain risks related to a bone marrow or peripheral blood stem cell (PBSC) transplant.  There 
are risks from the medications your child will receive as part of the conditioning for the transplant, and 
risks related to the transplant itself.  Most of these risks and side effects are listed below, but they will 
vary from person to person.  There may be more risks involved with transplantation, and there may be 
more side effects.  Your child’s doctor may give your child medications to lessen some of the side effects. 
 
Risks Related to the Transplant Conditioning Regimen 
 
Fludarabine: This is a medication used to treat cancer.  It is used in stem cell transplants to reduce the 
risk of rejecting the donor’s transplanted cells.  Likely side effects your child may experience are low 
white blood cell count with increased risk of infection, low platelet count with increased risk of bleeding, 
feeling tired or sleepy, and anemia (low red blood cell count).  Rare side effects your child may 
experience include confusion or coma, trouble seeing or problems with your child’s eyes, trouble 
breathing, diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting (throwing up), 
pneumonia, agitation, numbness and tingling of the fingertips and toes, and kidney problems. 
 
Busulfan: This medication disrupts the growth of cancer cells and destroys them.  While taking busulfan 
your child most likely will have diarrhea (loose stools), nausea (feeling sick to your stomach), vomiting 
(throwing up), lower white blood cell count that increases the risk of infection, lower platelet count that 
increases the risk of bleeding, hair loss, stopping of menstrual periods in girls who have reached puberty, 
temporary reduced or no sperm production in boys who have reached puberty.  Less likely side effects 
that your child may experience are fatigue, sores in the mouth or on the lips, fever, rash, loss of appetite, 
changes in color of the skin, seizure.  Rare side effects that your child may experience are damage to the 
lungs, which may cause him/her to cough, be short of breath, and have trouble breathing.  It is rare, but 
busulfan can also cause changes in your child’s liver function. 
 
Antithymocyte Globulin (ATG): This medication is given pre-transplant with the conditioning regimen 
medications to try and prevent both acute and chronic graft-versus-host disease.  While taking ATG your 
child will most likely will have, a fever and chills, a lower white blood cell count that increases your 
child’s risk of infection, a lower platelet count that increases your child’s risk of bleeding, and a skin rash.  
Less likely side effects your child may experience are fatigue, diarrhea, vomiting, muscle aches and 
headaches.  Rare side effects that your child may experience are changes in your blood pressures (either 
higher or lower blood pressure), rapid heart beat, be short of breath and have trouble breathing, chest pain 
and retention of fluids. 
 
 
Risks Related to the Infusion of Bone Marrow or Peripheral Blood Stem Cells (PBSC) 
 
The infusion of bone marrow or PBSC usually has few side effects.  Rarely the infusion may cause a 
headache, chest pain or trouble breathing, a slight fever, or blood in the urine.  Very rarely, it may cause 
an allergic reaction (which shows up as a severe drop in blood pressure and may cause loss of 
consciousness). 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-41 
Risks Related to the Medications Used to Help Prevent Graft-Versus-Host Disease (GVHD) 
 
Cyclosporine or Tacrolimus: These medications are used to try to prevent GVHD.  These two 
medications have similar side effects.  The immediate side effects your child may experience include 
nausea (feeling sick to your stomach) or vomiting (throwing up) when the medications are given orally.  
Other side effects your child may experience include high blood pressure (hypertension), shaking of the 
hands (tremor), increased hair growth and possibly an effect on mental function.  If your child 
experiences these effects they generally go away when the dose of the medication is decreased.  A few 
patients have had a seizure while taking these medications.  Your child may experience a change of liver 
or kidney function, in which case the medication dose will be reduced or possibly even withheld.  The 
effect on kidneys seems to increase when other medications, which might cause kidney problems, are 
given at the same time, especially antibiotics.  Occasionally, the kidney damage caused may require the 
use of an artificial kidney machine (hemodialysis). 
 
Some patients when given cyclosporine through a vein to treat GVHD, experience a painful sensation in 
their hands or feet or both.  The pain decreases or goes when the GVHD improves or when the 
cyclosporine is given by mouth instead of through a vein. 
 
Some patients given tacrolimus develop diabetes and must take insulin while taking tacrolimus. 
 
Methotrexate: This is also a medication used to try to prevent GVHD.  Methotrexate causes damage to 
cells, and therefore can affect many different tissues of your child's body.  It may cause or can worsen the 
mouth sores or inflammation of the mouth which your child may have already developed from the 
procedures and medications used to prepare him/her for the transplant.  Methotrexate may slow down the 
recovery of blood cells after transplantation. Methotrexate can cause kidney damage.  If your child’s 
kidney is already damaged for other reasons, it can worsen kidney function.  If kidney damage does 
occur, the methotrexate dose may be reduced or the medication may not be given at all. 
 
Cyclosporine, Tacrolimus, Methotrexate, and Steroids: These medications interfere with the body’s 
defense system (the immune system).  This may cause your child to have more infections (especially viral 
infections and pneumonia) for several months after transplant. 
 
If other agents are used for GVHD prophylaxis, then analogous paragraphs describing risk of those 
agents must be added to your version of the consent form. 
 
 
Risks Related to the Transplant Procedure 
 
The following risks are not specifically related to any one drug or the transplanted donor cells, but they are 
risks that are a part of the transplant procedure. 
 
Bleeding: Platelets help the blood to clot.  Your child’s platelets will be low until the new bone marrow 
grows and, as a result, bleeding may occur.  This can be minor bleeding, such as nosebleeds or bruising, 
but more serious, life-threatening bleeding in the lungs and brain can occur if the platelet count remains 
low.  Usually, there is success in preventing major bleeding problems with transfusions of platelets.  
However, some patients may not respond well to transfused platelets and may be at serious risk for 
bleeding. 
 
Veno-Occlusive Disease (VOD): This can occur as a result of high dose chemotherapy.  VOD causes 
severe damage to the liver.  Symptoms include jaundice (yellowing of the skin and eyes), weight gain, 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-42 
and extra fluid build-up in the abdominal cavity and other parts of the body.  It can often be managed 
successfully, and completely resolve.  However, complications can arise that may be fatal. 
 
Mouth Sores and Diarrhea: The large doses of medicines cause irritation in the lining of the mouth and 
intestines.  This can result in painful mouth sores and diarrhea.  If your child has severe mouth sores 
he/she will be given medicine to help control the pain.  If your child’s mouth sores are severe, he/she may 
not be able to eat normally until the sores are healed.  Mouth sores get better when the white blood count 
starts to rise, and engraftment occurs. 
 
Capillary Leak Syndrome: This may occur as a result of chemotherapy.  The blood vessels may become 
‘leaky’ and fluid enters the abdominal cavity, lungs, and other tissues.  Your child may gain water weight 
and not go to the bathroom as often as she/she normally does.  Capillary leak syndrome can be difficult to 
manage if extra fluid enters the lungs and causes difficulty breathing.  Your child may die if there is 
continued fluid collection in the lungs. 
 
Unexpected Organ Damage and Other Side Effects: It is possible your child may experience 
unexpected, life-threatening heart, lung, kidney, or liver damage as a result of the transplant.  
Occasionally, the high doses of chemotherapy cause severe lung damage that cannot always be treated.  If 
this happens, your child may need to use oxygen or even a respirator.  The lung damage may get worse 
and be life-threatening.  Rarely, multi-organ failure (such as lung and kidney failure) may occur, which is 
often fatal. 
 
Late Effects: Your child may experience side effects that occur several months to many years after the 
transplant.  Your child may experience poor function of the thyroid gland, requiring him/her to take 
thyroid medication.  It is rare, but your child’s kidneys could be affected, causing anemia (low red blood 
cell count) or high blood pressure.  There is also a risk your child may develop a second cancer as a result 
of the chemotherapy and/or underlying disease.  If secondary cancers occur they generally do not occur 
until 10 to 15 years after the transplant.  The long-term effects upon heart, lung, and brain are unknown. 
 
Fluid Build-up: Your child will receive intravenous fluids during the transplant process and he/she may 
have difficulty eliminating this fluid.  Furosemide is a medication that is often given to help eliminate this 
excess fluid.  This medication may cause hearing loss and loss of body chemicals such as potassium and 
sodium. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-43 
 
 
APPENDIX B-2 
 
DONOR CONSENT FORM 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-44 
NATIONAL MARROW DONOR PROGRAM® (NMDP) 
A PHASE III RANDOMIZED, MULTICENTER TRIAL COMPARING G-CSF MOBILIZED 
PERIPHERAL BLOOD STEM CELLS WITH MARROW TRANSPLANTATION FROM HLA 
COMPATIBLE UNRELATED DONORS 
 
DONOR/SUBJECT RESEARCH CONSENT FORM 
 
1. Why am I being asked to take part in this research study?  
Because you have been matched with a recipient in seeking a blood stem cell transplant, you are being 
asked to take part in a clinical trial (a type of research study).  This research study is sponsored by the 
NMDP and the Blood and Marrow Clinical Trials Network (BMT CTN).  In this clinical trial the blood-
forming cells will be collected from either the donor’s bone marrow or the donor’s bloodstream.  This 
research study will only include people who choose to be in it.  
This form contains key facts about the study and what you will be asked to do if you take part.  Please 
read it in detail and take your time to decide.  You might want to view the PBSC vs. Marrow Randomized 
Clinical Trial Donor Consent video as well (also offered as a CD-ROM and DVD).  If you do not want to 
take part in this study, you may still be asked to donate for this recipient.  
If you have any questions, please ask your Donor Center Coordinator or the Donor Center Medical 
Director.  If you agree to take part, you will be given a copy of this consent form for your records. 
 
2. Why is this study being done? 
The National Marrow Donor Program® (NMDP) uses bone marrow and blood-forming cells from the 
bloodstream of healthy donors for transplantation.  In the past, blood-forming cells were always taken 
from the bone marrow.  Now a drug called “filgrastim” can increase the number of blood-forming cells in 
the bloodstream so much that these cells can be collected from the bloodstream of donors and used for 
transplant.  When these blood-forming cells are collected from the bloodstream they are called peripheral 
blood stem cells (PBSC). 
When the NMDP compared recipients who received bone marrow with recipients who received PBSCs, 
there was no difference in survival between the two groups.  But because the recipients in each group did 
not have the same characteristics (age, disease type and so on) more research is needed. 
As a result, this study will randomly assign recipients and donors into the two groups (bone marrow or 
PBSC).   
The NMDP and the BMT CTN hope what they learn from this study will help doctors and future 
recipients and donors make the best choice for the type of blood-forming cells to use for transplant; bone 
marrow or PBSC.  If you would like to know more about why this study is needed, read Attachment A. 
This study has two main goals: 
1. To see if recipients given blood-forming cells from a donor’s bone marrow do better or worse 
than recipients given PBSCs. 
2. To compare three things about donors who donate bone marrow versus donors who donate 
PBSCs: 
 
What differences (if any) are there in physical side effects that donors feel? 
 
What differences are there in the time it takes donors to recover? 
 
How does the quality of life differ for the two types of donors?  For instance: how does a 
donor feel emotionally, how does donation affect a donor’s daily life, and what does the 
donor feel about the donation process? 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-45 
3. What will happen if I take part in this research study? 
If you agree to take part in this research study, your donation will be different in these three ways: 
1. How you donate – from your bone marrow or your bloodstream – will be chosen at random.  A 
computer will make this choice.  
2. You will be asked to give four extra blood samples for research purposes. 
3. You will be asked to answer questions about how you feel emotionally after the donation.  
 
Your safety is important.  After you join the study, your health will be checked just like any donor.  To 
protect both you and the recipient, you will have: 
 
A complete check-up. 
 
Standard blood tests. 
 
Blood tests for diseases like hepatitis, West Nile virus and HIV. 
 
A check for sickle hemoglobin (hemoglobin S). 
 
If you are a woman, a test to see if you are pregnant. 
 
These tests will help to make sure that donating is safe for both you and the recipient getting the donation.  
(If you have more questions about why the blood tests are needed, see Attachment B.)  All donors will 
have these tests.  You will have these tests before you know if you will donate bone marrow or PBSCs.  
You must be able to donate both ways – from your bone marrow or your bloodstream – to go forward in 
this study.  If you are able to donate only one way and cannot go forward in this study, you may still be 
asked to donate for this recipient. 
 
Either as part of your complete check-up or as part of some other scheduled blood draw, 9 teaspoons of 
blood will be drawn from a vein in your arm for research studies.  Your blood will be tested for antibodies 
specific to germs that cause infection, for example, Hepatitis B.  The antibody levels in your blood may 
be compared against the antibody levels in the recipient’s blood after the transplant.  These samples will 
also be used to better understand tissue matching between donors and recipients. 
 
If you are able to go forward in the study, you will be chosen at random to donate either from your bone 
marrow or your bloodstream.  This means that the way you donate will be picked by chance.  A computer 
program will make the choice.  You cannot choose how you will donate.  You will have an equal chance 
of giving blood-forming cells from bone marrow or from your bloodstream.  Your donation itself will be 
just the same as if you were not taking part in the study. 
 
If you are randomly assigned to donate bone marrow: 
1. Getting Ready to Donate Bone Marrow 
You may be asked to have your blood collected and stored for your own use (this is called 
“autologous” blood donation).  Depending on how much bone marrow you are asked to donate, 
you may need to have one to three units (each unit is about a pint or about two cups) of your 
blood drawn and stored before the donation.  You will be asked to sign a separate consent form 
each time you give a unit of blood.  If you need to receive blood after your marrow donation, 
your stored blood will be given back to you by transfusion.  Any of your stored blood not used by 
you will be destroyed by standard procedures. 
The doctors at the transplant center where the recipient is being treated may also ask for a sample 
of your blood before the transplant.  The blood will be used at the transplant center for tests 
needed in treating the recipient.  For instance, DNA from your cells may be used to help identify 
which blood cells growing in the recipient came from the donor’s (your) cells, and which came 
from the recipient’s cells.  You will not be asked to give more than about ½ cup (7 tablespoons) 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-46 
of blood.  The blood will be drawn from a vein in your arm.  This blood cannot be used for 
research studies without further consent from you. 
2. Donating Bone Marrow 
Bone marrow is collected in an operating room in a hospital.  You will be given either general 
anesthesia or spinal anesthesia.  Before the bone marrow donation, you will meet with a doctor to 
discuss the type of anesthesia that will be used.  (This consent form is not for the anesthesia or the 
actual bone marrow donation.  At the hospital you will be asked to sign another consent form for 
the anesthesia and the bone marrow donation.)  
The amount of bone marrow you will be asked to donate depends on the size of the recipient.  For 
safety reasons, no more than two teaspoons of bone marrow per pound of your body weight will 
be removed.  For instance: if you weigh 150 pounds, no more than 6 cups of bone marrow would 
be taken. 
You will lie on your stomach for the donation.  Your bone marrow will be taken out of your 
pelvic bone (iliac crest).  The doctor taking the bone marrow will make at least two, and maybe 
more, very small cuts in the skin of your back that covers the pelvic bones.  Hollow needles will 
be placed through these cuts and into the bone.  After a needle is put in the marrow space of the 
bone, a syringe will be attached to the needle and the marrow will be drawn out.  Once the bone 
marrow is taken, the anesthetic will be allowed to wear off and you will be returned to your 
hospital room. 
Your donated bone marrow may be tested to find out the number and types of cells, to make sure 
that it is sterile, and to learn other things that may be important to the transplant.  
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-47 
How much time will it take to donate bone marrow? 
A list of visits and calls is given in the following table (an X marks what will happen on each visit/call): 
Visit/Call 
Risks 
Assessed 
Unit of 
Blood 
Drawn and 
Stored  
Bone 
Marrow 
Donated 
Blood 
Drawn 
Quality of 
Life 
Assessed 
by Phone 
Screening check-up 
X 
 
 
X 
 
1st Quality of Life contact 
 
 
 
 
X 
Pre-donation appointment 1a 
 
X 
 
X 
 
Pre-donation appointment 2a 
 
X 
 
 
 
Pre-donation appointment 3a 
 
X 
 
 
 
Bone marrow donation 
X 
 
X 
X 
 
2 days after donation (call) 
X 
 
 
 
X 
1 week after donationb (call) 
X 
 
 
 
X 
1 month after donation 
X 
 
 
X 
 
6 months after donation 
X 
 
 
X 
X 
1 year after donation 
X 
 
 
X 
X 
2 years after donation  
X 
 
 
X 
 
3 years after donation 
(study ends) 
X 
 
 
X 
 
Yearly visits after donation as 
part of the NMDP’s routine 
donor follow up 
X 
 
 
 
 
a The number of autologous blood units you give depends on how much bone marrow will be taken. 
b Calls will continue weekly until complete healing from donation is reported. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-48 
What are the possible risks of donating bone marrow? 
Caution:  You should not take aspirin or aspirin-containing drugs for two weeks before your donation or 
for soreness after it, without a doctor’s approval.  
 BLOOD DRAW 
Risks 
Some people have: 
 
Bruising where the needle was put in. 
 
Fainting. 
Very few people have: 
 
An infection where the needle was put in. 
DONATING BONE MARROW 
Risks 
From the anesthetic: For a few hours after your bone marrow has been taken, you 
may feel groggy and sick from the anesthetic.  You will not be allowed to eat food or 
to get out of bed until you are wide awake and all the anesthetic has worn off.  Even 
after the anesthetic has worn off, you may still be sick and faint for a period of time. 
From the collection: You should expect to feel some pain from the collection of the 
bone marrow.  Most donors go through soreness in their lower back, like a back 
strain, that lasts for a few weeks.  You may find it hard to sit in a chair for long 
periods of time or to climb stairs.  You will most likely be less active than normal for 
the first two weeks after your donation. 
 
There are certain risks with donating bone marrow.  
Serious problems from bone marrow collection are rare but could occur due to an 
unexpected reaction to the anesthetic or trouble with the process of taking the bone 
marrow.  
Possible risks with anesthetics include: 
 
High fever. 
 
Allergic reaction. 
 
Low blood pressure and a slowed heart rate.  
 
Not able to pass urine for a brief time (spinal anesthesia). 
 
Headache (spinal anesthesia). 
 
Possible risks from donation include: 
 
Infection where the skin was cut to collect your bone marrow (requires 
antibiotic treatment). 
 
Pain or numbness in a leg. 
 
Bleeding where the skin was cut. 
 
More severe pain than normal. 
 
Bone, nerve or other tissue damage (requires more medical treatment or 
physical therapy). 
Life-threatening problems are extremely rare.  But you should know, that as with any 
surgery, there is a risk of death. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-49 
Additional Risks 
Donating can cause intense feelings, especially if the transplant does not succeed.  These feelings may 
range from stress during the process to great joy or the blues after the donation.  By donating for this 
recipient, you are doing all you can to help them.  You cannot control the success of the transplant, or 
whether the recipient lives or dies.  You are not personally responsible for the outcome. 
You may be asked to donate again for the recipient if the donated cells do not grow in the recipient or if 
the recipient’s disease is not cured.  If you are asked to donate again, you are free to say no. 
 
If you are randomly assigned to donate PBSCs: 
1. Getting Ready to Donate PBSCs 
The drug filgrastim has been shown to increase the number of blood-forming cells in the 
bloodstream.  You will get a shot of filgrastim under your skin once a day for five days.  Before 
each shot, you will be asked about any symptoms you may have.  You will have blood samples 
(1½ to 3 teaspoons) taken from a vein in your arm before your shots on Day 1 and on Day 5.  
These samples are used to see how the drug affects your blood cell counts. 
The doctors at the transplant center where the recipient is being treated may also ask for a sample 
of your blood before the transplant.  The blood will be used at the transplant center for tests 
needed in treating the recipient.  For instance, DNA from your blood may be stored to help see 
which blood cells growing in the recipient after the transplant come from your cells and which 
come from the recipient’s cells.  You will not be asked to give more than about 20 teaspoons of 
blood.  The blood will be drawn from a vein in your arm.  This blood cannot be used for research 
studies without further consent from you. 
2. Donating PBSCs 
PBSCs are donated in a hospital or blood center.  Before you donate, a needle will be placed in a 
vein in each of your arms.  Blood is removed through the needle in one arm and passed through a 
special machine called a blood cell separator.  This process is called “apheresis.”  The machine 
collects your PBSCs, and the rest of your blood is given back through the needle in your other 
arm.  You will make one or two PBSC donations, depending on the size of the recipient.  During 
each donation you will need to lie fairly still in a recliner chair for four to six hours. 
With each donation, 2 teaspoons of blood will be taken at the start and at the end of the process to 
measure your blood cell counts.  Your donation may be tested to find out the number and types of 
cells, to make sure that it is sterile, and to learn other things that may be important to the 
transplant. 
Using a Central Line 
Sometimes, the needles used in the apheresis process are too big for a donor’s arm veins.  In the NMDP’s 
experience, this happens in about 18% of women and 3% of men.  If it is thought that the needles will be 
too big for your arm veins, you may be asked to have a blood-drawing tube called a “central line” placed 
in a larger vein in your body.  The choice to use a central line may be made at your complete check-up 
(when your veins will be checked) or it could be made on the day you donate. 
Placing a central line requires a surgical procedure under local anesthesia.  A doctor does this in a 
hospital.  In this case, your collection will also take place in the hospital and, if you donate over two days, 
you will need to stay in the hospital the night between donations. 
Before a central line is placed, you will be asked to sign a separate consent form that explains the risks of 
central line placement.  You are free to say no to having a central line placed.  If you choose to not have 
the central line placement, you may be asked to donate bone marrow instead.  

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-50 
 
How much time will it take to donate PBSCs? 
A list of visits and calls is given in the following table (an X marks what will happen on each visit/call): 
Visit/Call 
Risks 
Assessed 
Filgrastim 
Shot Given 
PBSCs 
Donated 
Blood 
Drawn 
Quality of Life 
Assessed by 
Phone 
Screening check-up 
X 
 
 
X 
 
1st Quality of Life contact 
 
 
 
 
X 
Preparation, Day 1 
X 
X 
 
X 
 
Preparation, Day 2 
X 
X 
 
 
 
Preparation, Day 3 
X 
X 
 
 
 
Preparation, Day 4 
X 
X 
 
 
X 
First donation, Day 5 
X 
X 
X 
X 
 
Second donationa 
X 
 
X 
X 
 
2 days after donation (call) 
X 
 
 
 
X 
1 week after donationb (call) 
X 
 
 
 
X 
1 month after donation 
X 
 
 
X 
 
6 months after donation 
X 
 
 
X 
X 
1 year after donation 
X 
 
 
X 
X 
2 years after donation  
X 
 
 
X 
 
3 years after donation 
(study ends)  
X 
 
 
X 
 
Yearly visits after donation as 
part of the NMDP’s routine 
donor follow up 
X 
 
 
 
 
a If needed, based on size of the recipient. 
b Calls will continue weekly until complete healing from donation is reported. 
 
What are the possible risks of donating PBSCs? 
Cautions:  You should not take aspirin or drugs with aspirin in them while getting filgrastim and for two 
weeks after PBSC donation without a doctor’s approval.  During the PBSC donation, your platelet count 
may be lower because platelets are collected with the PBSCs.  Taking aspirin when your platelet count is 
lower may increase your chance of bleeding.  
You should not take filgrastim if you are pregnant.  You should not become pregnant while taking the 
drug.  This is because filgrastim may cause serious problems for an unborn child.  It is recommended that 
you wait to try to get pregnant until the drug is no longer in your blood.  Bothe men and women should 
wait at least 48 hours after the last dose of filgrastim to conceive a child. 
Mothers should stop breast feeding and not store breast milk while receiving filgrastim.  This is because it 
is not known whether filgrastim is passd into breast milk.  It is recommended to wit 48 hours after the last 
dose of filgrastim before resuming breast feeding. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-51 
The following table lists side effects and risks for receiving filgrastim and donating PBSCs. 
BLOOD DRAW 
Risks 
Some people have: 
 
Bruising where the needle was put in. 
 
Fainting. 
Very few people have: 
 
An infection where the needle was put in. 
 
GETTING SHOTS OF FILGRASTIM 
Risks 
Most people have: 
 
Pain from the shot. 
 
High white blood cell count. 
 
White blood cell counts usually return to normal levels within a few days to a 
few weeks after you stop receiving filgrastim. 
 
Aching pain in bones while getting the filgrastim. 
 
The aching bone pain is usually relieved by acetaminophen (Tylenol™) or 
ibuprofen (Motrin™, Advil™).  If you have pain that is not relieved by these 
drugs, you should contact the Donor Center Coordinator, 
_____________________ at (       ) _______________, and the dose of filgrastim 
may be reduced.  
Some people have: 
 
Headaches. 
 
Muscle aches. 
 
Being tired. 
 
Nausea and vomiting. 
 
Trouble sleeping. 
Very few people have: 
 
Allergy symptoms (all symptoms usually go away within two or three days after 
stopping filgrastim):  
– 
rapid heart rate. 
– 
dizziness. 
– 
shortness of breath. 
– 
itching or rash. 
 
 
Lowered platelet count.  
Filgrastim may cause your platelet count to be lower than normal. Platelets help 
stop bleeding.  Two out of 1400 NMDP donors had very low platelet counts that 
needed to be watched closely.  Although one donor went into the hospital for this, 
neither had symptoms from the low platelet count and both got well.  
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-52 
 
GETTING SHOTS OF FILGRASTIM (cont’d) 
 
Your platelet count will be measured on Day 5, before the first PBSC donation.  
You will be told if your platelet count is too low.  In this case, depending on the 
true value of your platelet count, a doctor will talk with you about other options, 
such as to: 
– 
Monitor your platelet count during the PBSCs donation. 
– 
Shorten the donation process. 
– 
Delay the donation for a day. 
– 
Cancel the PBSCs donation. 
– 
Ask you to consider a bone marrow donation. 
– 
Ask you to consider some other course of action that is okay with you. 
 
There is a small (about 1 in 1,200) risk of being hospitalized for observation of 
side effects from the filgrastim (for example bone pain, nausea). 
 
For a very small number of people filgrastim may cause a decrease in 
oxygen that can affect the heart, causing shortness of breath and chest 
pain.  The NMDP is aware of three NMDP donors who have had these 
symptoms.  These symptoms were not related to a heart attack.  However 
if you experience pain coming from your chest on the days of filgrastim 
injections, or during or after your PBSC donation, you should tell your 
doctor immediately.  Also, if you have a family history of heart problems, 
you should discuss this with the doctor during your physical exam prior to 
your PBSC donation. 
 
There is a small (about 1 in 5,000) risk of bleeding in the head.  The 
NMDP is aware of two NMDP donors who had bleeding in their head 
shortly after completing their filgrastim injections and PBSC donation.  It 
is not clear the bleeding was related to filgrastim; both donors had other 
factors that may have played a role in the bleeding.  Both donors 
recovered.  The major symptom from bleeding in the head is a severe 
headache, sometimes with other symptoms like numbness, muscle 
weakness, confusion or changes in vision.  If you experience a severe 
headache during the days of filgrastim injections or during or after your 
PBSC donation, you should tell your doctor right away 
 
There is a small (about 1 in 10,000) risk of pain and bleeding from the spleen. 
The NMDP is aware of five non-NMDP donors who had pain and bleeding from 
the spleen while getting filgrastim.  In four cases the spleen was taken out by 
surgery.  All five got well.  Symptoms of bleeding from the spleen are pain in the 
upper left side just below the rib cage.  If you feel pain in this area you should 
contact your Donor Center right away. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-53 
 
GETTING SHOTS OF FILGRASTIM (cont’d) 
 
 
Healthy individuals are at risk for developing cancer, including leukemia, 
lymphoma or other blood diseases throughout their life time.  Filgrastim 
stimulates normal blood cell growth.  In some patients with cancer or abnormal 
blood cells, it has been shown to stimulate leukemic blood cells.  It is unknown 
whether filgrastim increases or decreases an individual’s risk of developing 
cancer.  Based on available data from healthy people who have received 
filgrastim, no long-term risks have been found so far.  The data being collected 
during follow-up will help establish if there are any positive or negative long-
term effects from receiving filgrastim. 
 
If you think you are having any serious or unexpected symptoms, contact the 
Donor Center right away at (       ) ___________________________. 
 
DONATING PBSCs 
Risks 
Most people have: 
 
Pain and bruising where the needles are put into the arms. 
 
Lowered platelet count. 
In addition to collecting PBSCs, the blood cell separator also collects platelets.  
Platelets help stop bleeding.  If your platelet count after the first donation is too 
low, the second donation may be cancelled.  Platelet counts usually return to 
normal levels within two to four weeks after collection of PBSCs. 
 
Some people have: 
 
Lightheadedness. 
 
Nausea. 
 
Numbness and tingling. 
To prevent clotting, your blood will be mixed in the machine with a liquid called 
an “anticoagulant” during the PBSC collection.  When the blood is returned to 
you, the anticoagulant can cause numbness and tingling of the fingertips or 
around the mouth.  If you feel numbness and tingling, you must tell the nurse 
running the machine.  These symptoms are easily treated with calcium, but if not 
treated could progress to muscle cramps.  
 
Very few people: 
 
Faint due to short-term low blood pressure. 
 
Experience chills during the process. 
 
Experience severe bleeding in the arm. 
 
Have a loss of blood from a breakdown of the blood cell separator machine.  If 
the machine does breakdown you could lose about 1½ cups of blood.  This is 
unlikely to cause you harm. 
 
There is a small (about 1 in 1,200) risk of being hospitalized for observation of 
side effects from the donation (for example lightheadedness, nausea). 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-54 
 
Additional Risks 
Donating for a recipient can cause strong feelings, especially if the transplant does not succeed.  These 
feelings may range from stress during the process to great joy or feeling sad after the donation.  By 
donating for this recipient, you are doing all you can to help them.  You cannot control the success of the 
transplant, or whether the recipient lives or dies.  You are not personally responsible for the outcome. 
 
You may be asked to donate again for the recipient if the donated cells do not grow in the recipient or if 
the recipient’s disease is not cured.  If you are asked to donate again, you are free to say no. 
 
After You Donate Either Bone Marrow or PBSCs 
After your donation, you will be called on the phone and asked questions about how you are feeling 
physically.  These calls will start two days after the donation and will be made each week until you feel 
you are back to normal.  You will be called again at one month, six months and then yearly after that. 
You will also be asked to give a small blood sample (1½ teaspoons) at one month and six months after 
your donation, and then yearly for three years.  These samples will be used to measure your blood cell 
counts and to see how you are healing from the donation. 
Quality of Life Surveys 
To see how donation has affected your life, and how you have dealt with it, this study also asks questions 
about the quality of your life.  
If you can answer the following three questions with a “yes,” you will be called and asked questions 
about your quality of life.  
 
Do you read or speak English?  
 
Do you have access to a phone?  
 
Are you able to complete a survey?  
You can ask to have a written copy of the questions sent to you before you are called. The people calling 
will arrange a time that works for you.  The calls will take 30 minutes or less and will happen on this 
schedule: 
 
Within four weeks before your donation. 
 
On Day 4 of filgrastim injections (only for PBSC donors). 
 
At two days after your donation. 
 
Every week after your donation until you have reported that you are fully well again for four 
weeks in a row. 
 
At six months after your donation. 
 
At one year after the donation. 
The questions you will be asked include: 
 
How are you recovering physically? 
 
How well are you doing emotionally? 
 
How has the donation affected your everyday activities? 
 
How do you feel about the donation experience? 
 
What is your age, gender, race, marital status, work status, and what level of schooling have you 
had? 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-55 
What are the possible side effects and risks of answering questions? 
 
ANSWERING QUESTIONS FOR THE QUALITY OF LIFE STUDY 
There are no physical side effects or risks to being in the quality of life part of the study. It will take at 
least three extra hours of your time over one year.  Some people may feel awkward answering questions 
about themselves, but you may skip any questions that bothers you.  
 
4. What do I do if I am injured in this study? 
The risk of serious injury to donors participating in this study is thought to be small.  If you are injured, 
treatment (to include first aid, emergency treatment and other needed care) will be on hand for you.  The 
NMDP will pay for this treatment.  Please call your Donor Center Coordinator right away at  
(       ) __________________ if you are injured. 
In the case of an injury resulting from this study, you do not lose any of your legal rights to seek payment 
by signing this form. 
 
5. Do I have to agree to be in this study?  
No, it is up to you if you want to participate in this study.  If you decline to participate, the NMDP will 
not remove you from the Registry unless you ask for this to be done.  Your decision to decline 
participation will not change your relationship with your Donor Center or the NMDP.  There will not be 
any penalty or loss of benefits.  Your decision to decline participation will not affect your right or access 
to health care or any other service that you are entitled to receive at your Donor Center. 
 
6. Are there alternatives to being in this study?  
Yes.  If you decide you do not want to take part in this study, you may be asked to donate either bone 
marrow or PBSCs for the recipient without participating in this study.  In that case, the type of donation 
will not be decided randomly. 
 
7. How long will I be in this study?  
As part of your normal donor follow-up, each year you will be contacted to answer some questions about 
how you are feeling physically.  This information will be shared with the study for three years.  As part of 
the study you will also be asked to give a small blood sample each year for three years after your 
donation.  You will be called with questions about your quality of life for one year. 
You will be informed of any new finding which may affect your decision to continue your participation in 
this research study. 
 
8. Can I stop being in this study? 
Yes, you may stop taking part in this study at any time.  If you want to withdraw, you are asked to tell 
your Donor Center Coordinator.  Your choice to stop will not change your relationship with your Donor 
Center or the NMDP.  There will not be any penalty or loss of benefits.  Your choice to stop will not 
affect your right or access to health care or any other service that you are entitled to receive at your Donor 
Center. 
If you choose to stop before you donate bone marrow or PBSCs: It is important you know that if you 
decline to donate after the intended recipient begins to get treatment to get ready for the transplant, he or 
she will most likely die. If you have any questions about this statement, please contact your Donor Center 
Medical Director. 
 
9. Will it cost me money to be in this study? 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-56 
No.  There is no cost to you for the check-ups, donating the cells or the surveys. 
 
10. Will I be paid to be in this study? 
No.  You will not be given any payment for being in this study. 
 
11. Are there rewards to being in this study? 
You will not receive direct payment or reward for being in this study.  But, this study may help future 
recipients in need of transplants, as well as future donors. 
 
12. How does the NMDP use donor data? 
As part of your participation in this study, your demographic and health information will be entered into 
the NMDP Research Database.  The NMDP collects some data on all donors.  This helps the NMDP 
make sure it is doing the best job it can and learn how to improve where needed.  
By signing this consent form, you allow _____________________________ (Donor Center) to give the 
NMDP your demographic information (for instance: gender, age and ethnic background) and health 
information that was taken as part of the donation process (for instance: results from infectious disease 
testing and the physical exam and information on healing from the donation).  This information will be 
used by the NMDP to evaluate operation of the Registry, to report to its funding agencies, and to conduct 
research.  In addition, people doing studies approved by the NMDP may use this information for research. 
This authorization does not have an expiration date.  You have the right to cancel this authorization at any 
time by notifying the NMDP in writing that you are canceling the authorization.  The address for the 
NMDP is 3001 Broadway Street NE, Suite 500, Minneapolis, MN 55413.  If you cancel this 
authorization, any identifiable health information will be removed from the NMDP Research Database.  If 
you cancel your authorization, this will not affect your right or access to healthcare or any other services 
you are entitled to receive at _____________________________ (Donor Center). 
 
13. Will my health information and surveys be kept private? 
We will do our best to make sure that the personal information in your health record is kept private.  We 
cannot guarantee total privacy.  Your personal information may be given out if required by law.  If 
information from this study is published or presented at scientific meetings, your name and other personal 
information will not be used. 
Groups that may look at and/or copy health records for research, quality assurance and data analysis 
include: 
 
The NMDP 
 
The BMT CTN 
 
The NMDP Institutional Review Board (IRB) 
 
University of Pittsburgh IRB 
 
University of Pittsburgh Survey Research Program staff 
 
The National Institutes of Health (NIH) and other government agencies, like the Food & Drug 
Administration (FDA), involved in keeping research safe for people. 
 
Steps used to keep your data private are: 
 
To label your data with a nine-digit identification (ID) number instead of your name.  This ID 
number is chosen at random and does not contain any identifying information about you. 
 
To limit who sees your data. 
 
To keep your data in locked files. 
 
To destroy all papers when they are thrown away (for instance, by shredding). 
 
To use special, protected computer systems. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-57 
14. Who can I contact with questions or concerns about this study? 
The doctors for this study are:  
Dr. _______________ ___________________ (       ) ________________________ 
(Donor Center Medical Director) 
Dr. John Miller  
 
 
 
(800) 526-7809 
(NMDP Medical Director) 
For questions about your rights while taking part in this study, please contact Roberta King, Institutional 
Review Board (IRB) Administrator, at (800) 526-7809.  
 
14. Donor/Participant’s Signature (NMDP DID:______________) 
I have been given a copy of all 18 pages of this form. I have read it, or it has been read to me. I have been 
given the opportunity to ask questions and have had my questions answered. I agree to take part in this 
study. 
 
 _____________________________________ 
 ______________________________  
 Donor/Participant’s Signature  
 
 
 Date 
 
 _____________________________________ 
 Donor/Participant’s Name Printed 
 
 
 
 
 
 
 
Certification of Counseling Healthcare Professional 
I certify that the nature and purpose, the potential benefits, and possible risks associated with participation 
in this research study have been explained to the above individual and that any questions about this 
information have been answered. 
 
 _____________________________________ 
 ______________________________  
 Counseling Healthcare Professional 
 
 
 Date 
 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to 
obtain consent. 
An oral translation of this document was administered to the subject in ______________ 
(name of language) by an individual proficient in English and ______________________ (name of 
language). See the attached short form addendum for documentation. 
 _____________________________________ 
 ______________________________  
Interpreter’s Signature ____________________ 
Date 
 
 
NATIONAL MARROW DONOR PROGRAM® 
INSTITUTIONAL REVIEW BOARD 
CONSENT FORM APPROVAL DATE:  
MAY 21, 2009 
 
Do not sign this form after the  
Expiration date of: May 14, 2010 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-58 
ATTACHMENT A 
WHY IS THIS STUDY NEEDED? 
 
The main goal of this study is to find out if there are differences in the outcomes of unrelated donor 
transplants based on whether blood-forming cells are taken from the bloodstream (PBSCs) or from the 
bone marrow.  
Blood-forming cells are needed for transplantation.  The greatest number of blood-forming cells are found 
in the bone marrow, while only a few blood-forming cells are normally found in the blood.  In the past, 
blood-forming cells were always taken from the bone marrow.  However, it is now known that a drug 
called “filgrastim” can increase the number of blood-forming cells in the blood so much that transplants 
can be performed using these cells taken from the blood.  
When the NMDP compared the past survival of recipients who received an unrelated donor marrow 
transplant with recipients who received an unrelated donor PBSC transplant, there was no difference in 
survival between the two groups.  This may have been because the recipients in each group did not have 
the same characteristics (different ages, different disease stages). 
In this study, the donor and recipient will be randomly assigned (much like the toss of a coin) to either the 
PBSC group or the bone marrow group.  By randomly assigning the recipients to receive either PBSCs or 
bone marrow, the characteristics of the recipients in each group should be similar.  With similar types of 
recipients in each group, the study should be able to find out if recipients who receive one type of 
donation do better after transplant than recipients who receive the other type of donation, or if recipients 
in both groups have similar results from their transplant. 
There are also goals of this study specifically related to the donor.  These goals are: 1) to examine any 
difference in the physical side effects PBSC donors and bone marrow donors have; 2) to examine any 
difference in the time it takes donors to recover from PBSC donation and marrow donation; and, 3) to 
examine any difference in quality of life issues between the two types of donations, such as how the 
donation affects donors emotionally, how the donation affects the daily activities of donors, and how the 
donors feel about the donation experience. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-59 
ATTACHMENT B 
WHY DO I NEED THESE BLOOD TESTS? 
 
Standard Blood Tests 
Tests are done on your blood to make sure it is safe for you to donate PBSCs or bone marrow.  Any 
increased risk might mean that you would not be allowed to donate, or that only one of the two methods 
of donating would be advisable for you.  These tests also protect the recipient getting your donation.  
Blood Tests for Diseases 
Your blood will be tested for infectious diseases including HIV, Hepatitis and West Nile Virus. 
If your check-up or blood tests reveal anything that is not normal, you will be told.  The NMDP or your 
Donor Center may also be required by law to notify your state public health agency if you test positive for 
Hepatitis B, Hepatitis C, the virus that causes AIDS (HIV) or other infectious diseases.  
Check for Sickle Hemoglobin 
Your blood will be tested for sickle hemoglobin.  This test may result in genetic information that is new 
to you.  There have been reports of severe reactions to filgrastim in persons with sickle cell disease.  If 
your blood test is positive for sickle hemoglobin, you will not be able to participate in this study.  
However, you may still be asked to donate bone marrow for this recipient. 
Pregnancy Test 
If you are a woman of childbearing years, you will be required to take a pregnancy test.  You must not 
donate bone marrow if you are pregnant.  You must not take filgrastim if you are pregnant.  This 
medication could cause serious problems for an unborn child.  You must make sure that you do not get 
pregnant while taking filgrastim and for 48 hours after the last shot. 
 
Extra Blood Samples for Research in this Study 
Your blood will be tested for antibodies specific to germs that cause infection, for example, Hepatitis B.  
The antibody levels in your blood may be compared against the antibody levels in the recipient’s blood 
after the transplant. 
These samples are also used to better understand tissue matching between donors and recipients. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-60 
ATTACHMENT C 
DEFINITIONS 
 
Anesthesia is the giving of a drug or drugs designed to relieve pain and/or cause loss of consciousness. 
Apheresis is a process where a machine divides blood into its separate parts.  Blood is removed from one 
arm of the donor, passed through the machine, which separates out the needed type of cell(s), and returns 
the remaining blood to the donor.  Over time, the donor’s body naturally replaces the blood cells that are 
removed. 
A Central Line is a sterile tube put into one of the larger veins, usually in the groin area (femoral vein), 
the neck area (internal jugular) or just below the collarbone (subclavian vein). 
Demographic Information are facts about the part of the country where you live; what sex, race and age 
you are, and what ethnic group(s) you belong to.  These facts help people study the health data.  It does 
not include your name. 
Filgrastim is a drug that causes the bone marrow to produce more blood forming cells than usual.  When 
these cells go into the bloodstream they are often called peripheral blood stem cells (PBSC).  They can be 
collected from the bloodstream.  Filgrastim is also called “G-CSF” and marketed in the U.S. as 
Neupogen®. Filgrastim has been approved by the Food & Drug Administration (FDA) to collect PBSCs 
from recipients getting transplants of their own cells.  It is also approved to treat recipients with cancer 
getting chemotherapy, for recipients getting bone marrow transplants and for recipients with diseases 
causing very low white blood counts. 
An Institutional Review Board (IRB) is a group of people who review research methods and results to 
protect your rights and safety. 
PBSC are “peripheral blood stem cells.” This is another term for the blood forming cells circulating in 
your bloodstream that can be taken by a machine. 
Platelets are special blood cells that help you stop bleeding by making clots. 
Blood forming cells are cells found in the bone marrow and bloodstream that rebuild your blood, bone 
marrow and the immune system. 
A Syringe is used to inject or withdraw a fluid.  It has a hollow needle to break the skin and fluid is either 
injected into the body through the needle or fluids such as blood are withdrawn from the body. 
A Teaspoon is a common unit of measurement.  One teaspoon is equal to about five milliliters. There are 
three teaspoons in a tablespoon, 48 teaspoons in a cup. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-61 
 
 
APPENDIX B-3 
 
ASSENT TO PARTICIPATE FORMS 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-62 
Assent to Participate in Research (Ages 7 to 11 years old) 
 
 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cells 
with Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Institution  
Name/Title/Phone number/ 
 
3. Contact information for Emergencies after Hours or on Weekends or Holidays 
Name/Phone number/ 
 
You are being invited to be in a research project.  This research project is about deciding which kinds of 
donor cells work better for transplants.  Donor cells can come from bone marrow or blood.  Your doctors 
want to learn whether it is better to use bone marrow or blood for other children who need a transplant in 
the future. 
 
You should talk to your parents about this research project.  If you have questions, ask your parents or 
your doctor. 
 
You have a disease in your blood cells and the disease makes you sick.  To help you get better, the 
doctors will give you strong medicines to make the bad blood cells go away.   
 
The medicines may make you throw up, lose your hair and have mouth sores.   
 
After these strong medicines, you will get a transplant of new cells from a donor who is a person you do 
not know.  The cells will come from the donor’s bone marrow or from the donor’s blood.  The cells 
should make new and healthy blood in your body.   
 
Your parents, doctors, and nurses will explain what happens with the transplant.  You should ask them 
about anything you do not understand.  They will answer your questions. 
 
You don't have to be in this research project.  Your doctors and nurses will not be mad at you if you don't 
want to be in the research project.  If you decide you don't want to be in this research project, you may 
still receive a transplant for your disease. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-63 
Sign your name on the line below if you want to be in this research project.  You can keep a copy of this 
form at home. 
 
 
 
 _______________________________________________   ______________________________  
Minor’s Signature 
Date 
 
 _______________________________________________   ______________________________  
Print Name of Minor 
Age of Minor 
 
 
 
 
Certification of Counseling Healthcare Professional 
 
I certify that the nature and purpose, the potential benefits, and possible risks associated with participation 
in this study have been explained to the above individual and that any questions about this information 
have been answered. 
 
________________________________  
____________________________ 
Counseling Healthcare Professional 
 
 
Date 
 
 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was 
used to obtain assent: 
 
Print name of interpreter:  _____________________  Date:  ___________________  
 
Signature of interpreter:  ______________________   
 
An oral translation of this document was administered to the donor in __________ (state 
language) by an individual proficient in English and _______________ (state language).  See the 
attached short form addendum for documentation. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-64 
Assent to Participate in Research (Ages 12 to 17 years old) 
 
 
 
 
 
 
 
1. Title of Research Study 
A Phase III Randomized, Multicenter Trial Comparing G-CSF Mobilized Peripheral Blood Stem Cell 
versus Marrow Transplantation from HLA Compatible Unrelated Donors 
 
2. Principal Investigator Contact Information at Your Institution  
Name/Title/Phone number/ 
 
3. Contact information for Emergencies after Hours or on Weekends or Holidays 
Name/Phone number/ 
 
4. Invitation to Participate in a Research Study 
 
You are being invited to join a research study because you have a disease that may be treated with a 
transplant of bone marrow or blood cells from a healthy person not related to you.  This form gives 
you information to help you decide if you want to be in this study.  You should read this form and ask 
any questions you have before agreeing to be in the study. 
 
 
It is your choice whether or not to join this study.  The medical staff at your transplant center will tell 
you about other treatment options before you make your decision about joining this study.  If you do 
not join this study, you may still have a transplant for your disease. 
 
5. Purpose of the Study 
This study will look at two kinds of blood stem cell transplants, bone marrow and peripheral blood 
stem cell (PBSC), and their side effects.  At this time, doctors use both types of blood stem cells for 
transplant.  If you join this study, the type of cells used for your transplant will be picked by a 
computer program.  The goal of this study is to see which type of blood stem cell transplant (bone 
marrow or PBSC) has better results. 
 
An important part of this study will look at how patients recover after transplants.  Researchers want to 
know what the effects are from each type of blood stem cell used for the transplant and how long they 
last. 
 
Good effects might include: 
 Quick recovery of blood counts after 
transplant 
 No relapse (return) of disease 
 High cure rates 
 Few infections 
 Able to return to important activities in 
life 
Bad effects might include: 
 Slow recovery or no recovery of blood counts 
after transplant 
 Relapse (return) of disease 
 Severe graft-versus-host disease (GVHD) 
 Serious infections 
 Not able to return to important activities in 
life 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-65 
6. Study Procedures 
If you agree to join this study, the donor will also need to agree to join the study.  A donor could 
decide not to join this study, but still agree to give you cells for your transplant.  If that happens, you 
can still have your transplant without being in this study, or another donor who does want to join this 
study may be found. 
 
Since this study looks at the results of two different kinds of transplants, bone marrow and peripheral 
blood stem cell (PBSC), the kind of transplant you will receive will be decided randomly, like a coin 
toss.  Neither you nor your doctor chooses the type of transplant; the type of transplant you will 
receive is determined by a computer program.  Half of the patients in the study will have a bone 
marrow transplant.  The other half will receive a PBSC transplant.  Saying yes to joining the study 
means that you are willing to accept either type of transplant. 
 
One part of the study will involve collecting your medical information.  Your medical information 
will be collected for three years.  The study coordinators at your center will collect information from 
your medical record chart every week for 100 days, then at 6 months, 1 year, 2 years and 3 years. 
 
If you are 16 or 17 years old, another part of the study will ask questions about your physical and 
emotional health.  This information will be collected for five years.  A trained interviewer will contact 
you by telephone before your transplant, then 6 months, 1 year, 2 years and 5 years after your 
transplant.  These telephone interviews will last approximately 15-25 minutes and will be done at a 
convenient time for you.  They will include questions about side effects, health problems and how 
well you can do things that are important to you.  When you are contacted, you may skip any 
questions you don’t want to answer. 
 
As part of the standard transplant procedure, you will need to take many medications and have other 
medical treatments as part of your transplant.  Your doctors will explain these during discussion of 
your medical care.  Even if you decide not to join this research study, you will still need to take 
medications and have other medical treatments as part of your transplant. 
 
7. Possible Discomforts and Risks of Being in the Research Study 
The bone marrow and PBSCs from the donor contain blood stem cells, which allow your blood 
counts (red blood cells, white blood cells, and platelets) to recover.  Blood stem cells make all the 
blood cells in the bone marrow and serve the entire body.  It is possible that even after the transplant 
your bone marrow will not work well enough and you will be at an increased risk of infections and 
even death.  Early after transplant, the risk of getting an infection might be less after a PBSC 
transplant, because the blood counts return faster than with bone marrow.  Later, the risk of infections 
might be increased in PBSC transplants, because graft-versus-host disease (GVHD) might be worse 
and last longer. Blood counts will be done often to track recovery of the bone marrow.  You will get 
platelets and red cells as needed to keep your counts at a healthy level.   
 
There is a risk that the blood stem cells may not grow after being given to you.  This is called graft 
failure.  This risk may be less with PBSCs, since PBSCs contain more blood stem cells than bone 
marrow. 
Graft-versus-host disease (GVHD) is a common problem after unrelated donor transplantation.  After 
the cells in the product start to grow, there is a risk that the donor cells might react against your body. 
GVHD it can show up as a skin rash, or liver or stomach problems, like feeling sick to your stomach, 
throwing up, not feeling hungry, stomach cramps, diarrhea, and bleeding of the gut.  Chronic GVHD 
may occur later after transplantation and can cause problems with the eyes, mouth, lips, throat and 
liver.  You will get medicines to help prevent GVHD, but sometimes people get it anyway.  If you do, 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-66 
there are other medicines used to help treat it.  The chance of getting GVHD might be more with 
PBSCs, because PBSC transplants have more donor cells. 
 
Relapse of your disease might occur after transplant, especially in patients with advanced disease.  
This risk may be decreased by PBSC transplantation. 
 
If one type of transplant does have better results, and you are not randomly assigned to that study 
group, you may not receive the same benefits as those in the study group with overall better results. 
 
If you are 16 or 17 years old, you will complete quality of life interviews.  These interviews will not 
cause you any physical discomfort, although it is possible that you will find some of the questions or 
topics upsetting.  If you do, there will be someone available to speak with you.  They will be able to 
refer you to appropriate counselors or other support people. 
 
8. Possible Risks and Discomforts from the Standard Transplant Procedure 
As part of the standard transplant procedures, you will face risks from the transplant itself and from 
treatments given before and after the transplant.  These risks are no different than the risks you would 
face if you had a transplant but did not join the study.  Your doctor thinks these risks are less than the 
risk from the disease for which you are receiving a transplant. 
 
Your organs may be damaged by the chemotherapy or irradiation given to you to prepare you for the 
transplant, or by other medications given to you after the transplant.  We expect these risks to be the 
same whether you receive bone marrow or PBSCs.  If you want more information about additional 
risks and the drugs that will be used for your conditioning regimen, it is available for you.  
 
As part of a standard transplant procedure you may develop an infection after the transplant.  The new 
cells from the donor may not grow in you (graft failure).  You may develop graft-versus-host disease 
(GVHD). Your disease could relapse. 
 
When the bone marrow or PBSC are given to you through the catheter, there are usually few side 
effects.  Sometimes people may have a headache, chest pain or trouble breathing, a slight fever, or 
blood in the urine.  Very rarely, it may cause an allergic reaction. 
 
9. Alternatives Treatments Available if You Don’t Want to be in the Study 
Participation in this study is entirely voluntary.  You don't have to join this study.  What you and your 
family decide will not affect current or future health care you receive at this institution.  If you are not 
in this study, you might have a transplant with marrow or blood stem cells anyway. 
 
10. Possible Benefits to Participating in the Study  
This research study is comparing the treatment results of bone marrow and PBSC transplants.  At this 
time doctors do not know if one type of transplant has better results than the other, or if they both 
have the same results.  If one type of transplant does have better results, and you are randomly 
assigned to that study group, you may benefit from participating in the study.  The knowledge gained 
from this study may help future patients who need a blood stem cell transplant. 
 
As a result of the bone marrow or PBSC transplant your disease may be put in remission or continue 
in remission. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-67 
11. Withdrawing From the Study 
You can decide to leave the study at any time, for any reason, without notice.  If you want you can 
withdraw from the study but still get a blood stem cell transplant.  If you leave the study after you 
have had some or all of the pre-transplant treatments and decide to have no transplant at all, then your 
blood counts may not return and you could die.  
 
12. Protection of Your Privacy and Confidentiality of Your Research Records  
 
Your participation in this research study, and your medical and quality of life information, will be 
kept private and confidential. 
 
Scientific and medical findings resulting from a study may be presented at meetings and published so 
that the information can be useful to others.  Your name would not be used in these presentations and 
publications. 
 
For questions about access to your medical records, please contact /name / at/number/. 
 
13. Blood Samples for Research Purposes 
You will be asked to give blood samples to see if infection-fighting cells are working and to help 
better understand tissue matching between donors and recipients in this study.  You do not have to 
participate in this part of the study. 
 
If you agree, you will provide blood samples up to 7 times (10-100 mL each time or approximately  
1-7 tablespoons) between the time transplant is initiated and two years after (up to a total for all 7 
blood draws of 430 mL or approximately 2 cups).  The samples will be saved for future testing.  The 
blood can usually be drawn from your central line at the time of other blood collections.  If this is not 
possible, then it will be drawn directly from a vein. 
 
In addition, part of this study will look at if vaccinations after transplantation can help prevent infection.  
You will get vaccinations for diphtheria, tetanus, Hepatitis B and pneumococcus.  Blood will be 
drawn for medical tests to see if the vaccinations are working.  If you do not agree to give blood 
samples for research, your doctor may still recommend vaccinations as part of your medical 
treatment. 
 
The doctors conducting this study may choose to do some additional research tests on the blood 
samples. 
 
You don't have to be in this research.  If you don't want to give blood samples for research you can 
still be in the other parts of the study.  Your care will not be changed if you decide not to give these 
blood samples for research purposes.  Please mark your choice below (check only one box): 
 
 I agree to have blood drawn for research purposes. 
 
 I do not agree to have blood drawn for research purposes. 
 
 
____________________________________                     _______________________ 
 
 
Signature                                                                               Date 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
B-68 
14. Minor’s Assent 
 
I have been told about this study’s purpose, procedures, possible benefits and risks.  I have been given 
a chance to ask questions and they have been answered to my satisfaction.  I understand that I can ask 
more questions at any time. 
 
I voluntarily agree to participate in this study. 
 
By signing this consent form, I have not given up any of the legal rights, which I otherwise would 
have as a subject in a research study. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of Minor  
 
 
 
 
Date 
 
 
 
 
 
 
 
 
 
 
Print Name of Minor 
 
 
 
 
 
Certification of Counseling Healthcare Professional 
 
 
I certify that the nature and purpose, the potential benefits, and possible risks associated with 
participation in this study have been explained to the above individual and that any questions about 
this information have been answered. 
 
 
________________________________ 
 
____________________________ 
Counseling Healthcare Professional  
 
Date 
 
 
 
Use of an Interpreter: Complete if the subject is not fluent in English and an interpreter was used to 
obtain consent: 
 
Print name of interpreter:  ________________________  Date: _____________________  
 
Signature of interpreter:  _________________________   
 
An oral translation of this document was administered to the donor in __________(state language) by an 
individual proficient in English and _______________(state language).  See the attached short form 
addendum for documentation. 
 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-1 
 
 
APPENDIX C 
 
LABORATORY PROCEDURES 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-2 
APPENDIX C – LABORATORY PROCEDURES 
 
 
 
The laboratory procedures performed under this protocol include: 
1. HLA Typing 
2. Characterization of Graft 
3. Immune Reconstitution 
4. Chimerism 
5. Acquisition of Natural Killer Cell Receptors in Recipients of Unrelated Transplants 
 
LABORATORY PROCEDURES 
 
1. 
HLA TYPING 
 
Before Transplantation: HLA typing will be performed for all patients and donors in American 
Society of Histocompatibility and Immunogenetics (ASHI)-approved laboratories designated by 
the transplant centers.  HLA typing must be performed by DNA methods for HLA-A, -B, and -C 
at intermediate resolution, and DRB1 at high resolution, consistent with NMDP standard 
procedures. 
 
After Transplantation: High resolution HLA typing of cryopreserved patient and donor 
samples is conducted as an ongoing research study by the NMDP.  Data will be shared with the 
BMT CTN. 
 
 
2. 
GRAFT CHARACTERISTICS 
 
2.1 
Rationale: The impact of the cellular constituents of the graft on post-transplant outcome 
is likely a complex effect that is a function of the absolute numbers of immune cells in the graft 
(T cells, NK-cells, B-cells, monocytes, and dendritic cells) as well as interactions among these 
different donor cells, and their interactions with residual host cells.  Storek et al. has noted that 
the kinetics of CD45RAbright “naïve” CD4 T cells is most correlated to the numbers of 
CD45RAbright CD4 T cells in the allograft marrow or PBSC allo-graft from HLA matched 
siblings (Storek 2001).  A detailed analysis of the cellular constituents of the graft in patients 
receiving allogeneic marrow or PBSC could help validate or reject the hypothesis that the 
content of donor CD34 and donor dendritic cells are significant factors in regulating post-
transplant immune reconstitution and the incidences of post-transplant GVHD and relapse.  
Recent reports have suggested that the content of donor dendritic cells are associated with the 
incidences of chronic GVHD, and relapse (Waller, 2001), and that the number of transplanted 
CD34 cells is associated with the incidence of acute and chronic GVHD (Przepiorka, 1999).  
Other reports have shown that mobilization of PBSC with G-CSF results in a relative increase in 
the frequency of type 2 dendritic cell progenitors (DC2p) compared with un-stimulated blood 
mononuclear cells (Arpinati 2000).  Thus it is likely that the content of donor CD34 and type 2 
dendritic cells will vary significantly between allogeneic marrow grafts and PBSC grafts that are 
collected after G-CSF stimulation. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-3 
 
2.2 
Assays: Studies will be conducted in keeping with the BMT CTN MOP on graft 
characterization.  Samples of the marrow or PBSC graft will be sent to a central reference 
laboratory for flow cytometric analysis of the content of CD34 cells, the CD38-negative subset 
of CD34 cells, ALDH-bright progenitor cells, T cells, B-cells, NK-cells, monocytes, and 
dendritic cells.  The test samples will be shipped to the reference laboratory at the same time that 
the graft is shipped from the collection center to the transplant center, so that the analysis of the 
cell content will be performed at approximately the same time as the graft is infused into the 
recipient.  Samples will be shipped at 2-8oC on “cold-packs” in order to prevent accidental over-
heating that may impair cell viability. Pilot experiments storing samples of marrow or PBSC 
grafts at 2-8oC versus 20oC have not shown any significant differences in recovery of viable 
CD34 cells or the recovery of various subsets of immune cells (Table 2).  The flow cytometric 
analysis will be performed using a panel of flow cytometry assays, each containing multiple 
fluorescently labeled monoclonal antibodies.  The FACS panel that will be used is shown in 
Table 3. 
 
2.3 
Calculation of absolute cell counts for manipulated products: Some products are 
manipulated between the time of arrival at the transplant center and infusion.  In some cases, 
plasma or red cells are depleted, while in others a subset of the product is cryopreserved.  For 
such products, the doses of cell subsets transplanted can be estimated by adjusting the cell subset 
count at the reference lab multiplied by the proportion of total cells infused divided by the total 
cell received by the transplant center.  Such a method assumes that travel and manipulation of 
the product did not affect any cell subset in a selective manner. 
 
 
3. 
MEASUREMENTS OF POST-TRANSPLANT IMMUNE RECONSTITUTION 
 
3.1 
Sample shipping and analysis: Blood samples will be shipped at 2o-8o C to a central 
reference laboratory for measurement of peripheral T cell subsets, the numbers of T cell receptor 
excision circles (TREC)-positive CD4 and CD8 T cells, and the frequencies of anti-viral T cells 
using the tetramer assay and the pattern of cytokine synthesis by intracellular staining and flow 
cytometric assays.  Plasma samples will be analyzed for IL2 and IL7 levels.  Serum samples will 
be shipped to the reference laboratory for quantitative immunoglobulin levels and analysis of 
standard antibody titers to diptheria toxin and tetanus antigen (dT).  Serum for measuring 
pneumococcal antibodies, Haemophilus influenzae type B-specific IgG antibodies, Hepatitis B 
antibody as well as the titers of opsonophagocytic antibodies to pneumococcus will be sent to the 
central reference laboratory.  The schedule for obtaining and shipping samples is listed in Tables 
6 and 7 of Appendix C below. 
 
3.2 
Rationale and methods for measuring post-transplant T cell function: PBSC grafts 
contain more donor immune cells than marrow grafts and therefore may lead to improved 
reconstitution.  Storek, et al. compared the kinetics of immune reconstitution among 115 cancer 
patients randomly assigned to receive either marrow or PBSC allografts from HLA matched 
siblings (Storek 2001).  Recovery of CD4 T cells was slower among recipients of marrow versus 
PBSC allografts while proliferative responses of T cells to HSV, VZV, or PHA in vitro did not 
differ between recipients of marrow versus PBSC transplants.  There was a significant difference 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-4 
in the incidence of post-transplant infections, with recipients of marrow grafts experiencing a 2.4 
fold higher rate of severe infections.  The rate of fungal infections was 10/46 among recipients of 
marrow grafts and 2/36 among recipients of PBSC grafts (Storek 2001).  The frequency of T 
cells, NK cell, B cells and dendritic cells will be measured in the blood of transplant recipients in 
order to test the hypothesis that the content of donor CD34 cells and donor immune cells in the 
graft has a material impact on the kinetics and quality of post-transplant immune reconstitution.  
Tetramer staining and flow cytometric assays will measure anti-CMV and anti-EBV CD8 T cells 
in samples from A2+ and/or B7+ recipients (circa 60% of patients).  The frequency of functional 
anti-CMV specific T cells will be measured by the frequency of T cells that synthesize TNF in 
response to in vitro exposure to CMV antigens.  The frequency of anti-aspergillus T cells will be 
assessed by measuring cytokine (-IFN and IL-4) synthesis following incubation with aspergillus 
antigen in-vitro.  Plasma IL-7 and IL-2 levels will be measured by ELISA or chemiluminescence 
assays from the heparinized tube of blood used to measure peripheral blood T cells.  The levels 
of IL-2 and IL-7 will be correlated with the levels of T cells in the blood to test the hypothesis 
that poor cellular immune reconstitution may be due, in part, to low blood levels of these 
cytokines (Okamoto 2002).  
 
3.3 
Rationale and methods for measuring post-transplant B-cell function: Comparison 
of recovery of serum immunoglobulin levels among a 115 patients randomized to receive 
marrow or PBSC allo-grafts from HLA matched siblings did not reveal any significant difference 
in the levels of serum Ig or circulating B-cells post-transplant (Storek 2001).  Of note, this study 
did not compare humoral responses to vaccines, but did find lower rates of infections among the 
recipients of the PBSC grafts.  In order to compare in vivo functional humoral immunity between 
the PBSC and marrow recipients, the response to vaccination with the heptavalent pneumococcal 
conjugate vaccine and to Hepatitis B will be measured.  Pneumococcal infections are a long-term 
risk after transplant and, given the increased prevalence of penicillin resistant S. pneumonia, 
penicillin prophylaxis is not universally effective (Kulkarni 2000).  However, polysaccharide 
epitopes such as those in the 23-valent pneumovax vaccine, are T cell independent antigens.  As 
such, the pneumovax vaccine is not highly immunogenic, especially when administered in the 
first year after transplantation.  Conjugate vaccines, which are T cell dependent and provide 
longer lasting immunity have been found to be more immunogenic in both infants and bone 
marrow transplant recipients (Barra 1992).  A recent study administered the heptavalent 
pneumococcal conjugate vaccine (Prevnar, Wyeth Lederle Laboratories) to recipients (and half 
of the donors) at 3, 6, and 12 months after a T cell repleted allogeneic transplant (Molrine 2002).  
By month 12, over 60% of recipients had protective immunity to all 7 serotypes, although at 
month 3 and 6, humoral responses remained low in the half of patients whose donors had not 
been immunized.  An increase in the frequency of patients with protective antibodies was seen 
following the third vaccination with PPV23 at 12 months, indicating that multiple early 
vaccinations with the protein conjugate vaccine can elicit protective humoral antibody responses 
when given within the first year post-transplant (Molrine 2003).  Since the Wyeth vaccine is 
conjugated to a nontoxic variant of diphtheria toxin (CRM), an attractive strategy to augment 
humoral responses to the glycoprotein polysaccharide vaccines in adults within the first year 
post-transplant would be to sequentially immunize transplant recipients with the carrier protein 
(diptheria toxin) followed by vaccination with the pneumococcal conjugate vaccine (7 valent) 2 
weeks later, and finally the 23-valent polysaccharide pneumococcal vaccine a few months later.   
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-5 
Antibody response to the conjugated vaccine, however, represents a best-case scenario.  If 
patients do not respond to the conjugated vaccine, they will not respond to the unconjugated 
vaccine or wild type infection.  Unfortunately, the ability to respond to the conjugated vaccine 
does not predict for response to bacterial carbohydrate antigens.  To evaluate the recipient’s 
ability to produce an antibody response to wild type bacterial carbohydrate antigens, we will test 
for Haemophilus influenzae type B-specific IgG antibodies that cross-react against E. coli K-100 
present in gut flora. 
 
Immunization with Hepatitis B will serve as a potentially informative “neo-antigen” for the circa 
40-50% of donor-recipient pairs that are both sero-negative to test the integrity of the primary 
humoral immune response post-transplant and responding patients may be protected from 
infection.  The hypothesis would be that recipients of PBSC would receive more donor T cells 
and may respond to vaccinations starting at six months post-transplant at a higher frequency than 
recipients of marrow allografts.  Demonstration of immune-responsiveness among transplant 
recipients receiving vaccine starting at six months post-transplant could lead to a reduction of 
some of the morbidity and mortality due to infection seen within the first year post-transplant.   
 
3.4 
Immunophenotype assays of lymphoid subsets and dendritic cells:  Blood samples 
will be obtained from patients at 1, 3, 6, 12 and 24 months post-transplant.  Aliquots of 
peripheral blood will be stained with the panels described in Table 4 by the central reference 
laboratory, and the percentage of nucleated cells with each phenotype determined using standard 
Cell-Quest (or similar) analysis templates.  The reference laboratory will send the coordinating 
center the results from a CBC with differential performed on the shipped sample as well as the 
calculated numbers of cells/mcL of each phenotype as determined by the results of the FACS 
analysis.  The reference laboratory will calculate the absolute numbers of subsets of immune 
cells in the blood based upon the absolute number of leukocytes in the blood and the percentage 
of leukocytes that are T, B, NK, monocyte, or dendritic cells subsets as defined by 
multiparameter flow cytometry.  
 
3.5 
Assays for antigen-specific T cells: Blood samples from patients who receive 
transplants from donors who have the HLA A2 or B7 allele will be obtained at 3, 6, 12 and 24 
months post-transplant.  These will be shipped to the central reference laboratory for FACS 
analysis of the frequency of anti-CMV and anti-EBV specific T cells using a tetramer FACS 
assay on the mononuclear cell fraction obtained from fresh (not frozen) samples.  Tetramers will 
be incubated with PBMC obtained from transplant recipients at the time points described above, 
and the frequency of CD3, CD8, tetramer+ T cells will be assessed by flow cytometry (Altman, 
1996).  A subset of approximately 60% of transplant patients is predicted to be either A2+ and/or 
B7+, but they should be evenly distributed between the two arms.  Phycoerythrin-labeled HLA 
A2 and HLA B7 tetramers that stain antigen specific T cells that recognize immunogenic CMV 
peptides will be synthesized by the tetramer core facility at the central reference laboratory.  
HLA-B0702 tetramers loaded with (TPRVTGGGAM), the amino acid number 417-426 of lower 
matrix protein pp65-of CMV) and HLA-A 0201 tetramers, loaded with (NLVPMVATV), the 
amino acid number 495-503 of the pp65 protein will be used to identify CMV specific T cells 
from patients transplanted with HLA A2 and HLA B7 donors, respectively (Singhal, 2000; 
Keenan, 2001).  EBV specific T cells will be assayed using phycoerythrin-labeled HLA A2 
tetramers loaded with the EBV/BMLF1 peptide containing aa 280-288 (GLCTLVAML, Chen, 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-6 
2001).  In addition, the presence and number of aspergillus-specific, CMV-specific and tetanus-
specific T cells will be determined by secreted cytokines measured by ELISA and FACS 
following in-vitro incubation with antigens at 3, 6,12 and 24 months after transplant (Centeno-
Lima 2002; Hebart 2002).  For CMV, the assays will include FACS for cytoplasmic IL2, IFN-g 
and TNF-a, and no ELISA.  For Aspergillus, the assays will only include ELISA for IL2, IL4, 
IL10 and IFN-g and no FACS.  For Tetanus, the assays will include FACS for cytoplasmic IL2 
and ELISA for IL-2, IL-4, IL-10 and IFN-g.  Appropriate controls should be included in the 
assays.  See Table 1 below.   
 
Table 1:  Cytokines for FACS and ELISA Assays 
 
 
CMV 
Aspergillus 
Tetanus 
Control 
FACS IC Assay 
IL2 
INF-g 
TNF-a 
 
IL-2 
 
IL-2 
IFN-g 
TNF-a 
ELISA Assay 
 
IL-2 
IL-4 
IL-10, 
IFN-g 
IL-2 
IL-4 
IL-10 
IFN-g 
IL-2 
IL-4 
IL-10 
IFN-g 
IC = intracytoplasmatic 
 
 
3.6 
TREC assay for de novo T cell generation: The central reference laboratory will 
prepare a mononuclear cell suspension from patient blood samples collected at 3, 6, 12 and 24 
months post-transplant.  Cell separations will be performed to isolate CD3+/CD4+ and 
CD3+/CD8+ cell subsets for batch analysis of signal joint T cell receptor excised circles 
(TRECs). IL-7 and IL-2 levels will be measured by the central reference laboratory using ELISA 
or chemiluminescence assays on samples of plasma obtained from the tubes of blood used to 
measure T cell numbers.  The levels of IL2 and IL7 will be correlated with the numbers TREC 
CD4 and CD8 (Okamoto 2002).  A summary of post-transplant studies in cellular immune 
reconstitution is shown in Table 5.  
 
3.7 
Immunoglobulin levels: Quantitative immunoglobulin levels will be measured by the 
central reference laboratory on patient samples collected prior to transplant (baseline) and 6, 11, 
12 and 24 months post-transplant (Table 5).  
 
3.8 
Vaccination schedule: In order to increase the effectiveness of the pneumococcal 23 
valent polysaccharide vaccine administered post-transplant, transplant recipients will receive 
sequential vaccination with dT (tetanus diphtheria toxoid) at 6 months post-transplant followed 
by the heptavalent pneumococcal conjugate vaccine (PCV7) four weeks later at 7 months, and 
again at 9 months post-transplant, and then the 23-valent polysaccharide vaccine (PPV23) and 
the dT (tetanus diptheria toxiod) vaccine at 11 months post-transplant (Table 5).  The goal will 
be to evaluate the immunogenicity of the pneumococcal vaccine conjugate when it is 
administered after boosting with the dT carrier vaccine followed by sequential vaccination using 
the PCV7 and PPPV23 vaccines. ELISA and functional type-specific pneumococcal antibodies 
will be measured.  Diphtheria and tetanus antibody will be measured prior to the first vaccination 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-7 
and prior to the PPV23 vaccine.  Haemophilus influenzae type B-specific IgG antibody 
measurements will also be performed on samples collected at 6, 12 and 24 months post 
transplant to assist in evaluating the recipient’s ability to produce T cell independent immune 
responses to polysaccharide antigens.  Approximately 60% of recipients are predicted to be sero-
negative for Hepatitis A. Immunization with the Hepatitis B vaccine will be used a neo-antigen, 
in order to assess immune response to primary antigen.  The Hepatitis B vaccine will be 
administered at 6 months, 7 months, and 11 months after transplant, and antibody titers at 6, 12 
and 24 months will be determined to compare responses in the PBSC and bone marrow 
recipients.  All vaccinations should be given ± 1 week of the scheduled date.  Donor and pre-
transplant recipient serum will be collected to measure baseline antibody titers as specified in 
Table 5.  
 
3.9 
Laboratory assays for antibody titers: 
 
i) ELISA for diphtheria antibody and tetanus antibody will be performed at the central 
reference laboratory. 
 
ii) ELISA for S. pneumoniae antibody. IgG antibody levels for specific serotypes of S. 
pneumoniae will be assayed by a protocol developed by George Carlone, Ph.D. at CDC.  
These studies will be conducted at the central reference laboratory.  Serotypes that are 
PCV7 heptavalent pneumococcal conjugate vaccine (4, 6B, 9V, 14, 18C, 19F &23F) and 
a subset of serotypes present in the PPV23-valent polysaccharide vaccine (1, 3, 5, 7F, 
15B) vaccines will be measured at 6, 11, 12 and 24 months post-transplant. 
 
iii) Functional antibodies for S. pneumoniae.  Functional antibodies will be measured by 
an opsonophagocytic assay using HL-60 cells. Opsonophagocytic titers will be expressed 
as the reciprocal of the serum dilution with  50% killing compared with growth in the 
complement control wells.  These studies will be conducted at the central reference 
laboratory.  The opsonophagocytic assay will be performed only on 11 and 12 month 
post-transplant patient samples that show demonstrable IgG antibodies directed against 
one or more of the twelve S. pneumoniae serotypes evaluated in this study.  The 
measurement of functional antibodies will be limited to the analysis of the two serotype-
specific antibodies (one serotype, if IgG antibody detected to only one serotype) 
exhibiting the highest IgG titers. 
 
iv) Hepatitis B surface antigen antibody.  These will be measured using ELISA kits at the 
central reference laboratory.  Analysis will be performed on baseline donor serum 
samples and on patient serum samples collected at 6, 12 and 24 months post-transplant 
(Table 5). 
 
v) ELISA for Haemophilus influenzae antibodies.  Quantitative total IgG antibody levels 
against H. influenzae Type B (HIB) capsular polysaccharide will be measured using 
ELISA/EIA kits at the central reference laboratory.  Analysis will be performed on 
patient serum samples collected at 6, 12 and 24 months post-transplant. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-8 
vi) Stored serum and subsequent assays.  If, during the conduct of the study, investigators 
wish to analyze additional antibody assays, samples from frozen serum samples will be 
sent to the outside lab with no identifying information, except for a unique study number.  
All serum specimens will be stored for a 2-year period following enrollment of the last 
patient on the study.  Specimens will be stored in a locked freezer at –80C. 
 
 
4. 
CHIMERISM 
 
Recommendations for chimerism assay: Demonstration of donor cells in lymphoid and 
myeloid lineages can assess the relative engraftment potential of PBSC compared to marrow.  
Since all patients on this trial will receive myeloablative conditioning regimens, we hypothesize 
that there will be little if any difference in donor chimerism between PBSC recipients and 
marrow recipients.  Therefore, chimerism testing will not be mandatory in this study. However, 
routine chimerism data generated by transplant center laboratories will be reported.  Chimerism 
results will be reported as “percent donor DNA.” 
 
 
5. 
ACQUISITION OF NATURAL KILLER CELL RECEPTORS IN RECIPIENTS 
OF UNRELATED TRANSPLANTS 
 
This is a supplemental study to this protocol conducted by Jeffrey S. Miller, Daniel Weisdorf, 
Claudio Anasetti, and Peter Parham. 
 
5.1 
Background: Natural killer cells comprise approximately 10 – 15 % of resting normal 
donor blood.  Interestingly, they comprise a much higher proportion of blood lymphocytes early 
after bone marrow or peripheral blood stem cell transplantation.  There has been a growing 
interest in NK cells, given the discovery over the past five years of specific receptors that 
recognize Class I MHC molecules.  A recent publication by Ruggeri, et al, suggests that T-cell 
depleted haplo-identical transplant by donors who are mismatched at a known Killer 
Immunoglobulin-like Receptor (KIR) ligand (Cw3-group, Cw4-group or Bw4) correlates with 
protection from relapse, less GVHD and better survival.  The complexity of the KIR system is in 
part limited by the lack of known ligands for many of the receptors.  The Perugia analysis is 
clinically intriguing but leaves some complicated biologic questions unanswered.  Understanding 
this receptor status and how well it correlates with recipient KIR ligands may be of importance 
for better donor selection and improving unrelated donor (URD) transplant outcomes.  The 
principal study goal is to evaluate the NK cell receptor repertoire and the functional acquisition 
of these receptors on NK cells in patients who recover from unrelated donor transplant.  A 
functional NK repertoire may be associated with better protection from GVHD and infections 
and might differ in patients receiving PBSC or BM transplantation. 
 
5.2 
Preliminary Data: We have already accessed donor/recipient samples from the National 
Marrow Donor Program Sample Repository.  From this repository, donor peripheral blood 
mononuclear cells (PBMNC) are available as well as cells from the recipient at approximately 
Day 100. We have used several approaches to analyze NK cell receptor acquisition after 
transplant including flow cytometry, quantitative RT-PCR, and intracellular cytokine staining. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-9 
Our current data on 36 donor/recipient sample pairs (collected retrospectively) can be 
summarized as follows: 1) KIR reconstitution early after transplant is diminished in a majority of 
patients, 2) KIR reconstitution is diminished to a greater extent in recipients of unmanipulated 
compared to T-cell depleted grafts, and 3) less KIR expression is associated with enhanced 
interferon- production in developing NK cells and CD94/NKG2A is reciprocally increased in 
those with low KIR expression.  Further study will correlate these laboratory endpoints with 
clinical outcomes after URD transplantation.  
 
5.3 
Limitations to Current Retrospective Analysis and Samples Requested: Despite rapid 
progress in studies using retrospectively collected donor/recipient pairs, there are important 
limitations with this analysis.  Available repository samples are limited to a single, early post-
transplant time point.  Our in vitro studies predict that NK cell receptor acquisition develops 
progressively over time.  This is supported by studies from the Parham laboratory in allogeneic 
transplant patients.  Therefore, kinetic analyses are needed to study the completeness of NK cell 
receptor reconstitution.  To accomplish this goal, we propose prospective sample collection (30 
ml blood at each time point) from the donor and recipient pre-transplant and from the recipient at 
3, 6, and 12 months after transplant.  Applying this analysis to the randomized trial also provides 
the advantage of correlation with detailed immunologic and infectious disease outcomes that will 
be collected in conjunction with this trial. 
 
5.4 
Objectives 
 
a. The primary objective of this study is to assess NK cell receptor acquisition (KIR, 
NKG2, LILR, NKp30/44/46, others) and NK cell function (cytotoxicity and cytokine 
production) during the first year after allogeneic URD transplantation.  Until the BMT 
CTN Protocol 0201 trial is complete, this objective will be met irrespective of knowledge 
of graft source, transplant variables or clinical outcomes.  
 
b. The secondary objective will not be reached until after completion of and reporting of 
the randomized study.  We plan to determine whether graft source (BM vs. PBSC) 
impacts on the frequency and completeness of NK cell receptor reconstitution and NK 
cell function.  In this large prospective cohort, we will determine whether NK cell 
receptor status correlates with clinical outcomes (infectious disease, relapse, GVHD) and 
the number of activating vs. inhibitory NK receptors.  We will test the hypothesis that 
KIR reconstitution is delayed by GVHD, favors CD56+bright NK cell (cytokine producing) 
reconstitution and this diminishes CD56+dim NK cell (directly cytotoxic) alloreactivity as 
a mechanism to protect against relapse.  These analyses will be performed in conjunction 
with the BMT CTN database for the BMT CTN Protocol 0201 trial, which will collect 
the relevant clinical endpoints. 
 
5.5 
Experimental Plan: Paired donor /recipient samples will be thawed (including at least 2 
post-transplant time points) and analyzed in parallel.  We have a 2-tiered approach to analyze 
KIR expression.  The first is based on flow cytometry using antibodies recognizing one or more 
KIR gene products (DX9 recognizes KIR3DL1), (GL183 recognizes KIR2DL2, KIR2DL3, 
KIR2DS2), (EB6 recognizes KIR2DL1, KIR2DS1).  The limitations of this analysis are that 
some antibodies recognize more than one gene product and that monoclonal antibodies are not 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-10 
currently available for all KIR.  Therefore, in addition to flow cytometry, RNA extracts will be 
amplified for KIR expression.  We have already validated real time quantitative PCR reactions 
for a majority of KIR genes.  To control for NK cell number, quantitative real time PCR will be 
performed from gene products expressed in all NK cells (KIR2DL4 and CD56/NCAM).  We will 
need genotyping studies to further investigate whether the absence of a KIR transcript is due to 
the absence of a gene or the absence of expression.  Control cell lines and a panel of known 
normal donors will be included with each analysis.  We have already established a good 
correlation between protein level by flow cytometry and real time quantitative PCR data using 
standard curves.  We will also analyze other NK receptors including NKG2, LILR, and 
NKp30/44/46 receptors and other families as reagents become available and validated.  Function 
will be measured by cytotoxicity or cytokine productions assays in the presence or absence of 
KIR ligands.  As new reagents or NK cell related genes or receptors are identified, these samples 
may be used for new studies.  However, within this study, analyses are limited to studies on NK 
cell expressed gene products and NK cell function.  They will not be used for other purposes. 
 
5.6 
Samples: 
 
Donor:      30 mL heparinized blood (green top tubes), pre-donation (prior to G-CSF if PBSC) 
Recipient: 30 mL heparinized blood (green top tubes), pre-transplant (before conditioning) 
 
       30 mL heparinized blood (green top tubes) at 3, 6 and 12 months post-transplant 
 
To limit blood drawing volumes, if needed, the post-transplant samples can be collected a few 
days or up to 4 weeks before or after the requested times. 
 
For pediatric subjects, the volume requested is 15-20 mL heparinized blood at the same time 
points. 
 
Samples are to be sent by overnight express in a temperature certified shipping kit: 
 
Dr Jeffrey Miller  
Attn: Sue Fautsch 
University of Minnesota 
Cancer Center Research Building, Room 521 
425 E. River Road 
Minneapolis, MN  55455 
 
Phone: 612 625-6165 
 
 
6. 
LABORATORY SPECIMEN COLLECTION, STORAGE AND SHIPPING 
PROCEDURES 
 
Standard procedures for collection, storage, and shipping of specimens will be followed 
according to the NMDP and the NHLBI guidelines.  Samples will be given a unique 
alphanumeric code that contains no personal identifiers.  Transplant Center Coordinators will 
hold the link to the code.  Laboratory staff will not have access to the link. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-11 
 
 
7. 
LABORATORY CONTRACTS AND REMAINING SAMPLES 
 
All laboratory studies will be performed at laboratories under contract with the NMDP on behalf 
of the BMT CTN.  The laboratory contract specifies that any remaining serum must be stored at 
the laboratory for the duration of the study.  If the investigators choose to perform additional 
studies on these remaining samples, a formal amendment will be made to the protocol.  Any 
amendments to the protocol are subject to the DSMB and IRB approval process. 
 
At the end of the study, the BMT CTN will either instruct the laboratory to destroy any 
remaining samples or to transfer the remaining samples to the NHLBI sample repository in 
Maryland.  These samples will be paired with the respective donor or recipient sample and given 
unique bar code designations that cannot be linked back to the donor or the recipient.  An 
NHLBI Biologic Specimen Repository Utilization Committee will advise the Institute on 
requests for specimens to perform research with these anonymous samples.  If an investigator 
request for these samples is approved by the committee, the NHLBI may provide a panel of the 
specimens requested using unique code numbers.  Laboratory test results, clinical information, 
etc., associated with the coded samples are provided to the investigator only after completion of 
his/her research protocol.  Samples sent to researchers cannot be linked with any remaining 
sample at the repository. 
 
After completion of all cellular assays, the samples will be destroyed.  Only serum samples 
remaining from the laboratory assays for antibody titers will be shipped to the NHLBI sample 
repository.   
 
 
Table 2:  Effect of Storage Time and Storage Temperature on the Numbers of Viable CD34 
Cells, T cells and Dendritic Cells in Blood and Marrow Grafts 
 
Analyses after 72 
hours:  
Median percentages 
of initial value 
2-8C Marrow 
HPC 
Room Temp 
Marrow HPC 
2-8C Blood 
HPC 
Room Temp 
Blood PBSC 
Viable CD34 
100% 
100% 
40% 
16% 
Viable CD3 
60% 
51% 
54% 
48% 
Viable DC2p 
74% 
54% 
67% 
32% 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-12 
 
Table 3:  Flow Cytometry for Graft Characterization 
 
Tube 
# 
Class of 
Cells 
Cell Types 
Measured Blood Cell 
Subsets 
Antibodies 
1 
Progenitor 
Cell  
Viable CD34 
cells 
Viable nucleated cells 
CD34 cells 
CD34/CD38- cells/kg 
anti-CD45 (FITC) 
anti-CD34 (PE) 
anti-CD38(APC) 
7AAD 
2 
Progenitor 
Cell  
ALDHbright 
cells 
ALDHbright CD34 cells 
ALDHbright CD34-negative 
cells/kg 
BAAA (FITC) 
anti-CD34 (APC) 
anti-CD45(PE) 
3 
Progenitor 
Cell  
ALDH 
negative 
control 
Negative control for 
BAAA staining 
BAAA (FITC) + DEAB 
IgG1-(APC negative control) 
IgG1-(PE negative control) 
4 
Progenitor 
Cell  
ALDH 
compensation 
BAAA control 
BAAA 
IgG1 (APC negative control) 
IgG1-(PE negative control) 
5 
Progenitor 
Cell  
ALDH 
compensation 
PE control 
BAAA 
IgG1-(APC negative control) 
CD3-(PE) 
6 
Progenitor 
Cell  
ALDH 
compensation 
APC control 
BAAA 
CD3-(APC) 
IgG1-(PE negative control) 
7 
Lymphoid 
Subsets 
T cell subsets 
CD4 
CD8 
CD25+ 
anti-CD4 (PerCP) 
anti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3 (APC) 
8 
Lymphoid 
Subsets 
NK and  T 
cells 
CD56+ 
  T cells 
anti-CD56 (PE) 
anti- TCR (FITC) 
anti-CD16 (PerCP) 
anti-CD3 (APC) 
9 
Lymphoid 
Subsets 
B-cells & 
monocytes 
CD5+ B-cells  
CD14+ monocytes 
anti-CD5 (PerCP) 
anti-CD14(PE) 
anti-CD2 (FITC) 
anti-CD19 (APC) 
10 
Dendritic 
Cell 
Subsets 
DC subsets 
DC1 and DC2 subsets 
anti-lineage (FITC) 
anti-CD123(PE) 
anti-HLADR (PerCP) 
anti-CD11c(APC) 
11 
Isotype 
Controls 
Isotype Ig 
Non-specific staining 
irrelevant (FITC) (PE) (PerCP) (APC) 
conjugates to murine monoclonal Ab 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-13 
 
Table 4:  Flow Cytometry for Immune Reconstitution 
 
Tube 
# 
Class of 
Cells 
Cell Types 
Measured Blood Cell 
Subsets 
Antibodies 
1 
Lymphoid 
Subsets 
T cells 
CD4 
CD8 
CD25+  
anti-CD4(PerCP) 
anti-CD8 (FITC) 
anti-CD25 (PE) 
anti-CD3(APC) 
2 
Lymphoid 
Subsets 
NK and  T 
cells 
CD56+  
 T cells 
anti-CD56 (PE) 
anti- TCR (FITC) 
anti-CD16 (PerCP) 
anti-CD3 (APC) 
3 
Lymphoid 
Subsets 
CD8 T cell 
Subsets 
Naïve and activated 
CD8 T cells 
anti-CD8 (APC) 
anti-Ki67(FITC) 
anti-CD62L (PE) 
anti-CD45RA (TC) 
4 
Lymphoid 
Subsets 
CD4 T cell 
Subsets 
Naïve and activated 
CD4 T cells 
anti-CD4 (APC) 
anti-Ki67(FITC) 
anti-CD62L(PE) 
anti-CD45RA (TC) 
5 
Lymphoid 
Subsets 
B-cells & 
monocytes 
CD5+ 
CD27 
B cells 
CD14+ monocytes 
anti-CD5 (PerCP) 
anti-CD27 (FITC) 
anti-CD14(PE) 
anti-CD19 (APC) 
6 
Dendritic 
Cell Subsets 
DC subsets 
DC1 and DC2 subsets 
anti-lineage (FITC) 
anti-CD123(PE) 
anti-HLADR (PerCP) 
anti-CD11c(APC) 
7 
Isotype 
Controls 
Isotype Ig 
Non-specific staining 
irrelevant (FITC) (PE) (PerCP) 
(APC) conjugates to murine 
monoclonal Ab 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-14 
Table 5:  Summary of Immune Reconstitution Assays for Donors and Patients 
and Post-transplant Vaccination Schedule for Patients  
 
 
Baseline 
Donor 
Baseline 
Patient 
1 m 
3 m 
6 m 
7 m 
9 m 
11 m 
12 m 
24 m 
 
Measures of Cellular Immunity  
FACS analysis  
 
 
X 
X 
X 
 
 
 
X 
X 
Tetramers assay 
 
 
 
X 
X 
 
 
 
X 
X 
TREC analysis 
 
 
 
X 
X 
 
 
 
X 
X 
Plasma IL-7 and IL-2 
levels 
 
 
 
X 
X 
 
 
 
X 
X 
T cell responses to tetanus, 
CMV, and Aspergillus 
antigens  
 
 
 
X 
X 
 
 
 
X 
X 
 
Immunoglobulin and Antibody Titers1 
dT Antibodies  
 
X 
 
 
X 
 
 
X 
X 
X 
S. pneum. Ab and ops 
 
 
 
 
X 
 
 
X 
X 
X 
Anti-HBsAg titer 
X 
 
 
 
X 
 
 
 
X 
X 
Quantitative Ig 
 
X 
 
 
X 
 
 
X 
X 
X 
H. influenzae B Ab Titer 
 
 
 
 
X 
 
 
 
X 
X 
Natural Killer Cell 
Receptor Acquisition 
X 
X 
 
X 
X 
 
 
 
X 
 
1 Antibody titers should be drawn just before vaccination. 
 
 
Baseline 
Donor 
Baseline 
Patient 
1 m 
3 m 
6 m 
7 m 
9 m 
11 m 
12 m 
24 m 
 
Vaccination Schedule2 
dT vaccine 
 
 
 
 
X 
 
 
X 
 
 
PCV7 vaccine 
 
 
 
 
 
X 
X 
 
 
 
PPV23 vaccine 
 
 
 
 
 
 
 
X 
 
 
Hep B vaccine 
 
 
 
 
X 
X 
 
X 
 
 
2 Vaccinations should be given ±1 week of the scheduled dates. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-15 
Table 6: Collection and Shipping Procedures and Collection Schedule for Patient Blood Samples 
 
 
TYPE OF  
SAMPLE 
TYPE OF PROCESSING AND 
STORAGE 
DATES SAMPLES 
OBTAINED 
SHIPPING SPECIFICATIONS 
LOCATION OF TEST 
PERFORMED 
FACS Analysis 
17 mL peripheral blood 
((2) 8.5 mL fill ACD-A 
yellow top tubes) 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
1, 3, 6, 12, and 24 
months post-transplant. 
Ship priority overnight FedEx on frozen gel 
packs to Emory University; samples should 
not be in direct contact with the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
CBC with 
Differential 
3 mL peripheral blood 
((1) 3 mL fill EDTA 
lavendar top tube) 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
1, 3, 6, 12, and 24 
months post-transplant. 
Ship priority overnight FedEx on frozen gel 
packs to Emory University; samples should 
not be in direct contact with the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
TREC analysis; T 
cell responses to 
tetanus, CMV, and 
Aspergillus antigens; 
Tetramer FACS 
analysis 
34 mL peripheral blood 
sample for all analyses 
((4) 8.5 mL fill ACD-A 
yellow top tubes) 
 
 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
3, 6, 12, and 24 months 
post-transplant. 
Ship priority overnight FedEx on frozen gel 
packs to Emory University; samples should 
not be in direct contact with the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
Immunoglobulin and 
Antibody Titers 
10 mL peripheral blood 
((1) 10 mL fill red top 
tube, no anticoagulant) 
 
Sample should be placed upright in a 
sample rack and allowed to clot at 
room temperature for 30 minutes.  
Centrifuge red top tube at 900 x g or 
2100 rpm.  Extract serum carefully 
without disturbing the clot.  Transfer 
500 μL aliquots to 10 cryovials and 
freeze at –70ºC in a scientific grade 
freezer. 
At baseline prior to 
transplant and at 6, 11, 
12, and 24 months post-
transplant. 
Batch ship quarterly, frozen on dry ice in a 
provided shipping container, FedEx priority 
overnight to the NHLBI Repository. 
Esoterix Laboratory 
Plasma Il-7 and Il-2 
Levels 
6 mL peripheral blood 
((1) 7 mL fill EDTA 
lavendar top tube) 
Centrifuge the EDTA containing 
whole blood samples at 900 x g or 
2100 rpm for 10 minutes within 30 
minutes of collection.  Extract the 
separated plasma.  Transfer 500 μL 
aliquots to 6 cryovials and freeze at 
 -70ºC in a scientific grade freezer. 
3, 6, 12, and 24 months 
post-transplant. 
Batch ship quarterly, frozen on dry ice in a 
provided shipping container, FedEx priority 
overnight to the NHLBI Repository. 
Esoterix Laboratory 
Natural Killer Cell 
Receptor Acquisition 
30 mL peripheral blood 
((3) 10 mL fill sodium 
heparin green top tube) 
No additional processing; do not 
centrifuge.  Store at 2-8 oC until 
shipped. 
At baseline prior to 
transplant and at 3, 6, 
and 12 monts post-
transplant. 
Ship priority overnight FedEx on frozen gel 
packs to University of Minnesota; samples 
should not be in direct contact with the gel 
packs. 
Dr. Jeffrey Miller’s Lab at 
University of Minnesota 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-16 
Table 7: Collection and Shipping Procedures and Collection Schedule for Donor Blood and Product Samples 
 
TEST 
TYPE OF  
SAMPLE 
TYPE OF PROCESSING AND 
STORAGE 
DATES SAMPLES 
OBTAINED 
SHIPPING SPECIFICATIONS 
LOCATION OF TEST 
PERFORMED 
Baseline Antibody 
Titer 
10 mL peripheral blood 
((1) 10 mL fill red top 
tube, no additive) 
 
Sample should be placed upright in a 
sample rack and allowed to clot at 
room temperature for a minimum of 
30 minutes prior to packaging the 
sample for shipment. 
At baseline: any time 
after donor signs 
consent and prior to 
first filgrastim 
injection/marrow 
collection. 
Ship priority overnight FedEx at room 
temperature to Esoterix Laboratory. 
Esoterix Laboratory 
Cellular Composition 
2-4 mL product sample 
((2) 5 mL sterile 
polyethylene screw top 
tubes, no additive) 
 
Collect and package an aliquot of 
product for shipment.  If two day 
PBSC collection, first sample is 
stored overnight at 2-8 C and 
shipped with Day 2 sample. 
Day of collection. 
Ship priority overnight FedEx at 2-8 C on 
frozen gel packs to Emory University; 
samples should not be in direct contact with 
the gel packs. 
Dr. Edmund Waller’s Lab at 
Emory University 
Natural Killer Cell 
Receptor Acquisition 
30 mL peripheral blood 
((3) 10 mL fill sodium 
heparin green top tube) 
No additional processing; do not 
centrifuge.   
At baseline: any time 
after donor signs 
consent and prior to 
first filgrastim 
injection/marrow 
collection. 
Ship priority overnight FedEx at 2-8 C on 
frozen gel packs to University of Minnesota; 
samples should not be in direct contact with 
the gel packs. 
Dr. Jeffrey Miller’s Lab at 
University of Minnesota 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-17 
Appendix C References 
 
Altman JD, Moss PAH, Goulder PJR, et al.  Phenotypic analysis of antigen-specific T 
lymphocytes.  Science 1996; 274: 94. 
 
Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C.  Granulocyte-colony stimulating 
factor mobilizes T helper-2-inducing dendritic cells.  Blood 2000; 95: 2484-2490. 
 
Barra AA, Cordonnier C, Presiosi MP et al. Immunogenicity of Haemophilus influenzae type b 
conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 1992; 1666: 1021-1028. 
 
Chen G, Shankar P, Lange C, et al.  CD8 T cells specific for human immunodeficiency virus, 
Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of 
infection.  Blood 2001; 98: 156. 
 
Centeno-Lima S, Silveira H, et al. Kinetics of cytokine expression in mice with invasive 
aspergillosis: lethal infection and protection. FEMS Immunology and Medical Microbiology 
2002; 32:167. 
 
Hebart H, Bollinger C, Fisch P, et al., Analysis of T cell responses to Aspergillus fumigatus 
antigens in healthy individuals and patients with hematologic malignancies. Blood 2002;100: 
4521. 
 
Keenan RD, Ainsworth J, Khan N, et al.  Purification of cytomegalovirus-specific CD8 T cells 
from peripheral blood using HLA-peptide tetramers.  Br J Hematol 2001; 115: 428.  
 
Kulkarni S, Powles R, Treleaven, J et al. Chronic graft-versus-host diseases is associated with 
long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 
2000:  95: 3683. 
 
Molrine DC, Antin JH, Guinan EC. et al. Donor immunization with pneumococcal conjugate 
vaccine and early protective antibody responses following allogeneic hematopoietic cell 
transplantation. Blood 2003; 101: 831-36.  
 
Okamoto Y, Douek DC, McFarland RD, Koup RA. Effects of exogenous interleukin-7 on human 
thymus function. Blood 2002;99:2851 
 
Przepiorka D, Smith TL, Folloder J, et al.  Risk factors for acute graft-versus-host disease after 
allogeneic blood stem cell transplantation.  Blood 1999; 94:1465. 
 
Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of Donor Natural Killer Cell Alloreactivity 
in Mismatched Hematopoietic Transplants.  Science 2002; 295: 2097-2100. 
 
Storek J, Dawson, MA, Storer, B, et al. Immune reconstitution after allogeneic marrow 
transplantation compared with blood stem cell transplantation. Blood 2001; 97: 3380-3389. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
C-18 
Singhal S, Shaw J, Ainsworth J, et al.  Direct visualization and quantitation of cytomegalovirus-
specific CD8 Cytotoxic T-lymphocytes in liver transplant patients.  Transplantation 2000; 69: 
2251.  
 
Waller EK, Rosenthal H, Jones TW, et al.  Larger numbers of CD4(bright) dendritic cells in 
donor bone marrow are associated with increased relapse after allogeneic bone marrow 
transplantation.  Blood 2001; 97: 2948-56. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
D-1 
 
 
APPENDIX D 
 
HUMAN SUBJECTS 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
D-2 
APPENDIX D – HUMAN SUBJECTS 
 
 
Subject consent: Candidates for the study will be identified as described in Chapter 4.  The PI or 
his/her designee at each transplant or donor center will contact the candidates, provide 
information about the purpose of the study, obtain consent and register them onto the study.  A 
template of the consent form will be provided by the network for each center to customize to 
meet the local requirements and have reviewed and approved by the local IRB. 
 
Confidentiality: Confidentiality will be maintained by assigning patients and donors identifier 
codes.  The keys relaying to the patient’s or donor's identity with the ID code will be kept at each 
Center and at the NMDP separately from the research database.  
 
Participation of women and minorities, children and other populations: Women and ethnic 
minorities will be included in this study.  There is no lower age for participants. 
 
Justification for including minors: The transplant procedures described in this protocol are 
considered non-research, standard therapy at U.S. transplant centers.  Both bone marrow and 
peripheral blood stem cell (PBSC) transplants have been successfully used to treat blood 
disorders such as leukemias and myelodysplasia in pediatric and adult populations.  In addition, 
the conditioning regimens and GVHD prophylaxis regimens included in the protocol are non-
research, standard regimens.  Therefore, in this protocol, the transplant procedure itself is not 
considered a research procedure and was not included in the risk/benefit analysis for inclusion of 
minors in research. 
 
The following research procedures were included in the risk/benefit analysis: 
 Randomization 
 Quality of life interviews (16 and 17 years of age only) 
 Blood draws for immune reconstitution studies 
 
The research in this protocol satisfies the conditions set forth in 45 CFR 46.406: “Research 
involving greater than minimal risk and no prospect of direct benefit to individual subjects, but 
likely to yield generalizable knowledge about the subject’s disorder or condition.” 
 
The research meets the following conditions: 
 
1. The risk represents a minor increase over minimal risk. 
 In all likelihood, all children invited to participate in this protocol will receive a 
hematopoietic stem cell (HSC) transplant regardless of whether they participate in this 
protocol.  Since it is unknown if the overall survival from a HSC transplant differs 
depending on whether the source of the stem cells is bone marrow or peripheral blood, 
the randomization process represents a minor increase over minimal risk to the standard 
transplant procedure.  
 Quality of life (QOL) interviews will only be conducted on minors 16 and 17 years of 
age.  There are no physical risks associated with the QOL interviews, but there is a minor 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
D-3 
increase over minimal risk as to loss of confidentiality or psychological distress caused 
by the questions.  There are procedures in place to decrease these risks. 
 Blood draws for immune reconstitution studies are an optional part of the study.  The 
minor may participate in the randomization, and if applicable, the QOL interviews, and 
opt-out of the blood draws for the immune reconstitution studies.  Although these blood 
draw volumes fall well within the minimal risk limits for healthy adults, the fact that 
these are pediatric, post-transplant patients slightly increases the risk of the blood draw.  
However, since these tests have no bearing whatsoever on patient care, the patient’s 
physician would eliminate the blood draw if it posed additional risk for the patient. 
 
2. The intervention or procedure presents experiences to subjects that are reasonably 
commensurate with those inherent in their actual or expected medical, dental, psychological, 
social, or educational situations. 
 In all likelihood, all children invited to participate in this protocol will receive a 
hematopoietic stem cell transplant regardless of whether they participate in this protocol.  
Randomly assigning the transplant product the minor will receive does not inherently 
alter the standard transplant procedure.  The transplant experience on the protocol is 
commensurate with the transplant experience off the protocol. 
 The majority of minors invited to participate on this protocol will not take part in the 
QOL portion of the study.  For those 16 and 17-year-old minors who will participate in 
the QOL interviews, the interviews are commensurate with the interviews these minors 
would have with Child Life Coordinators or other similar support staff at the transplant 
center following a standard transplant. 
 The blood drawn for the immune reconstitution studies will most likely be drawn at the 
time of other blood draws for the standard transplant procedure.  Since in most cases 
additional vein sticks will not be required, and the amount of blood drawn for these 
research tests is relatively minor in relation to all the other blood draws that are part of 
the standard transplant procedure, these blood draws are commensurate with those of the 
standard transplant procedure. 
 
3. The intervention or procedure is likely to yield generalizable knowledge about the subject’s 
disorder or condition, which is of vital importance for the understanding or amelioration of 
the subject’s disorder, or condition. 
 Within the transplant community there is shift in medical practice from performing bone 
marrow transplants to performing peripheral blood transplants despite the fact that there 
are presently no data to support this shift in practice.  This study is the first prospective, 
randomized clinical trial to compare the results of these two types of transplant using 
unrelated donors.  This study is of vital importance in understanding the best treatment 
options for patients in need of an unrelated donor hematopoietic stem cell transplant.  The 
results could well be different in pediatric populations than in adult populations; 
therefore, it is important to include pediatric patients in this study.  
 Since quality of life issues are an important aspect of evaluating the results of each type 
of transplant, the quality of life interviews in the 16 and 17 year olds will provide 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
D-4 
valuable information in determining the impact each type of transplant has on the quality 
of life of older minors.  
 The additional research tests examining immune reconstitution after transplant will 
provide data on any differences the source of the hematopoietic stem cells may make in 
restoring immune reconstitution after a transplant.  Since immune reconstitution is 
directly related to post-transplant infections, a major contributor to transplant-related 
mortality, results of this portion of the study will be important to further understanding 
and treating this significant complication of unrelated donor hematopoietic stem cell 
transplantation. 
 
4. Adequate provisions are made for soliciting assent of the children and permission of their 
parents or guardians, as set forth in CFR 46.408. 
 The research procedures do not provide any direct benefit to the health and well being of 
the minors; therefore, assent will be sought from all minors aged 7 to 17 years old. 
 Age appropriate assent forms will be used to obtain assent from minors 7 to 11 years old 
and minors 12 to 17 years old.  Minor assent must be documented by a signature on the 
Assent Form for Participation in the study. 
 The research in this protocol is covered by 45 CFR 46.406; therefore, the signatures of 
both parents are required on the legal guardian consent form, unless one parent is 
deceased, unknown, incompetent, or not reasonably available, or when only one parent 
has legal responsibility for the care and custody of the child. 
 The minor may only participate in the research if the minor and both parents agree to the 
minor’s participation.  If either parent or the minor declines participation in the study, the 
minor shall not be enrolled in the study. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
E-1 
 
 
APPENDIX E 
 
DONOR MANAGEMENT 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
E-2 
APPENDIX E – DONOR MANAGEMENT 
 
 
Donor eligibility will be confirmed as described in Section 2.5 of the protocol.  In addition, 
donor management will be in accordance with the NMDP Donor Center Manual of Operations. 
 
Donors’ eligibility determinations and enrollments will occur following issuance of a work-up 
request.  Because none of the work-up requirements are unique to the protocol, the donor consent 
decision may be made at any time prior to donor clearance.  However, the invitation to 
participate in the protocol must be extended at the donor information session.  At any time 
during the work-up procedure, if the donor declines to participate in the protocol, this decision 
must be communicated immediately to the NMDP Search and Transplant Services Department.  
At the donor information session, the following information will be provided: 
 
PURPOSE OF THE TRIAL 
This trial has been undertaken to compare the established blood stem cell source, bone marrow, 
against the newer source, PBSC.  In making this comparison, we are interested in both donor and 
recipient experiences (outcomes).  There is no foregone conclusion that one product is better 
than the other (for either donors or recipients), if that were the case, the trial would not be 
necessary.  While some experts may have opinions about the comparison, these opinions cannot 
be verified by facts.  The purpose of this trial is to provide scientifically valid information to 
allow a comparison. 
 
POTENTIAL ADVANTAGES OF EACH PRODUCT 
Donors will be informed about what is being compared to determine the potential advantages of 
each product for themselves and their recipients.  The major outcome for donors is the incidence 
of adverse events and serious adverse events.  We are also interested, however, in the donors’ 
quality of life experiences with each type of donation.  For transplant recipients, we will be 
measuring engraftment, graft-versus-host disease, risk of relapse and survival.  
 
The NMDP has been conducting a non-randomized comparison of bone marrow and PBSC since 
July 1999.  This comparison suggests, but does not prove, the following associations. 
 
For Donors1 –  
Symptoms from donation 
Similar in both groups. PBSC donors experience most 
of their symptoms before donation, but bone marrow 
donors have symptoms after donation. 
Recovery from donation 
PBSC donors recover faster after donation.  
Satisfaction with donation 
Both bone marrow and PBSC donors are comfortable 
with their decisions to donate and both groups feel the 
donation experience was positive. 
 
                                                   
1 Data provided by Galen Switzer who has conducted an NMDP-funded comparison of donor experiences following 
bone marrow and PBSC donation. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
E-3 
For Recipients –  
Engraftment of neutrophils and 
platelets 
Clearly occurs earlier with PBSC, but no difference in 
overall engraftment 
Risk of graft-versus-host 
disease 
May be higher with PBSC, particularly chronic GVHD 
Immune reconstitution 
May be faster with PBSC 
Risk of relapse 
No obvious differences 
Survival  
No obvious differences 
 
 
RECIPIENT DROPOUT 
Donors should receive information about the enrollment process for donors and recipients.  They 
should understand that the recipient has consented to participate in the clinical trial, but will 
ultimately be confirmed eligible only in the days immediately preceding the start of conditioning 
therapy.  It is anticipated by the study investigators that up to 15% of enrolled donor-recipient 
pairs will be removed from study before the start of conditioning. In this instance, participation 
in the study will be terminated.  Donors should understand that they may still be asked to provide 
a blood stem cell product for the recipient if an alternative approach to transplantation is 
available.  But, in such cases, the transplant and the results of the transplant will not be included 
in the clinical study. 
 
DONOR EDUCATIONAL MATERIALS 
The NMDP has developed educational materials for donors considering the randomized clinical 
trial.  These materials should be provided prior to the donor’s consent decision.  Questions from 
donors may be directed to donor center personnel or to Dr. Dennis Confer, NMDP Chief Medical 
Officer (612-362-3425, dconfer@nmdp.org) or Dr. John Miller, NMDP Donor Center Medical 
Director (612-884-8534, jmiller5@nmdp.org). 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-1 
 
 
APPENDIX F 
 
REFERENCES 
 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-2 
APPENDIX F – REFERENCES 
 
 
                                                   
 
Chapter 1 
 
1 Storb R, Prentice RL, Thomas ED. Marrow transplantation for treatment of aplastic anemia. 
An analysis of factors associated with graft rejection. N Engl J Med 1977; 296:61-6. 
 
2 Clift RA, Buckner CD, Thomas ED, et al. The treatment of acute non-lymphoblastic leukemia 
by allogeneic marrow transplantation. Bone Marrow Transplant 1987; 2:243-58. 
 
3 Bacigalupo A, Piaggio G, Podesta M, et al. Influence of marrow CFU-GM content on 
engraftment and survival after allogeneic bone marrow transplantation. Bone Marrow Transplant 
1995; 15:221-6. 
 
4 Mavroudis D, Read E, Cottler-Fox M, et al. CD34+ cell dose predicts survival, post transplant 
morbidity, and rate of hematologic recovery after allogeneic marrow transplants for hematologic 
malignancies. Blood 1996; 88:3223-9. 
 
5 Bittencourt H, Rocha V, Chevret S, et al. Association of CD34 cell dose with hematopoietic 
recovery, infections, and other outcomes after HLA-identical sibling bone marrow 
transplantation. Blood 2002; 99: 2726. 
 
6 Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplantation from 
related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow 
Transplantation Group. N Engl J Med 1997; 337: 373-81. 
 
7 Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placental-
blood transplants from unrelated donors. N Engl J Med 1998; 339:1565-77. 
 
8 Reisner Y, Martelli MF. Bone marrow transplantation across HLA barriers by increasing the 
number of transplanted cells. Immunol Today 1995; 16:437. 
 
9 Aversa F, Tabilio A, Velardi A, et al. Treatment of high-risk acute leukemia with T-cell-
depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J 
Med 1998; 339:1186. 
 
10 Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unrelated donors 
for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, 
and marrow cell dose. Blood 1997; 89: 4226–35. 
 
11 Sierra J, Storer B, Hansen JA, et al. Unrelated donor marrow transplantation for acute 
myeloid leukemia: an update of the Seattle experience: Bone Marrow Transplant 2000; 26, 397-
404. 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-3 
                                                                                                                                                                    
 
12 Dini G, Rondelli R, Miano M, et al. Unrelated-donor bone marrow transplantation for 
Philadelphia chromosome-positive chronic myelogenous leukemia in children: experience of 
eight European Countries. The EBMT Paediatric Diseases Working Party. Bone Marrow 
Transplant 1996; 18 Suppl. 2, 80-5. 
 
13 Peters C, Balthazor M, Shapiro EG, et al. Outcome of unrelated donor bone marrow 
transplantation in 40 children with Hurler syndrome. Blood 1996; 87, 4894-902. 
 
14 Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood 
mononuclear cells collected after administration of recombinant granulocyte stimulating factor. 
Blood 1993; 81: 3158–63. 
 
15 Weaver CH, Buckner CD, Longin K, et al. Syngeneic transplantation with peripheral blood 
mononuclear cells collected after the administration of recombinant human granulocyte colony-
stimulating factor. Blood, 82: 1981–1984, 1993. 
 
16 Dreger P, Haferlach T, Eckstein V, et al. G-CSF-mobilized peripheral blood progenitor cells 
for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. Br J 
Haematol 1994; 87: 609–13, 1994. 
 
17 Korbling M, Katz RL, Khanna A, et al. Hepatocytes and epithelial cells of donor origin in 
recipients of peripheral-blood stem cells. N Engl J Med 2002; 346:738. 
 
18 Rice A and Reiffers J. Mobilized blood stem cells: Immunophenotyping and functional 
characteristics. J Hematother 1992; 1: 19–26. 
 
19 Ottinger HD, Beelen DW, Scheulen B, et al. Improved immune reconstitution after 
allotransplantation of peripheral blood stem cells instead of bone marrow. Blood 1996; 88: 2775–
79. 
 
20 Arpinati M, Green C, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T 
helper 2-inducing dendritic cells. Blood 2000; 95: 2484. 
 
21 Mielcarek M, Martin P, Torok-Storb B. Suppression of alloantigen-induced T-cell 
proliferation by CD14+ cells derived from granulocyte colony-stimulating factor (G-CSF)-
mobilized peripheral blood mononuclear cells. Blood 1997; 89: 1629–34. 
 
22 Kusnierz-Glaz CR, Still BJ, Amano M, et al. Granulocyte colony-stimulating factor induced 
comobilization of CD4–CD8– T cells and hematopoietic progenitor cells (CD34+) in the blood 
of normal donors. Blood 1997; 89: 2586–95. 
 
23 Arpinati M, Green C, Heimfeld S, et al. Granulocyte-colony stimulating factor mobilizes T 
helper 2-inducing dendritic cells. Blood 2000; 95: 2484. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-4 
                                                                                                                                                                    
24 Rowley SD, Donaldson G, Lilleby K, Bensinger, WI, Appelbaum, FR. Experiences of donors 
enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell 
transplantation [erratum appears in Blood 2001; 98:1301]. Blood 2001; 97:2541-2548. 
 
25 Anderlini P, Przepiorka D, Champlin R, et al. Biologic and clinical effects of granulocyte 
colony-stimulating factor in normal individuals (Review). Blood 1996; 88: 2819–25. 
 
26 Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes 
in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506–14. 
 
27 Cavallaro AM, Lilleby K, Majolino I, et al. Three to six year follow-up of normal donors who 
received recombinant human granulocyte colony stimulating factor. Bone Marrow Transplant 5: 
85–9, 2000. 
 
28 Anderlini P, Körbling M, Dale D, et al. Allogeneic blood stem cell transplantation: 
considerations for donors (Editorial). Blood 1997; 90: 903–8. 
 
29 Becker PS, Wagle M, Matous S, et al. Spontaneous splenic rupture following administration 
of granulocyte colony-stimulating factor (G-CSF): occurrence in an allogeneic donor of 
peripheral blood stem cells. Biol Blood Marrow Transplant 1997; 3: 45–9. 
 
30 Falzetti F, Aversa F, Minelli O, et al. Spontaneous rupture of spleen during peripheral blood 
stem-cell mobilisation in a healthy donor (Research Letter). Lancet 1999; 353: 55. 
 
31 Confer DL, Haagenson M, Anderlini P, et al. Collection of rhG-CSF-mobilized blood stem 
cells from 395 unrelated donors. Blood 2001; 857a #3560. 
 
32 Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with 
peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl 
J Med 2001; 344: 175–81. 
 
33 Blaise D, Kuentz M, Fortanier C, et al. Randomized trial of bone marrow versus lenograstim-
primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from 
the Société Française de Greffe de Moelle. J Clin Oncol 2000; 18: 537–71. 
 
34 Heldal D, Tjonnfjord GE, Brinch L, et al. A randomised study of allogeneic transplantation 
with stem cells from blood or bone marrow. Bone Marrow Transplant 2000; 25: 1129–36. 
 
35 Mahmoud HK, Fahmy OA, Kamel A, et al. Peripheral blood vs. bone marrow as a source for 
allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 1999; 24: 355–58. 
 
36 Powles R, Mehta J, Kulkarni S, et al. Allogeneic blood and bone-marrow stem-cell 
transplantation in haematological malignant diseases: a randomized trial. Lancet 2000; 355: 
1231–37. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-5 
                                                                                                                                                                    
37 Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood 
cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761. 
 
38 Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, Shore TB, 
Walker IR, Browett P, Messner HA, Panzarella T, Lipton JH. A randomized multicenter 
comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic 
transplants for myeloid malignancies. Blood 2002; 100:1525-31. 
 
39 Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective comparison of 
allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of 
haematological malignancies. Bone Marrow Transplant 22: 1145–1151, 1998. 
 
40 Schmitz N, Beksac M, Hasenclever D, et al. Transplantation of mobilized peripheral blood 
cells to HLA-identical siblings with standard-risk leukemia. Blood 2002; 100: 761. 
 
41 Bensinger WI, Storb R. Allogeneic peripheral blood stem cell transplantation. (Review). Clin 
Exp Hematol 2001; 5:67-86. 
 
42 Couban S, Simpson DR, Barnett MJ, Bredeson C, Hubesch L, Howson-Jan K, Shore TB, 
Walker IR, Browett P, Messner HA, Panzarella T, Lipton JH. A randomized multicenter 
comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic 
transplants for myeloid malignancies. Blood 2002; 100:1525-31. 
 
43 Nash RA, Pepe MS, Storb R, et al. Acute graft-versus-host disease: analysis of risk factors 
after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. 
Blood 1992; 80: 1838–45. 
 
44 Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with 
peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl 
J Med 2001; 344: 175–81. 
 
45 Stockschläder M, Loliger C, Kruger W, et al. Transplantation of allogeneic rh G-CSF 
mobilized peripheral CD34+ cells from an HLA-identical unrelated donor. Bone Marrow 
Transplant 1995; 16: 719–22. 
 
46 Hagglund, H., Ringden, O., Remberger, M. et al. Faster neutrophil and platelet engraftment, 
but no differences in acute GVHD or survival, using peripheral blood stem cells from related and 
unrelated donors, compared to bone marrow. Bone Marrow Transplant 1998; 22: 131–6. 
 
47 Schwinger W, Urban C, Lackner H, et al. Unrelated peripheral blood stem cell transplantation 
with ‘megadoses’ of purified CD34+ cells in three children with refractory severe aplastic 
anemia. [Journal Article] Bone Marrow Transplant 2000; 25(5):513-7. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-6 
                                                                                                                                                                    
48 Blau IW, Basara N, Lentini G, et al. Feasibility and safety of peripheral blood stem cell 
transplantation from unrelated donors: results of a single-center study. Bone Marrow Transplant 
2001; 27: 27-33. 
 
49 Ringden O, Remberger M, Runde V, et al. Peripheral blood stem cell transplantation from 
unrelated donors: a comparison with marrow transplantation. Blood 1999; 94: 455–64. 
 
50 Remberger M, Ringden O, Blau IW, et al. No difference in graft-versus-host disease, relapse, 
and survival comparing peripheral stem cells to bone marrow using unrelated donors. Blood 
2001; 98:1739. 
 
51 Elmaagacli AH, Basoglu S, Peceny R, et al. Improved disease-free-survival after 
transplantation of peripheral blood stem cells as compared with bone marrow from HLA-
identical unrelated donors in patients with first chronic phase chronic myeloid leukemia. Blood 
2002; 99:1130. 
 
 
Chapter 2 
 
52 Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al.  Revised 
recommendations of the international working group for diagnosis, standardization of response 
criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid 
leukemia.  J Clin Oncol 21(24): 4642-9, 2003. 
 
53 Kottaridis PD, Milligan DW, Chopra R, et al. In vivo CAMPATH-1H prevents graft-versus-
host disease following nonmyeloablative stem cell transplantation. Blood 2000; 96:2419-25. 
 
54 Product Information: Fludara ®, fludarabine phospate.  Berlex Laboratories, Richomnd, CA, 
USA. 
 
55 Product Package Insert Information. VFEND, Voriconazole. Pfizer, New York, NY, USA. 
 
56 Bolan CD, Carter CS, Wesley RA, et al.: Prospective evaluation of cell kinetics, yields and 
donor experiences during a single large-volume apheresis versus two smaller volume 
consecutive day collections of allogeneic peripheral blood stem cells. British J Haematol 2003; 
120:801-7. 
 
57 Bolan CD, Cecco SA, Wesley RA, et al.: Controlled study of citrate effects and response to 
i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. 
Transfusion 2002; 42:935-46. 
 
58 Powles R, Mehta J, Kulkarni S, et al: Allogeneic blood and bone marrow stem cell 
transplantation in haematological malignant diseases: a randomised trial. Lancet 2000; 355: 
1231-37. 
 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-7 
                                                                                                                                                                    
Chapter 3 
 
59 Klein J, Keiding N, Shu Y, Szydlo R, Goldman J. Summary curves for patients transplanted 
for chronic myeloid leukemia salvaged by a donor lymphocyte infusion: the current leukemia-
free survival curve. Br J Hematol. 2000; 109(1), 148-52. 
 
60 Anasetti, C., Amos, D., Beatty, P.G. et al. (1989). Effect of HLA compatibility on 
engraftment of bone marrow transplants in patients with leukemia or lymphoma. New England 
Journal of Medicine, 320, 197-204. 
 
61 Ottinger, H.D., Rebmann, V., Pfeiffer, K.A. et al. (2002). Positive serum crossmatch as 
predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. 
Transplantation, 73, 1280-5. 
 
 
Chapter 5 
 
62 Zhang MJ and Klein JP: Confidence bands for the difference of two survival curves under 
proportional hazards model. Lifetime Data Analysis, 7(3), 243-254, 2001 
63 Klein J, Andersen P, and Rosthøj S. From Summary Statistics to Generalized Linear Models 
for Pseudo Observations with Applications to Multistate Models. Biometrika, 2002 (In Press). 
 
 
Chapter 7 
 
64 Altmaier EM, Gingrich RD, Fyfe MA. Two-year adjustment of bone marrow transplant 
survivors. Bone Marrow Transplant 1991; 7:311-6. 
 
65 Baker F, Wingard JR, Curbow B, et al. Quality of life of bone marrow transplant long-term 
survivors. Bone Marrow Transplant 1994; 13:589-96. 
 
66 Andrykowski MA. Psychosocial factors in bone marrow transplantation: a review and 
recommendations for research. Bone Marrow Transplant 1994; 13:357-75. 
 
67 Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6-
18 years after bone marrow transplantation. Soc Sci Med 1995; 40:479-90. 
 
68 Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow 
transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 
1997; 19:1129-36. 
 
69 Grant M. Assessment of quality of life following hematopoietic cell transplantation. In: 
Thomas ED, Blume KG, Forman SJ, eds. Hematopoetic cell transplantation. Malden: Blackwell 
Sciences, Inc., 1999:407-413. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-8 
                                                                                                                                                                    
70 Kiss TL, Abdolell M, Jamal N, Minden MD, Lipton JH, Messner HA. Long-term medical 
outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at 
least 10 years after allogeneic bone marrow transplantation. J Clin Oncol 2002; 20:2334-43. 
 
71 Syrjala KL, Chapko MK, Vitaliano PP, Cummings C, Sullivan KM. Recovery after allogeneic 
marrow transplantation: prospective study of predictors of long-term physical and psychosocial 
functioning. Bone Marrow Transplant 1993; 11:319-27. 
 
72 Sutherland HJ, Fyles GM, Adams G, et al. Quality of life following bone marrow 
transplantation: a comparison of patient reports with population norms. Bone Marrow Transplant 
1997; 19:1129-36. 
 
73 Belec RH. Quality of life: perceptions of long-term survivors of bone marrow transplantation. 
Oncol Nurs Forum 1992; 19:31-7. 
 
74 Andrykowski MA, Brady MJ, Greiner CB, et al. ‘Returning to normal’ following bone 
marrow transplantation: outcomes, expectations and informed consent. Bone Marrow Transplant 
1995; 15:573-81. 
 
75 McQuellon RP, Russell GB, Rambo TD, et al. Quality of life and psychological distress of 
bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year. Bone 
Marrow Transplant 1998; 21:477-86. 
 
76 Andrykowski MA. Psychosocial factors in bone marrow transplantation: a review and 
recommendations for research. Bone Marrow Transplant 1994; 13:357-75. 
 
77 Zittoun R, Suciu S, Watson M, et al. Quality of life in patients with acute myelogenous 
leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or 
autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial. 
Bone Marrow Transplant 1997; 20:307-15. 
 
78 McQuellon RP, Russell GB, Rambo TD, et al. Quality of life and psychological distress of 
bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year. Bone 
Marrow Transplant 1998; 21:477-86. 
 
79 McQuellon RP, Russell GB, Cella DF, et al. Quality of life measurement in bone marrow 
transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow 
Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997; 19:357-68. 
 
80 Cella D. Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales. 
Evanston: Northwestern University, 1997. 
 
81 Veit CT, Ware JE, Jr. The structure of psychological distress and well-being in general 
populations. J Consult Clin Psychol 1983; 51:730-42. 
 

BMT CLINICAL TRIALS NETWORK 
 
PBSC vs. Marrow Randomized Trial – Protocol 0201 
Version 9.0 dated October 28, 2009 
F-9 
                                                                                                                                                                    
82 Kornblith AB, Herndon JE, 2nd, Silverman LR, et al. Impact of azacytidine on the quality of 
life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer 
and Leukemia Group B study. J Clin Oncol 2002; 20:2441-52. 
 
83 Lee SJ, Cook EF, Soiffer RJ, Antin JH. Development and validation of a scale to measure 
symptoms of chronic graft-versus-host disease (in press). Biol Blood Marrow Transplant 2002. 
 
84 Lee SJ, Fairclough D, Parsons SK, et al. Recovery after stem-cell transplantation for 
hematologic diseases. J Clin Oncol 2001; 19:242-52. 
 
85 Schluchter MD. Methods for the analysis of informatively censored longitudinal data. Stat 
Med 1992; 11:1861-70. 
 
86 Ibrahim JG, Chen MH, Sinha D. Bayesian methods for joint modeling of longitudinal and 
survival data with applications to cancer vaccine studies. Under revision for Applied Statistics 
2001. 
 
 
Chapter 8 
 
87 Auguier P, Macquart-Moulin G, Moatti JP, et al. Comparison of anxiety, pain and discomfort 
in two procedures of hematopoietic stem cell collection: leukacytapheresis and bone marrow 
harvest. Bone Marrow Transplant 1995; 16:541-547. 
 
88 Heldal, D, Brinch, L, Tjonnfjord, G, et al. Donation of stem cells from blood or bone marrow: 
results of a randomised study or safety and complaints. Bone Marrow Transplant 2002; 29: 479-
486. 
 
89 Switzer, GE, Goycoolea, JM, Dew, MA, Graeff, EC, Hegland, J. Donating stimulated 
peripheral blood stem cells vs. bone marrow: do donors experience the procedures differently? 
Bone Marrow Transplant 2001; 27:917-923. 
 
90 Rowley, SD, Donaldson, G, Lilleby, K, Bensinger, WI, Appelbaum, FR. Experiences of 
donors enrolled in a randomized study of allogeneic bone marrow or peripheral blood stem cell 
transplantation. Blood 2001; 97: 2541-2548. 
 
91 Ware, JE, Kosinski, M, Turner-Bowker, DM, Gandek, B.  How to Score Version 2 of the SF-
12 Health Survey (with a Supplement Documenting Version 1). Lincoln, RI: Quality Metric 
Incorporated, 2002. 
 
92 McNair DM, Lorr M, Droppleman LF: EITS Manual for the Profile of Mood States. San 
Diego CA, Educational and Industrial Testing Service, 1971.